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Résumé 
Le remodelage cardiaque est le processus par lequel la structure ou la 
fonction cardiaque change en réponse à un déséquilibre pathophysiologique tel 
qu'une maladie cardiaque, un contexte d'arythmie prolongée ou une modification de 
l'équilibre hormonal. Le système rénine-angiotensine (SRA) est un système 
hormonal largement étudié et il est impliqué dans de nombreuses activités associées 
au remodelage cardiovasculaire. L’existence d'un système circulatoire couplé à un 
système de tissus locaux est une représentation classique, cependant de nouvelles 
données suggèrent un SRA indépendant et fonctionnellement actif à l'échelle 
cellulaire. La compréhension de l'activité intracellulaire du SRA pourrait mener à de 
nouvelles pistes thérapeutiques qui pourraient prévenir un remodelage 
cardiovasculaire défavorable. L'objectif de cette thèse était d'élucider le rôle du SRA 
intracellulaire dans les cellules cardiaques.  
Récemment, les récepteurs couplés aux protéines G (RCPG), les protéines G 
et leurs effecteurs ont été détectés sur des membranes intracellulaires, y compris sur 
la membrane nucléaire, et les concepts de RCPG intracellulaires fonctionnels sont en 
voie d'être acceptés comme une réalité. Nous avons dès lors fait l'hypothèse que la 
signalisation du SRA délimitant le noyau était impliquée dans le contrôle de 
l'expression des gènes cardiaques. Nous avons démontré la présence de récepteurs 
d'angiotensine de type-1 (AT1R) et de type-2 (AT2R) nucléaires dans les 
cardiomyocytes ventriculaires adultes et dans une fraction nucléaire purifiée de tissu 
cardiaque. Des quantités d'Ang II ont été détectées dans du lysat de cardiomyocytes 
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et des microinjections d'Ang-II-FITC ont donné lieu à des liaisons préférentielles aux 
sites nucléaires. L'analyse transcriptionnelle prouve que la synthèse d'ARN de novo 
dans des noyaux isolés stimulés à l'Ang-II, et l'expression des ARNm de NF-κB 
étaient beaucoup plus importants lorsque les noyaux étaient exposés à de l'Ang II 
par rapport aux cardiomyocytes intacts. La stimulation des AT1R nucléaires a 
engendré une mobilisation de Ca2+ via les récepteurs de l'inositol trisphosphate 
(IP3R), et le blocage des IP3R a diminué la réponse transcriptionnelle.  
Les méthodes disponibles actuellement pour l'étude de la signalisation 
intracrine sont limitées aux méthodes indirectes. L'un des objectifs de cette thèse 
était de synthétiser et caractériser des analogues d'Ang-II cellule-perméants afin 
d’étudier spécifiquement dans les cellules intactes l'activité intracellulaire du SRA. 
Nous avons synthétisé et caractérisé pharmacologiquement des analogues 
photosensibles Ang-II encapsulée en incorporant un groupement 4,5-diméthoxy-2-
nitrobenzyl (DMNB) photoclivable sur les sites actifs identifiés du peptide. Chacun 
des trois analogues d'Ang II encapsulée synthétisés et purifiés: [Tyr(DMNB)4]Ang-II, 
Ang-II-ODMNB et [Tyr(DMNB)4]Ang-II-ODMNB a montré une réduction par un 
facteur deux ou trois de l'affinité de liaison envers AT1R et AT2R dans les dosages 
par liaison compétitive et une activité réduite dans la contraction de l'aorte 
thoracique. La photostimulation de [Tyr(DMNB)4]Ang-II dans des cellules HEK a 
augmenté la phosphorylation d'ERK1/2 (via AT1R) et la production de cGMP (via 
AT2R) alors que dans les cardiomyocytes isolés elle générait une augmentation de 
Ca2+ nucléoplasmique et initiait la synthèse d'ARNr 18S et d'ARNm du NF-κB. 
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Les fibroblastes sont les principaux générateurs de remodelage cardiaque 
structurel, et les fibroblastes auriculaires sont plus réactifs aux stimuli profibrotiques 
que les fibroblastes ventriculaires. Nous avons émis l'hypothèse que l’Ang-II 
intracellulaire et l'activation des AT1R et AT2R nucléaires associés contrôlaient les 
profils d'expression des gènes des fibroblastes via des systèmes de signalisation 
distincts et de ce fait jouaient un rôle majeur dans le développement de la fibrose 
cardiaque. Nous avons remarqué que les fibroblastes auriculaires expriment l’AT1R 
et l’AT2R nucléaire et l'Ang-II au niveau intracellulaire. L’expression d'AT1R nucléaire 
a été régulés positivement dans les cas d’insuffisance cardiaque (IC), tandis que 
l'AT2R nucléaire a été glycosylé post-traductionnellement. La machinerie protéique 
des protéines G, y compris Gαq/11, Gαi/3, et Gβ, a été observée dans des noyaux 
isolés de fibroblastes. AT1R et AT2R régulent l'initiation de la transcription du 
fibroblaste via les voies de transduction de signal d'IP3R et du NO. La 
photostimulation de [Tyr(DMNB)4]Ang-II dans une culture de fibroblastes auriculaire 
déclenche la libération de Ca2+ nucléoplasmique, la prolifération, et la synthèse et 
sécrétion de collagène qui ne sont pas inhibées par les bloqueurs d'AT1R et/ou 
AT2R extracellulaires.  
 
Mots-clés: Système rénine-angiotensine (SRA), récepteurs intracellulaires, 
signalisation, remodelage cardiovasculaire   
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Abstract 
Cardiac remodelling is the process by which cardiac structure and/or function change 
in response to pathophysiological imbalances such as hypertension, cardiac disease, 
prolonged arrhythmia or altered hormonal balance. The renin-angiotensin system 
(RAS) is an extensively studied hormonal system involved in numerous processes 
associated with cardiovascular remodelling. Classically viewed as a circulating and a 
local tissue system, emerging evidence suggests an independent and functionally 
active RAS within individual cells. Understanding intracellular RAS actions might lead 
to new therapeutic avenues that could prevent adverse cardiac remodelling. The 
purpose of this thesis was to elucidate the role of intracellular RAS in cardiac cells. 
Recently, G protein-coupled receptors (GPCRs), G proteins, and their 
downstream effectors have been detected on intracellular membranes, including the 
nuclear membrane, and the concept of functional intracellular GPCRs is slowly being 
accepted as a reality. We therefore hypothesized that nuclear-delimited angiotensin II 
(Ang-II) signalling is involved in controlling cardiac gene expression. We 
demonstrated the presence of nuclear angiotensin-type 1 (AT1R) and angiotensin-
type 2 (AT2R) receptors in adult ventricular cardiomyocytes and in a purified nuclear 
preparation from cardiac tissue. Ang-II was detected in cardiomyocyte lysate and 
microinjected Ang-II-FITC preferentially bound to nuclear sites. Transcriptional 
analysis demonstrated that Ang-II enhanced de novo RNA synthesis in isolated 
nuclei and NF-κB mRNA expression was much greater when nuclei were exposed to 
Ang-II. Nuclear AT1R-stimulation produced Ca2+ mobilization via nuclear inositol 
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1,4,5-trisphosphate receptor (IP3R) Ca2+-channels, and IP3R-blockade attenuated 
the AT1R-mediated transcriptional responses in isolated nuclei.  
Current methods available to study intracrine RAS signalling are limited to 
indirect methodologies because of a lack of selective intracellularly-acting probes. An 
aim of this thesis was to synthesize and characterize cell-permeant Ang-II analogues 
to probe intracellular RAS action with spatial and temporal precision. Using solid-
phase peptide technology we synthesized and pharmacologically characterized light-
sensitive caged Ang-II analogues. This was achieved by incorporating a 
photocleavable 4,5-dimethoxy-2-nitrobenzyl (DMNB) moiety on sites of Ang-II 
responsible for receptor recognition and activation. All of the three synthesized and 
purified caged-Ang-II analogues: [Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and 
[Tyr(DMNB)4]Ang-II-ODMNB, showed two-to-three orders of magnitude reduced 
binding affinity towards the AT1R and AT2R in competition binding assays and 
reduced potency in contraction assays using thoracic aorta. Photolysis of 
[Tyr(DMNB)4]Ang-II in HEK cells increased ERK1/2 phosphorylation (via AT1R) and 
cGMP production (via AT2R) whereas in isolated cardiomyocytes it induced an 
increase in nucleoplasmic Ca2+ and increased the abundance of 18S rRNA and NF-
κB mRNA. 
Fibroblasts are the main drivers of cardiac structural remodelling. Atrial 
fibroblasts are more responsive to pro-fibrotic stimuli than ventricular fibroblasts. We 
hypothesized that intracellular Ang-II and associated nuclear AT1R and AT2R 
activation control fibroblast gene-expression patterns via discrete signalling systems 
and thereby play a key role in cardiac fibrosis. Atrial fibroblasts were found to express 
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Ang-II, and nuclear AT1R and AT2R. The nuclear localisation of AT1R was increased 
in fibroblasts isolated from failing hearts whereas nuclear AT2R showed alterations in 
glycosylation. Heterotrimeric G protein subunits including Gαq/11, Gαi/3, and Gβ 
were observed in isolated fibroblast nuclei. AT1R and AT2R increased fibroblast 
transcription initiation via IP3R and NO signal transduction pathways, respectively. 
Photolysis of [Tyr(DMNB)4]Ang-II in cultured atrial fibroblasts induced an increase in 
nucleoplasmic Ca2+, proliferation, collagen synthesis and secretion that was not 
prevented by extracellular AT1R and/or AT2R blockers. 
 
Keywords: Renin-angiotensin system (RAS), intracellular receptors, signalling, 
cardiovascular remodelling 
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1.1 Overview  
Cardiovascular diseases (CVDs) remain the major cause of morbidity and 
mortality in the industrialized world. Epidemiologists predict that by 2030 - in a mere 
fifteen years - CVDs will be responsible for 30% of all deaths and will remain the 
single leading cause of mortality [1]. G-protein coupled receptors (GPCRs) are a 
conserved family of heptahelical receptors and are one of the largest and most 
diverse classes of receptors in the human genome to be targeted by therapeutics in 
clinical use [2]. Among 200 GPCRs expressed in various cardiac cell types, 
pharmacological drugs targeting only adrenergic and angiotensin GPCR signaling 
mechanisms account for the majority of clinical prescriptions in regulation of the 
cardiovascular system [3]. However, heart failure progression with high morbidity and 
mortality rates continues. Studies of the newly recognized GPCRs, in particular 
intracellular GPCRs and investigations that define their molecular signaling 
mechanisms, expression patterns, cross-talk with other sub-systems, and regulation 
in cardiac diseases may provide a mechanistic basis and new attractive targets for 
improving heart failure treatment.  
 
1.2 Cardiovascular System 
The cardiovascular system is powered by the body’s hardest working vital 
organ for sustaining life – the heart. The heart is a muscular pump and is divided into 
four pumping chambers: the right and left atria and the right and left ventricles (Figure 
1). The right side of the heart is where the deoxygenated or ‘‘bad’’ blood enters from 
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our body. The left side of the heart sends the oxygenated ‘‘good’’ blood to the rest of 
our body through the aortic valve to serve physiological needs. At rest, the average 
human heart efficiently pumps approximately 5 liters of blood throughout the body 
every minute and helps to deliver oxygen to cells and maintain homeostasis of 
nutrients, metabolic wastes and gases [4]. Angiotensin II (Ang-II) via Ang-II type 1 
(AT1R) and Ang-II type 2 (AT2R) receptors, endothelin-1 via ETA and ETB receptors, 
acetylcholine via muscarinic receptors, adenosine via A1 and A2 receptors and 
catecholamines via α-/β-adrenergic receptors are among the most widely studied 
extracellular ligands that control cardiac pump performance by recognizing and 
binding to specific GPCRs. These signals can regulate heart rate and contractile 
strength to preserve continuous perfusion of all vascular system with oxygenated and 
nutrient-rich blood. Whereas acute activation of GPCR signaling system is beneficial, 
prolonged activation can also promote remodeling of the heart by increasing cardiac 
cell dimensions, tissue fibrous composition, chamber size, heart size and altered 
expression of proteins that control cardiac excitability and contractility [5]. The main 
cellular constituents of the heart are cardiac myocytes, cardiac fibroblasts, vascular 
smooth muscle cells and endothelial cells. The heart’s five central components are: 
the muscle, the arteries, the valves, the electrical system and the pericardium.     
 
1.2.1 The Cardiac Muscle 
The main pumping part of the heart responsible for contraction of cardiac 
tissue and distribution of blood is the cardiac muscle, or the myocardium. The heart 
muscle contains cardiac contractile cells and sarcomeres, highly resistant to fatigue, 
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which allows the heart to beat our entire lifetime. The cardiac contractile cells, or 
cardiomyocytes, are surrounded by a sarcolemma, which invaginates, perpendicular 
to the length of the cell to form transverse tubules (T-tubule) (Figure 2A). T-tubules 
are rich in calcium (Ca2+) channels, carriers, pumps and control the contraction of the 
muscle [6]. Ca2+ signals in cardiomyocytes are modulated by the actions of Ang-II and 
overexpression of AT1R alters excitation-contraction coupling [7]. Cardiomyocyte 
contraction is initiated by a transient increase in intracellular Ca2+ as the action 
potential from the sinoatrial node sweeps over the heart. The cellular depolarization 
subsequently activates voltage-operated Ca2+ channels, which triggers the release of 
Ca2+ fom the sarcoplasmic reticulum into the cytoplasm. Ryanodine-sensitive Ca2+ 
release channels activated by the voltage-dependant Ca2+ influx, a process termed as 
Ca2+-induced Ca2+-release. Relaxation occurs as Ca2+ returns back to resting levels 
through the actions of both sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) and 
sarcolemma Na+/Ca2+ exchanger (NCX) [8]. The sarcomeres are composed of 
fibrous protein filaments, myosin and actin, and originate muscle contraction after 
sliding [9]. The heart’s contraction efficacy, clinically termed as the ejection fraction, is 
a measurement of the percentage of blood pumped out of a filled ventricle with every 
heartbeat. A healthy human heart’s ejection fraction is in the range of 55% to 70% 
and may decrease by thickening, stiffening or weakening of the heart muscle [10].   
 
1.2.2 The Cardiac Arteries 
Coronary arteries are the blood vessels that encircle the heart like a crown and 
are vital to heart function as they carry virtually all of the blood that supplies the heart. 
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The major coronary arteries are the right coronary artery, the left coronary artery, the 
circumflex coronary artery and the left anterior descending artery. The endothelium, 
skin-like tissue that lines the aforementioned arteries, maintains vascular tone 
through the release of nitric oxide (NO), prostacyclin, bradykinin, endothelium-derived 
hyperpolarizing factor, endothelin and Ang-II. Ang-II activates endothelial 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and upregulates 
nuclear factor κB (NF-κB) [11]. In arteries, NF-κB promotes CVD through the 
activation of genes involved in inflammation, oxidation and adhesion. NADPH oxidase 
plays a fundamental role in the generation of reactive oxygen species (ROS) and 
catalyzes the production of superoxide anion (O2-) which in turn is broken down to 
hydrogen peroxide (H2O2) by superoxide dismutases [12]. The balance between ROS 
and NO governs the state of health of the endothelium. The endothelium also 
regulates vascular smooth muscle cell (VSMC) proliferation, thrombogenesis and 
fibrinolysis [13-15].  
 
1.2.3 The Cardiac Valves 
The cardiac valves, composed of papillary muscle, chordae tendineae and 
mitral valve annulus, regulate the blood flow through the four pumping chambers. The 
four heart valves include: right atrioventricular (triscupid) valve, left atrioventricular 
(mitral) valve, pulmonary valve and aortic valve. An abnormal valve opening when the 
valve should remain closed, medically termed regurgitation, permits blood to leak 
abnormally (e.g. the left atrium for mitral regurgitation) and causes a heart murmur. 
Rupture of a papillary muscle, which sometimes occurs after myocardial infarction 
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(MI), causes severe mitral regurgitation and is often a surgical emergency that 
requires rapid intervention for optimal outcomes [16]. Narrowing of a valve orifice, 
known as stenosis, inhibits the ability of the heart to pump efficiently. Ang-II 
contributes to the pathogenesis of aortic valve disease by inducing monocyte 
chemoattractant protein-1 gene expression as well as collagen synthesis through the 
activation of transforming growth factor-beta (TGF-β) [17]. Aortic stenosis is typically 
triggered by rheumatic heart fever or aging-related calcification and affects up to 5% 
of the elderly population [18,19]. 
 
1.2.4 The Cardiac Electrical System 
The electrical impulses generated and conducted through specialized 
myocardial cells initiate and control the heartbeat in a coordinated fashion. Resting 
average normal heart rate is in the range of 100 to 160 beats per minute (bpm) for an 
infant and 60 to 100 bpm for adults [20,21]. A fast sustained adult heart rate (>100 
bpm) is referred to as tachycardia and a slow adult heart rate (<60 bpm) is termed 
bradycardia. The electrical signals that set the contractions in motion begin in the 
sinoatrial (SA) node. The impulse rapidly propagates through the atrium to the 
atrioventricular (AV) node and after encountering a delay in the AV node, the impulse 
rapidly spreads through the bundle of His, then the bundle branches, the Purkinje 
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FIGURE 1. ANATOMY OF THE HEART, STRUCTURAL CONSTITUENTS OF 
CARDIAC MUSCLE FIBER AND TRACES OF CARDIAC CONDUCTION 
SYSTEM’S ELECTRICAL EVENTS. 
Schematic of the heart. The heart is composed of four chambers: right and left atria 
and right and left ventricles. Blood passes through valves before leaving each cardiac 
chamber. The four heart valves (red lines) include: aortic, mitral, pulmonary and 
tricuspid. The rhythmic heart beat is maintained by the cardiac conducting system 
which fires sequentially from atria to ventricle (blue lines) composed of SA node, AV 
node, bundle of His, bundle branches, and Purkinje network. The blood flow in the 
heart is represented by white arrows.  
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network, and finally the ventricular myocardium. The electrocardiogram (ECG), used 
to diagnose heart conditions, records cardiac electrical activity (Figure 2B). In an ECG 
a P wave is caused by atrial depolarization (atrial contraction), QRS wave complex is 
generated by ventricular depolarization (ventricular contraction) and the T wave is 
generated by ventricular repolarization (ventricular relaxation). Abnormalities in the 
cardiac electrical system are called arrhythmias (e.g. atrial fibrillation, ventricular 
fibrillation) and their occurrence and underlying electrophysiological properties, 
among other factors, are influenced by gender-related dynamics [22-24]. Cardiac 
electrical activity is associated with the generation of action potentials in single 
cardiac cells and reflects the coordinated activation and inactivation of ion channels 
that regulate depolarization (inward Na+, Ca2+) and repolarization (outward K+) 
membrane currents [25]. Ang-II modulates the electrical properties of the myocardium 
by downregulating L-type Ca2+ current and transient outward current (Ito) and by  
regulating the membrane expression of the pore-forming α-subunit underlying Ito, Kv 
4.3 [26]. Ang-II also induces arrhythmic events by modulating gap junctions formed by 
connexins, key channels for impulse propagation between neighboring 
cardiomyocytes [27].  Furthermore, Ang-II initiate delayed after-depolarization in 
pulmonary vein cardiomyocytes [28].    
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FIGURE 2. STRUCTURAL CONSTITUENTS OF CARDIAC MUSCLE FIBER AND 
TRACES OF CARDIAC CONDUCTION SYSTEM’S ELECTRICAL EVENTS. 
A- Characteristics of cardiac muscle fiber. The sarcolemma is the membrane bilayer 
that surrounds each muscle cell/fiber. T-tubules, perpendicular to the length of the 
cell, are invaginations of the sarcolemma and are rich in ion channels and proteins 
critical for synchronous activation of the cardiac muscle. T-tubules are surrounded 
with two terminal cisternae (triads in skeletal muscle, dyads in cardiac muscle) that 
serve as Ca2+ stores. The sarcoplasmic reticulum contains high levels of the ATP-
dependent Ca2+ pump (SERCA) and controls cardiac muscle contractility. The 
contractile units (sarcomeres) of the cardiac cell are composed of thin and thick 
filaments. 
B- Upper panel: ECG recordings of normal heart rhythm. P wave (atrial 
depolarization) precedes each QRS complex (ventricular depolarization) and follows 
T wave (ventricular repolarization). The P-waves are much smaller in size and shape 
compared to the QRS complex. Lower panel: ECG recordings from irregular 
“fibrillating” heart rhythm. The baseline appears noisy, no distinct P waves are seen 
and the QRS complexes appear at erratically irregular intervals.  
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1.2.5 The Pericardium 
The fibroelastic sac that encloses the heart, also known as the pericardium, 
consists of mesothelial cells and a dense fibrous layer primarily composed of collagen 
with interspersed elastic fibrils. The pericardium separates the heart from the rest of 
the thoracic cavity, preventing the heart from overfilling with blood, and protects it 
from nearby infection. Pericardial inflammation, manifested by elevated erythrocyte 
sedimentation rate, leukocytosis and abnormal C-reactive protein (CRP) levels,      
produces severe retrosternal chest pain and triggers vagally-mediated reflexes 
[29,30]. The pericardium secrets prostaglandins, in the pericardial fluid, hence the 
pericardium modulates cardiac electrophysiological properties and coronary tone [31].   
 
1.3 Cardiac Remodelling   
Heart failure is the common end product of CVD and the leading cause of 
mortality worldwide, despite recent progresses in treatment [32]. The fundamental 
pathophysiological process leading to heart failure is cardiac remodelling. Adverse 
cardiac remodelling is strongly associated with increases in cardiovascular morbidity 
and mortality [33]. Cardiac functional and structural changes, including ventricular 
enlargement and/or progressive ventricular dilatation are manifestations of the clinical 
progression of heart failure and cardiac dysfunction [34]. There is great interest in 
understanding the basic mechanisms of cardiac remodelling, to allow better 
understanding of the pathophysiological progression, which may generate novel 
clinical therapies to attenuate and/or reverse the remodelling.   
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Heart failure (HF) patients can now be classified into subcategories according 
to their ejection fraction:  heart failure associated with reduced ejection fraction 
(HFrEF) and heart failure with a preserved ejection fraction (HFpEF). The occurrence 
of these subcategories varies with age, HFrEF being more common in younger 
patients and more repetitively connected with a history of myocardial infarction, 
whereas patients hospitalized with HFpEF tend to be much older than those with 
HFrEF and are more frequently female [35]. HFrEF is more regularly associated with 
the result of loss of myocardial tissue due to a myocardial damage and therefore 
results into weakening of the pumping ability of the heart. Excessive neurohumoral 
activation, mitral valve insufficiency, ventricular remodelling, and comorbidities 
contribute to the severity of HFrEF. In contrast, HFpEF is an important heart failure 
syndrome with classical haemodynamic and neurohumoral changes of heart failure. 
Because of the important comorbidities (e.g. hypertension, diabetes, atrial fibrillation, 
aging) associated with HFpEF, advances in pharmacologic therapy had little positive 
effect in patients with HFpEF [36]. There are fundamental structural differences 
between HFrEF and HFpEF. Left ventricular dilation is a key characteristic of HFrEF 
while wall thickness relative to chamber dimension is increased in HFpEF, with 
normal ventricular chamber size [37,38]. There are also important differences at the 
cardiomyocyte, intracellular and interstitial level (Table 1) [37,39-41].        
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Table 1. Differences between HFpEF and HFrEF at the Cardomyocyte, 
Intracellular and Interstitial Level  
 HFpEF HFrEF 
   
Cardiomyocyte diameter ↑ ↓ 
Myofibrillar density ↑ ↓ 
Cardiomyocyte resting tension ↑↑ ↑ 
Cardiomyocyte calcium sensitivity ↑↑ ↑ 
Abnormal phosphorylation of 
sarcomeric proteins 
↑↑ ↑ 
Myocardial protein kinase G activity ↓ ↑ 
Myocardial oxidative stress ↑ ↔ 
Myocardial cyclic guanosine 
monophosphate concentration 
↓ ↑ 
Myocardial pro-B-type natriuretic 
peptide-108 expression 
↔/↑ ↑↑ 
Mysial collagen volume fraction ↑ ↓ 
Perivascular collagen volume fraction ↑ ↑↑ 
Scar-related collagen volume fraction ↑ ↑↑ 
Myocardial advanced glycation end 
products in diabetic HF 
↑ ↑↑ 
   ↑, increased; ↑↑, highly increased ↓, decreased; ↔, no change 
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1.4 Concepts of Cardiac Remodelling 
Cardiac remodelling is a maladaptive process by which the function, shape, 
and size of the heart are influenced by genetic factors, haemodynamic load, 
neurohormonal activation, inflammation, apoptosis, necrosis and fibrosis [42]. The 
cardiac structural and functional equilibrium can be challenged by internal and 
external factors causing altered transcriptional (RNA), posttranscriptional (microRNA), 
translational (protein), cellular, electrophysiological and interstitial changes of the 
heart. Compensatory mechanisms are triggered to reduce the adverse effects of 
remodelling and if possible, restore the equilibrium. Cardiac remodelling may be 
“physiological” and adaptive during normal growth, in healthy individuals after 
endurance training, and throughout pregnancy or may be “pathological” due to MI, 
pressure overload (aortic valve stenosis, long-standing hypertension), volume 
overload (valvular regurgitation), myocarditis, and/or cardiomyopathy [33]. Although 
the origins of remodelling are varied, they share similar molecular, biochemical and 
cellular behaviours that jointly change the structure and function of the myocardium.  
Cardiac remodelling following an acute MI results from myocyte necrosis and a 
rapid increase in loading conditions. In MI, neutrophils, monocytes and macrophages 
migrate to the infarct zone to initiate the reparation of the necrotic area [43]. The 
healing of necrotic tissue after MI triggers a cascade of cellular events that initiates 
reparative structural alterations, including dilatation, hypertrophy, and the formation of 
a collagen scar (Figure 3). The degree of cardiomyocyte loss, stimulation of the 
sympathetic nervous system, activation of the neurohormonal systems and release of 
natriuretic peptides govern the degree of remodelling. Postinfarction remodelling has  
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FIGURE 3. DIAGRAM REPRESENTING THE PATHOPHYSIOLOGICAL 
MECHANISMS OF THE EARLY AND LATE REMODELLING 
The early phase of postinfarction remodelling result in expansion of the infarct zone, 
whereas late remodelling is associated with time dependent dilatation, hypertrophy 
and fibrosis.   
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been divided into the early phase (<72 hours after coronary occlusion) which involves 
expansion and stretching of the infarct zone and late phases (>72 hours) which 
involves stretching of the left ventricle globally, dilatation with subsequent distortion of 
ventricular shape, hypertrophy and deterioration of systolic function [44-46]. Most of 
above-mentioned cardiac remodelling stimuli initially lead to compensatory cardiac 
hypertrophy in order to maintain cardiac pump function and reduce ventricular wall 
tension, but in the long run, cardiac hypertrophy itself predisposes patients to 
progressive heart failure, life-threatening arrhythmia and sudden cardiac death. The 
cardiac myocytes and cardiac fibroblasts, vital cells for the maintenance of electrical, 
biochemical, and biomechanical responsive nature of the heart, are strongly involved 
in the remodelling process (Figure 4).              
 
1.5 Components of Cardiac Remodelling 
1.5.1 The Role of Cardiac Myocyte Growth 
Cardiomyocytes are profoundly involved in cardiac remodelling processes. In 
contrast to other cell types in the heart, cardiomyocytes lose the ability to differentiate 
soon after birth [47]. Therefore, in response to an increase in biomechanical stress or 
to high levels of neurohormonal stimulation, cardiomyocytes become elongated or 
hypertrophied as part of a primary compensatory process to preserve stroke volume. 
Stretching of cardiomyocytes by pressure and/or volume overloading ultimately leads 
to the increased synthesis of the products of early-response genes: c-myc, c-fos, c-
jun and the fetal genes: beta-myosin heavy chain (β-MyHC), atrial natriuretic factor 
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(ANF) and skeletal alpha-actin (SKA), which are employed as biomarkers of cardiac 
hypertrophy [48,49]. These changes in gene expression result in the assembly of 
additional sarcomeres. The arrangements in which these sarcomeres are laid down 
(parallel vs. longitudinal) define whether cardiomyocytes elongate or increase in 
thickness.    
 
1.5.2 The Role of Cardiomyocyte Apoptosis, Necrosis, and 
Autophagy 
Programmed cellular death or apoptosis, of cardiomyocytes in the adult 
mammalian heart is activated by cardiac injury (MI, ischemia, reperfusion) and 
contributes to adverse cardiac remodelling. At the cellular level, apoptosis can be 
induced by biomechanical stretch, ROS, insufficiencies of nutrients/oxygen/survival 
factors, cell cycle perturbations and deoxyribonucleic acid (DNA) damage [50]. 
Intracellular cysteine-aspartic proteases or caspases that trigger the apoptotic 
response can also be activated by cell death receptor ligands such as tumor necrosis 
factor alpha (TNFα). The apoptotic rate in the myocardium is correlated with 
ventricular dilation, wall thinning and symptomatic evidence of heart failure [51,52]. 
Necrotic cardiomyocyte death plays a critical role in myocardial infarction and 
heart failure. In contrast to apoptotic cell death, necrosis is characterized by 
cardiomyocyte and organelle swelling, cell membrane rupture and loss of ATP. 
Necrotic cell death originates at the level of the mitochondria following sustained Ca2+ 
stress, oxidative damage, hypoxia and mitochondrial permeability transition pore 
(MPTP) opening [52,53]. Activation of TNFα represents alternative necrosis pathway 
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in cardiomyocytes under heart failure and activation of neurohumoral factors such as 
norepinephrine and Ang-II induces TNFα biosynthesis through PKC-dependent 
pathway [54,55]  
One of the crucial cellular mechanisms that mediate ischemia-induced 
adaptation and damage control is authophagy. In cardiomyocytes autophagy occurs 
via the mammalian target of rapamycin (mTOR)-dependent process in response to 
ROS, hypoxia, nutrient deprivation, injured organelles to maintain intracellular 
homeostasis and cell integrity [56]. Recent evidence suggests that autophagosome 
processing is impaired in response to prolonged cardiac stress and promote 
cardiomyocyte death, contractile dysfunction and heart failure through excessive 
digestion of vital organelles and proteins [57,58].       
  
1.5.3 The Role of Fibroblast Proliferation  
Fibroblasts make up the largest nonexcitable cellular populations of the heart. 
The role of cardiac fibroblasts in the pathogenesis of cardiac remodelling is well 
established. In response to various biological stressors, fibroblasts can migrate, 
proliferate and differentiate into myofibroblasts [59,60]. Myofibroblasts, which express 
several smooth muscle proteins, are the main sources of production of cytokines, 
growth factors (TNFα, TGF-β, platelet-derived growth factor (PDGF), interleukin (IL)-
1β, IL-6) and extracellular matrix (ECM) proteins (collagens, glycoproteins, 
proteoglycans, proteases). Disturbances of the balance between collagen synthesis 
and the activity of enzymes that degrade collagen molecules (matrix 
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metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs)) can 
induce fibrotic changes that contribute significantly to cardiac remodelling [61]. 
Furthermore, mechanical stress can elicit differentiation of fibroblasts into 
myofibroblasts both in vitro as seen in response to cyclic stretching or extended 
culture conditions and in vivo in pressure overload heart failure models [62]. The 
differentiation of fibroblast into myofibroblast is marked by increased α-smooth 
muscle actin (αSMA). The myofibroblasts contain a widespread rough endoplasmic 
reticulum and are remarkably different in terms of gene expression and phenotype 
[63]. There is growing evidence that Ang-II by inducing TGF-β secretion and PKC-
NADPH oxidase-ROS pathway induces fibroblasts to differentiate into myofibroblasts 
and plays a critical role in the progression of pathological cardiac remodeling [64,65].     
 In addition, fibroblasts may be connected to cardiomyocytes through gap 
junctional channels, composed mainly of connexins (Cx40, Cx43, and Cx45), that are 
critical for maintaining cardiac intercellular electrical and metabolic communications 
[66]. Fibrosis can form a barrier between cardiomyocytes and/or fibroblasts 
(generating abnormal cardiac electrical activity) and produce changes in cardiac 
mechanical properties that in the long run can lead to profound cardiac dysfunction 
[67].      
 
1.6 Influences on Cardiac Remodelling 
Cardiovascular remodelling can be initiated in the myocardium by means of 
two functionally disparate triggers: mechanical and neurohormonal.  
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1.6.1 Mechanical Signals  
The biomechanical stress generated by the physical stretching of adult 
cardiomyocytes is sufficient to trigger a phenotypic hypertrophic response (heart 
geometry changes from elliptical to spherical), even in the absence of neurohumoral 
signalling.  
When the heart faces increased hemodynamic/pressure load in conditions 
such as hypertension or aortic stenosis, initial changes in the ventricular morphology, 
including increased mural thickness and ventricular mass due to the enlargement of 
cardiomyocytes, assumes a crucial role in the compensation for overload and 
maintains cardiac output. This early remodelling leads to concentric hypertrophy, in 
which the ratio of wall thickness/chamber dimension increases. On the other hand, 
when the heart faces increased hemodynamic/volume load in conditions such as 
aortic regurgitation or mitral regurgitation, salt and water retention increases 
ventricular volume. Volume overload leads to compensatory eccentric hypertrophy 
with cavity dilation and decrease in the ratio of wall thickness/chamber dimension 
[68].  
According to LaPlace’s law, cardiac wall stress can be altered by changes in 
the pressure, radius or thickness of the ventricle: (pressure × radius) / (2 × wall 
thickness). However, myocardial wall tension and stress increase as a result of 
progressive ventricular dilation and insufficient development of compensatory 
ventricular hypertrophy deviating clearly from LaPlace’s feedback loop [69]. The 
mechanisms of stress-induced remodelling are not fully elucidated to date, even 
though there seems to be some overlap in the origin between mechanical and 
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neurohormonal remodelling. Nevertheless, mechanical stretch is sufficient to 
upregulate the expression of AT1R mRNA in cardiomyocytes and cause a rapid 
secretion of vasoactive Ang II [70]. Clarifying the underlying molecular mechanisms of 
mechanical stress induced remodelling may be a major factor in the early prognosis 
of heart failure.     
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FIGURE 4. THE PROGRESSION OF MYOCARDIAL REMODELLING 
Myocardial stress including a rise in hemodynamic load, neurohormonal activation 
and cardiac injury may induce a remodelling process, both at the cardiomyocyte and 
fibroblast level that over time may cause functional and structural deterioration of the 
heart leading to cardiac dysfunction and failure. 
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1.6.2 Neurohormonal Signals  
Initially, hormonal signals intervene and mediate compensatory changes in 
response to abnormal cardiac output; however, similar to mechanical signals, they 
are deeply involved in disease continuum and in the remodelling process [71]. Ang-II 
is one of the most important hormonal stimuli that is related to pathological cardiac 
remodelling and progression of heart failure. Mediators of Ang-II signaling in 
fibrogenic and hypertrophic responses consist of growth factors including: TGF-β, 
fibroblast growth factor (FGF), insulin-like growth factor (IGF), PDGF and connective 
tissue growth factor (CTGF). This will be expanded upon in succeeding sections.  
 
 
1.7 Renin-Angiotensin System 
Circulatory and tissue renin-angiotensin systems (RAS) remain one of the most 
important cardiovascular pathophysiological regulatory systems. In the human body, 
RAS play a crucial role in conserving haemodynamic stability, electrolyte and water 
homeostasis. Overstimulation of RAS is an important contributor to the 
pathophysiology of cardiac hypertrophy, failure, and arrhythmias.   
RAS activation starts when angiotensinogen, a serum α2-globulin produced in 
the liver, is excreted and converted into a decapeptide, angiotensin I, through 
hydrolysis by renin. Renin is a glycoproteolytic enzyme produced by the 
juxtaglomerular cells of the afferent arterioles of the kidney. The biologically inactive 
angiotensin I is cleaved by a dipeptidyl carboxypeptidase, angiotensin converting 
enzyme (ACE), to form the major bioactive product of the system, Ang-II [72]. ACE, 
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FIGURE 5. RENIN-ANGIOTENSIN SYSTEM 
In the classical renin-angiotensin system, angiotensinogen released from the liver is 
cleaved by renin, secreted from the kidney, to form the inactive decapeptide 
angiotensin-I. Angiotensin-converting enzyme cleaves bradykinin into inactive 
fragments and also the two amino acids from angiotensin-I to produce the active 
hormone of the system, Ang-II. The effects of Ang-II on the cardiovascular system are 
principally mediated by receptors (AT1R, AT2R) or via the release of aldosterone. 
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apart from playing a fundamental role in the production of vasoactive octapeptide 
Ang-II, it degrades bradykinin, a potent endothelium-dependent vasodilator (Figure 5) 
[73]. Ang-II, the key effector of the RAS with a variety of cardiac physiological and 
pathophysiological actions, can also be produced directly from angiotensinogen via 
ACE-independent pathways, including ACE-2-dependent pathways, tonin, tissue 
plasminogen activator (tPA), kallikrein, cathepsin G and chymase [74-77].  
A large body of evidence now indicates that the heptapeptide Ang-(1-7) plays 
an important biological role in the cardiac RAS. Ang-(1-7) is formed directly from Ang-
II through hydrolysis by angiotensin-converting enzyme (ACE-2), as well as 
prolylcarboxypeptidase (PCP) and prolylendopeptidase (PEP). [78,79] In 
cardiomyocytes, Ang-(1-7) binds to the Mas receptor and activates the 
phosphatidylinositol 3-kinase (PI3-K)-protein kinase B (Akt)-signaling cascade, 
causing nitric oxide synthase (NOS) 3 activation and NO/cGMP generation [80]. 
Furthermore, Ang-(1-7) prevents Ang-II-induced pathological remodeling by 
preventing nuclear factor of activated T cells (NFAT)  translocation to the nucleus and 
activation of hypertrophic genes [81]. Cardiomyocyte specific genetic ablation of  the 
Mas receptor leads to reduced SERCA2 expression, Ca2+ transients and slower 
Ca2+ uptake [80].  
Ang-II mediates its physiological effects by stimulating two distinct biological 
receptors, AT1R and AT2R and by inducing secretion of aldosterone from the adrenal 
gland. Both Ang-II receptors are formed by seven transmembrane-spanning α-helices 
and are members of the GPCR superfamily commonly recognized as integral plasma 
membrane proteins. In the human myocardium, both AT1R and AT2R are expressed 
 25 
 
at the mRNA and protein levels and have similar affinities for Ang-II [82]. Radioligand 
binding studies on rat cardiomyocyte membrane-enriched preparations revealed that 
cardiomyocytes possess similar levels of AT1R and AT2R and that their expression is 
upregulated during the neonatal period and after myocardial infarction[83]. Similarly, 
RT-PCR experiments confirmed that both AT1R and AT2R are expressed in human 
cardiac fibroblasts with AT1R being the predominant isoform [84].   
 
1.7.1 Angiotensin Type 1 Receptor Signalling 
The AT1R mediates most of the known physiological actions of Ang-II in 
cardiovascular, neuronal, renal, endocrine, hepatic and other target cells. The 
physiological effects are initiated when the ligand binds to the extracellular side of the 
receptor, causing a change in receptor conformation. This leads to an interaction 
between the receptor and a heterotrimeric GTP-binding protein (G protein) consisting 
of alpha (α), beta (β) and gamma (γ) subunits. Agonist binding promotes the receptor 
to adopt an active conformational status that accelerates the hydrolysis of guanosine 
5′-triphosphate (GTP) to guanosine 5'-diphosphate (GDP) by the Gα subunit and 
causes dissociation of the Gα from the Gβγ complex. Both Gα and Gβγ may interact 
with effectors or ion channels and regulate their activity. 
AT1R signalling involves the activation of multiple Gα subunits including Gq/11, 
Gi, Go, G12, G13 in various cellular contexts, followed by activation of effectors such as 
phospholipase C (PLC) and adenylyl cyclase (AC) (Figure 6) [85]. Once activated, 
PLC hydrolyses PIP2 to generate IP3 plus 1,2-diacylglycerol. IP3, in turn, binds to IP3 
receptors, releasing calcium ions (Ca2+) from intracellular stores. The resulting rise in 
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FIGURE 6. SIGNAL TRANSDUCTION PATHWAYS ACTIVATED BY AT1R / AT2R 
AT1R signalling involves the hydrolysis of PIP2 by PLC to produce DAG and IP3. IP3 
stimulates the release of calcium, whereas DAG activates PKC. AT1R leads to the 
activation of Rac-NADPH oxidase, a major source of cellular ROS. Activated AT1R 
can also transactivate RAS-RAF-MEK-ERK1/2 and RhoGEF-RhoA-ROCK-JNK 
signalling cascades. AT2R signalling is coupled to protein phosphatases (SHP-1, 
MKP-1, PP2A) that leads to inhibition of ERK1/2 pathway. AT2R also regulates the 
NO-cGMP system and stimulates PLA2. Signalling pathways activated by Ang-II have 
been correlated to specific negative responses in cardiomyocytes, VSMCs, 
endothelial cells and fibroblasts. 
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Ca2+ concentration can activate downstream Ca2+-dependent enzymes and induce 
cell growth responses in cardiac myocytes, cardiac fibroblasts and VSMCs [86-88]. 
AT1R also activates receptor and non-receptor tyrosine and serine/threonine kinases 
such as extracellular-signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase 
(JNK), protein kinase B (Akt/PKB), PI3K and protein kinase C (PKC) [89]. Ang-II can 
also activate small GTP-binding proteins including Ras, Rac, Rho, and Arf through 
AT1R in cardiomyocytes. Ang-II activates Ras by recruitment of guanine nucleotide 
exchange factors (GEFs) such as SOS (son of sevenless) through adaptor proteins 
Shc (Src homology 2 domain containing) and Grb2 (growth factor receptor-bound 
protein 2) and consequently activates ERK1/2-dependent pathways [90]. In cardiac 
cells, Rac mediates Ang-II stimulation of ROS production through NADPH-oxidase 
activation [91,92]. Rho plays an essential role in actin cytoskeleton remodelling and in 
the Ca2+ sensitization of VSMC contraction: Rho/Rho-kinase (ROCK) signalling is 
critical for vascular remodelling induced by Ang-II [90]. In cardiomyocyte AT1R 
activation via G12/13 Rho/ROCK through RhoGEF mediate JNK and p38 MAPK 
activation and leads to increased cell contraction and hypertrophy [93].  
β-arrestin and the GTPase activity of dynamin-dependent process play a 
central role in regulating AT1R desensitization (uncoupling of AT1R from G-protein 
signalling) through G protein-receptor kinase (GRK)-mediated phosphorylation at 
physiological Ang-II concentrations [94]. Moreover, increasing experimental evidence 
suggests that selective activation of AT1R signaling through β-arrestin, referred to as 
biased signaling, promotes cardioprotective biochemical signaling in cardiac cells 
[95]. Selective activation of AT1R by β-arrestin-biased AT1R ligand, TRV027, 
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increases cardiac contractility, promotes cardiac unloading, promotes cardiomyocyte 
survival, and blocks cardiac hypertrophy [96,97]. AT1R endocytosis (ligand bound cell 
surface AT1R internalization) in rat aortic smooth muscle and adrenal glomerulosa 
cells occurs via clathrin-coated vesicles [98,99]. Internalized receptors are either 
degraded in lysosomes or dephosphorylated and recycled (Figure 7). In cardiac 
muscle cells, lipid raft-associated caveolins (Cav1, 2, and 3) have been identified as 
trafficking chaperones and serve a central role in AT1R maturation and transport to 
the cell surface [100].      
 
1.7.2 Angiotensin Type 2 Receptor Signalling 
The AT2R shares almost 35% sequence homology with the AT1R and 
contains in its extracellular N-terminus five glycosylation sites [101]. AT2R is distinct 
from AT1R in tissue specific expression, intracellular signal transduction mechanisms 
and physiological actions. AT2R is the predominant subtype during fetal 
development, is particularly expressed in the heart, adrenals, and uterus and is 
upregulated in pathological conditions associated with tissue remodelling or 
inflammation. The expression of AT2R is modulated by IGF, TGF-β and basic 
fibroblast growth factor (bFGF) [101]. In contrast to AT1R, AT2R exerts anti-growth, 
anti-hypertrophic and pro-apoptotic effects. The growth-inhibitory actions of AT2R are 
mediated by the activation of a series of cytosolic protein serine-threonine and 
tyrosine phosphatases (PTPases) including Src homology region 2 domain-containing 
phosphatase-1 (SHP-1), the serine/threonine protein phosphatase 2A (PP2A) and the 
mitogen-activated protein kinase phosphatase-1 (MKP-1), resulting in inactivation of 
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ERK 1/2 [102,103]. In neonatal cardiac myocytes and fibroblasts, AT2R activation 
negatively regulates AT1R-dependent growth, suggesting that Ang-II simultaneously 
exerts divergent actions on myocardial biology [83,104]. Proapoptotic effects of AT2R 
have been observed in adult rat VSMCs, R3T3 mouse fibroblasts, human umbilical 
venous endothelial cells, PC12W cells and R3T3 mouse fibroblasts [105-108]. In 
vascular endothelial cells, AT2R-Gi activation triggers the production of cyclic 
guanosine 3’,5’-monophosphate (cGMP) through a mechanism involving bradykinin 
receptors and NO. Unlike AT1R, AT2R does not undergo rapid desensitization and 
internalization. AT2R is phosphorylated by PKC, but not GRK. Thus AT2R does not 
interact with β-arrestins, which may explain its lack of agonist-induced internalization 
[109].   
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FIGURE 7. AT1R MEDIATED DESENSITIZATION, INTERNALISATION, 
RECYCLING AND DEGRADATION   
Upon Ang-II stimulation, the AT1R is phosphorylated on serine/threonine residues by 
GRK, which facilitates the translocation and binding of β-arrestins. β-arrestin binding 
sterically precludes the interaction between the AT1R and heterotrimeric G proteins 
leading to termination of intracellular signalling. The AT1R/β-arrestin complex then 
recruits and binds components of the clathrin-mediated endocytic pathway, including 
clathrin and adaptor protein 2 (AP-2). Following receptor sequestration, the AT1R 
accumulate in endocytic vesicles and are sorted for either degradation or recycling 
back to the membrane.  
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1.7.3 RAS Inhibition to Prevent Cardiac Remodelling 
RAS inhibition has become one of the most successful therapeutic approaches 
in cardiovascular medicine. RAS inhibition has repeatedly been shown in clinical trials 
to attenuate adverse myocardial remodelling and improve cardiac function in heart 
failure patients.   
1.7.3.1 ACE Inhibitors  
ACE inhibitors (ACEI) block the ACE-mediated conversion of angiotensin-I to 
Ang-II and also antagonize the breakdown of vasoactive bradykinin into inactive 
fragments. However, because of the existence of several alternative enzymatic 
pathways, the ability of ACEIs to completely suppress Ang-II production may be 
limited.   
 
1.7.3.2 AT1R blockers 
AT1R blockers (ARBs) prevent the interaction of Ang-II with AT1R receptor 
and hence inhibit the activation of intracellular cascades leading to adverse changes 
at the transcriptional level. Because ARBs block the effects of Ang-II from any source 
(including non-ACE systems) they might be expected to be more effective than ACEI 
in heart disease. However, clinical trials have not provided convincing evidence for 
the superiority of ARBs compared to ACEI. ARBs remain an excellent substitute in 
ACEI-intolerant patients. Despite the attractiveness of the pharmacological rationale, 
clinical evidence does not support the superiority of dual blockade of RAS with a 
combination of ARBs and ACEIs.         
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1.7.3.3 Renin inhibitors 
Incomplete inhibition of RAS with ACEIs and ARBs lead to a substantial 
compensatory increase in the circulating levels of renin. Inhibition of RAS with renin 
inhibitors was an attractive pharmacological option since it prevents the formation of 
Ang-II, the activation of AT1R and the alterations in bradykinin metabolism. Clinical 
trials are currently underway to study this promising means of blocking the RAS.        
 
1.8 Heart diseases in which the RAS is implicated in 
adverse cardiac remodelling 
1.8.1 Cardiac Hypertrophy 
Left ventricular hypertrophy (LVH) is a fundamental manifestation of an 
adaptive response to long-lasting increases in systemic blood pressure directed to 
counterbalance left ventricular wall stress [110]. The defining features of hypertrophy 
at the cellular level are an increase in cardiomyocyte size, enhanced protein 
synthesis, and a higher organisation of the sarcomere. Changes in cardiomyocyte 
phenotype, both in the case of concentric (muscle fiber thickening) and eccentric 
hypertrophy (muscle fiber lengthening), are accompanied by a reinduction of the fetal 
gene program [111]. LVH, clinically detected using electrocardiographic and cardiac 
magnetic resonance imaging (MRI) techniques, strongly predicts cardiovascular 
morbidity and mortality events in patients with uncomplicated essential hypertension 
[112]. Aortic or mitral regurgitation, aortic stenosis, coronary heart disease and dilated 
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cardiomyopathy contribute to the pathogenesis of LVH. Induction of LVH is 
multifactorial, sustained by a number of circulating or locally produced growth factors, 
cytokines, and hormones including aldosterone, Ang-II, and inflammatory mediators 
[113]. In its early stages, LVH is able to compensate in the face of increased load, but 
in later stages the diastolic and systolic functions of the left ventricle become 
impaired, resulting in decompensation leading to heart failure.   
The cardiac circulatory and tissue RAS play a key role in the pathophysiology 
of cardiac hypertrophy. The cardiac RAS is able to regulate Ang-II production levels 
within the myocardium, independent of systemic Ang-II synthesis. Mechanical stretch, 
and in vitro model of load-induced cardiac hypertrophy, induces the release of Ang-II 
from cardiomyocytes, which acts as an initial mediator of stretch-induced hypertrophic 
remodelling [70]. In neonatal cardiomyocytes, Ang-II induces the expression of 
immediate-early genes including c-fos, c-jun, jun B, Egr-1, and c-myc (predominantly 
via AT1R) and fetal genes including SKA and ANF. Furthermore Ang-II augments 
protein synthesis, enhances TGF-β and PDGF production, and increases cell size 
[114]. AT1R and AT2R expression, angiotensinogen mRNA, ACE mRNA and activity 
are all increased in hypertrophy [115,116]. Multiple signal transduction cascades are 
activated in response to AT1R stimulation to promote molecular and morphological 
features of the hypertrophic response. Ang-II, acting via AT1R, activates the PLC-
PKC-SRE pathway, which induces c-fos gene expression [117]. Ang-II regulates 
overall protein synthesis, a cardinal feature of hypertrophy, through rapid and 
sustained activation of 70-kDa S6 kinase (p70S6K) [118]. The ERK1/2 pathway 
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mediates the Ang-II induced increase in ANF expression whereas RhoA mediates the 
Ang II–induced sarcomeric actin reorganization in cardiac myocytes [119]. 
In rat models of MI induced by coronary artery ligation, immediate therapy with 
losartan (ARB) and captopril (ACEI) were equally effective in reducing cardiomyocyte 
hypertrophy and long-term mortality [120]. In a heart failure model, ACEI and ARBs 
have a cardioprotective effect manifested by reduction of left ventricular remodelling 
[121]. In the recent Losartan Intervention For Endpoint reduction in hypertension 
(LIFE) trial, hypertensive patients with electrocardiographically documented LVH were 
randomly assigned to receive either losartan or atenolol (β1-adrenergic receptor 
blocker).  Patients taking losartan displayed significantly less hypertrophy; although 
the blood pressure lowering effects were similar with atenolol, losartan was more 
effective in preventing cardiovascular morbidity and mortality [122]. Similarly, in the 
Heart Outcomes Prevention Evaluation (HOPE) study, the ACEI ramipril prevented 
the development of LVH in hypertensive patients with controlled blood pressure and 
furthermore was associated with reduced risk of adverse cardiovascular events and 
improved survival [123]. In patients receiving hemodialysis, ACEI and ARB treatment 
reduced the incidence of LVH, but the combination of ACEI with ARB did not translate 
into a prognostic benefit [124]. The Ongoing Telmisartan Alone and in Combination 
With Ramipril Global End Point Trial (ONTARGET) provided further evidence that the 
combination of telmisartan (ARB) with Ramipril does not provide any additional 
benefit in preventing LVH  in patients at high risk [125].   
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1.8.2 Atrial Fibrillation 
Atrial fibrillation (AF) is the most frequent disorder of cardiac rhythm 
encountered in clinical practice. During AF episodes, atrial contractions are irregular 
and chaotic; the atria fire very rapidly at rates ranging from 300 to 600 bpm; the 
electrical impulses propagate in a highly irregular manner through the AV node; and 
the blood flow from the atria to the ventricles is often disturbed [126]. The incidence of 
AF raises dramatically with advancing age, with an annual incidence of 3.1 cases in 
man and 1.9 cases in women per 1000 person for those who fall within the age range 
of 55 to 64, increasing to 38.0 cases in man and 31.4 cases in women per 1000 
person for those who fall within the age range of 85 to 94 [127]. The risk of stroke 
associated with AF also increases with age, from 1.5% for the 50 to 59 age group to 
23.5% for the 80 to 89 age group [128]. AF is a progressive cardiac arrhythmia and its 
likelihood increases with the presence of structural heart disease. Early episodes of 
erratic electrical signals and rapid heart rate resolve spontaneously within a week 
(paroxysmal AF) but it can also continue for longer periods (persistent AF). Over time, 
frequent and longer lasting episodes of paroxysmal and persistent AF can result in 
permanent AF [129]. The progressive nature of this arrhythmia is consistent with 
observations that AF causes electrical, contractile and structural remodelling such 
that AF begets AF [130]. The cornerstones of AF management are rate control and 
rhythm control, along with anticoagulation therapy.   
A hallmark of continuous structural remodelling of the atria associated with AF 
is atrial dilatation and increased atrial pressure. Atrial dilation cause atrial tissue 
stretching, modifies effective atrial refractoriness, and triggers activation of hormonal 
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RAS, which leads to atrial fibrosis [131]. Ang-II production induces atrial dilatation 
with marked increase in fibrous tissue content, AF and sudden death in a mouse 
model with 100-fold cardiac ACE overexpression [132]. Ang-II concentrations and 
ERK1/2 phosphorylation are increased in a canine congestive heart failure model and 
in patients with atrial fibrosis [133,134]. Ang-II has a direct influence in stimulating 
atrial fibroblast proliferation and collagen synthesis via the AT1R/MAPK 
phosphorylation pathway [134]. Levels of ECM-related molecules in the atrium 
correlate with atrial fibrotic pathophysiology [135,136]. Ang-II interferes with collagen 
degradation by governing tissue MMP and TIMP expression [137]. Ang-II also 
upregulates growth factors such as TGF-β, and activates downstream signalling 
cascades to promote the expression of collagen and enhance atrial fibrosis [138].  
Since RAS plays a central role in the development of atrial fibrosis that favours 
prolonged episodes of AF, inhibitors including ACEIs and ARBs should, in theory, be 
beneficial in preventing the occurrence and progression of AF. In the recent GISSI-AF 
trial, valsartan (ARB) didn’t reduce the risk of recurrences of AF in patients with a 
history of AF associated with cardiovascular disease, type 2 diabetes, or left atrial 
dilatation [139]. In a different clinical trial, irbesartan (an ARB) was not able to reduce 
cardiovascular events in patients with permanent AF [140]. In ANTIPAF, a 
prospective multicenter trial, one year olmesartan (ARB) therapy didn’t reduce the 
number of AF episodes in paroxysmal AF patients [141]. The ongoing Canadian Trial 
on AF (CTAF-2) is presently testing the effect of perindopril (ACEI) on recurrences of 
AF [142].  
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1.8.3 Heart Failure 
HF is a major clinical and public health problem, associated with substantial 
mortality, morbidity and healthcare costs, occurring most frequently in the elderly 
[143]. HF can result from any number of cardiac structural or functional changes and 
can be subdivided into HFrEF and HFpEF). In HFrEF, cardiac contractility is 
decreased, whereas in HFpEF there is impaired ventricular relaxation.  
Initially, neurohormonal (e.g., SNS, RAS) activation can maintain blood 
pressure and circulatory homeostasis by increasing cardiac contractility, heart rate 
and vascular tone in HF. However, in the long run these neurohormones lead to 
adverse remodelling and result in clinical deterioration of HF and progressive left 
ventricular dysfunction [144]. In cardiac cells, Ang-II can trigger necrosis, apoptosis 
and myocardial fibrosis by altering the composition of ECM. 
ACE inhibitors are routinely used as first line treatment in all patients with a 
recent history of MI and reduced ejection fraction to prevent symptomatic HF [145]. 
The benefits of ACE inhibitors in reducing overall mortality and morbidity have been 
demonstrated in large, prospective and randomized clinical trials. However, 5% to 
20% of patients treated with ACE inhibitors develop renal dysfunction, angioedema, 
hyperkalemia, and/or cough. ARBs offer an alternative approach to inhibit the RAS for 
ACE-intolerant patients. In the Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM)-Alternative trial, candesartan was well 
tolerated and reduced cardiovascular mortality and morbidity in HF patients, however 
no benefit was seen in patients with HFpEF [146]. In another clinical trial, the 
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combination of valsartan (ARB) and captopril (ACEI) showed an increase in the rate 
of adverse events without improving survival versus either agent alone [147]. 
 
1.9 Mediators of RAS Communication in Fibrogenic 
and Hypertrophic Responses 
1.9.1 Transforming growth factor-β 
TGF-β is a ubiquitously expressed protein that activates the fibrotic response 
principally through the activation and differentiation of cardiac fibroblasts. TGF-β 
exists in three isoforms including TGF-β1, TGF-β2 and TGF-β3 and is primarily 
produced as a complex bound to latent TGF-β binding protein (LTBP) [148]. TGF-β 
expression can be increased by mechanical stretch, altered pH, high-energy 
radiation, Ang-II, MMPs, plasmin, or integrins and its synthesis is markedly enhanced 
in animal models of heart failure [149-151]. Once activated, TGF-β binds directly to 
the TGF-β type II receptor (TGF-βR2) and subsequently recruits and dimerizes with 
the TGF-β type I receptor (TGF-βR1) to activate downstream signalling pathways. 
TGF-β receptors contain a serine/threonine kinase domain that allows TGF-βR2 to 
phosphorylate TGF-βR1 and then to propagate the signal through the 
phosphorylation of receptor regulated SMADs (small mothers against 
decapentaplegic) (rSMADs: SMAD 1,2,3,5, and 8). Phosphorylated rSMADs undergo 
homotrimerization and associate with a common-mediator SMAD (coSMADs: SMAD 
4). The activated SMAD complexes are then translocated into the nuclear 
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compartment where they bind to transcription promoters/DNA-binding cofactors and 
regulate the expression of target genes. The inhibitory SMADs (iSMADs: SMAD 6 
and 7) compete with rSMADs or coSMADs to negatively regulate TGF-β signalling 
[152]. Similarly, ubiquitylation of SMADs in the nucleus followed by proteasome-
mediated degradation terminates TGF-β signalling [153].  
TGF-β critically modifies fibroblast phenotype, promotes myofibroblast 
differentiation and enhances ECM protein synthesis, particularly of collagen and 
fibronectin [149]. Responses to Ang-II, which play a fundamental role in producing 
maladaptive hypertrophy in the failing heart, are mediated in part when Ang-II initiates 
TGF-β signalling (Figure 8). Serum TGF-β1 levels are correlated with left ventricular 
mass and diastolic internal dimension in hypertensive patients [154]. Peripheral 
venous TGF-β1 plasma levels are also increased in aortic stenosis patients and are 
associated with increased aortic transvalvular gradients and hypertrophy [155]. In 
addition, atrial myocardial expression of TGF-β1, TGF-βR2 and SMADs (1, 2, 4, 7) 
are upregulated and lead to structural atrial remodelling/fibrogenesis in patients with 
AF [156]. Transgenic mice overexpressing TGF-β1 exhibit important myocardial 
hypertrophy accompanied by increased deposition of ECM constituents [157]. In a rat 
model of cardiac pressure overload, produced by constricting the suprarenal 
abdominal aorta, TGF-β expression levels are significantly higher, myocardial fibrosis 
is progressive and severe diastolic dysfunction develops. In this model, TGF-β 
blockade reverses pressure overload triggered fibroblast activation, collagen mRNA 
synthesis, cardiac fibrosis and diastolic dysfunction [158]. Furthermore, in a rat model 
of chronic NO-synthase inhibition, neutralizing monoclonal antibodies raised against  
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FIGURE 8. SCHEMATIC ILLUSTRATING THE NETWORKING BETWEEN ANG-II 
AND TGF-β IN CARDIAC REMODELLING 
Ang-II released upon pressure overload upregulates TGF- β mRNA and protein in 
fibroblasts and cardiomyocytes. TGF-β via paracrine and autocrine cellular responses 
can induce fibrotic and hypertrophic changes leading to cardiac structural remodeling. 
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TGF-β inhibited fibroblast proliferation and supressed the expression of inflammation-
promoting proteins (MCP-1, ICAM-1 and P-selectin) [159]. 
 
1.9.2 Connective tissue growth factor    
CTGF is a profibrotic actor playing an important role in the pathophysiology of 
myocardial remodelling. CTGF is a matricellular regulatory protein expressed in 
cardiomyocytes and fibroblasts, and is involved in intracellular signal transduction 
pathways leading to hypertrophy, angiogenesis, cellular adhesion and migration, 
proliferation and myofibroblast differentiation, with subsequent ECM deposition and 
remodelling ultimately leading to scar formation, tissue remodelling and myocardial 
fibrosis [160]. CTGF, first extracted from human umbilical vein endothelial cells, is a 
member of the CCN (Cyr61, Ctgf, Nov) gene family, and contains four conserved 
structural modular domains composed of insulin-like growth-factor (IGF-1) binding 
protein domain, von Willebrand factor type C (VWC) repeat domain, thrombospondin 
type 1 (TSP-1) repeat domain, and a carboxyl-terminal (CT) cysteine-knot domain 
[161].  
In experimental animal models as well as in humans, CTGF mRNA and protein 
expression are upregulated in heart failure of both ischemic and non-ischemic 
etiologies and the degree of upregulation is associated with the severity of disease 
[162,163]. Similarly, in genetically hypertensive rats, cardiac CTGF levels are 
positively associated with blood pressure [164]. In addition, cardiac CTGF secretion is 
upregulated by mechanical stretch, static pressure, Ang-II, endothelin-1 (ET-1), 
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aldosterone, TGF-β and brain natriuretic peptide (BNP) [165,166]. Treatment with the 
AT1R antagonist losartan prevents the induction of myocardial CTGF mRNA in 
experimental post-MI rats [167]. Similarly, in adult mouse atrial cells, ETA (BQ123) 
and ETB (BQ788) inhibitors abolished ET-1 induced CTGF expression and CTGF 
silencing attenuated ECM accumulation [168]. Cardiovascular remodelling associated 
with diabetes was reversed in a rat model treated with CTGF inhibitor FG-3019 [169].      
CTGF signal transduction triggers changes in cellular responses through 
interactions with multiple molecules including cytokines and growth factors (IGF-1, 
BMP, TGF-β, VEGF), matrix proteins (fibronectin, heparin sulfate proteoglycans), 
integrins and receptors (LRP1, LRP6, TrkA) [169,170]. Luciferase-based gene 
reporter assays revealed that TGF-β induces CTGF expression by activating its 
promoter and in cardiac cells CTGF upregulation is correlated with increased 
production of collagen type I, fibronectin, and plasminogen activator inhibitor-1 [171]. 
Furthermore, in normal rat kidney (NRK) fibroblasts and human foreskin fibroblast 
cultures, blockade of CTGF with both specific anti-CTGF antibodies and antisense 
CTGF gene constructs inhibits TGF-β stimulated collagen synthesis [172]. In cardiac 
allografts, TGF-β and IL-6 induce CTGF expression and CTGF neutralization 
improves graft fibrosis and hypertrophy associated with cardiac rejection. SMAD and 
STAT3 binding response elements were identified in the 5’ region upstream of the 
CTGF promoter, supporting the role of CTGF as downstream regulator and an 
interesting target for HF therapy [173].    
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1.9.3 Platelet-derived growth factors  
PDGFs are multifunctional prototypic growth factors with wide-ranging actions, 
extensively involved in stimulation of cell growth and cell division, and contribute to 
the maintenance of connective tissue in the adult heart [174]. They are composed of 
four inactive isoforms (PDGF-A, B, C, D); these form homodimers and/or 
heterodimers through intermolecular disulfide linkages to become functional after 
biosynthesis and processing [175]. To exert their biological activities, PDGFs signal 
through tyrosine kinase α and β PDGF-receptors (PDGFRα, PDGFRβ). PDGF 
activated cell proliferation is mediated via ligand induced dimerization of PDGFRα 
and/or PDGFRβ and subsequent phosphorylation resulting in activation of 
downstream RAS/ERK1/2 signalling pathways [176]. PDGF contributes to Janus 
tyrosine kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway activation through ROS production, and plays a key role in cell 
transformation and inflammatory processes [177]. PDGF also activates cell migration, 
attachment, proliferation and collagen expression through the focal adhesion kinase 
(FAK)-phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway [178,179].  
PDGF isoforms and receptors are expressed in cardiomyocytes and fibroblasts 
and are significantly upregulated in the infarcted myocardium, in cardiac hypertrophy, 
fibrosis and AF [180-183]. PDGF-C overexpression in a transgenic mouse heart using 
the α-myosin heavy chain promoter induces progressive fibrosis and hypertrophy 
leading to dilated cardiomyopathy and HF [184]. Recombinant adeno-associated virus 
(AAV) PDGF-A, PDGF-B, and PDGF-D gene transfer in mice accelerated cardiac 
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fibrosis development compared to PDGF-B that displayed minimal fibrotic effect [185]. 
PDGF-D/PDGFRβ signal transduction promotes fibrogenesis through enhanced 
synthesis of TGF-β, MMP1, MMP2, MMP9 and TIMP1, TIMP2 in cardiac fibroblasts 
[186]. In addition, desoxycorticosterone (DOCA) induced salt-sensitive hypertensive 
rats experience massive collagen deposition through PDGF/PDGFR signalling, and 
stimulate the growth, differentiation and migration of fibroblasts, resulting in 
myocardial fibrosis [179]. Similarly, Ang-II upregulates PDGF-A expression through 
the activation of the Kruppel-like zinc-finger transcription factor (KLF5). KLF5 is a key 
determinant of cellular response and tissue remodelling. Hearts of KLF5 knockout 
mice infused continuously for 14 days with Ang-II had comparatively thinner 
ventricular walls, reduced heart weight to body weight ratio and significantly lower 
interstitial and perivascular fibrosis compared to wild type Ang-II infused animals 
[182].   
 
1.9.4 Fibroblast growth factors  
FGFs mediate cardiac fibroblast behaviours and restore ECM homeostasis and 
regulation. They play distinct but overlapping roles in cardiac remodelling. Of the 23 
FGF isoforms identified to date, FGF-2 is predominantly expressed in the heart and is 
the most studied. FGF-2, also recognized as basic FGF (pI>9.0), consists of a low 
molecular weight (Lo-FGF-2) and a high molecular weight (Hi-FGF-2) isoform 
produced by alternate initiation of translation from the FGF-2 mRNA, and is highly 
conserved amongst different species [187]. FGF-2 may be released through 
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exocytosis by means of Na+/K+-ATPase, transient membrane disruptions due to 
sustained increase in cardiac work, cardiomyocyte contraction and migration of 
endothelial cells [188-191]. The biological actions of FGF-2 in the heart are mediated 
by a cell surface tyrosine kinase FGF receptor (FGFR-1). Stimulation of FGFR-1 in 
cardiac cells results in activation of its downstream target PLC, translocation of PKCɛ 
to the plasma membrane and opening of mitochondrial K+/ATP channels. PKC can 
also phosphorylate connexin43 leading to decreased cardiomyocyte metabolic 
coupling [192]. In addition, FGF-2 can also activate ERK1/2, JNK and p38 kinases 
[193]. 
Initial studies provided evidence that FGF-2 is a cardioprotective and a 
physiological survival growth factor acting via autocrine/paracrine actions on cardiac 
cells. FGF-2 regulates survival of cardiomyocytes early in cardiogenesis and is a key 
factor in the maintenance of cardiovascular physiology [194]. During ischemia–
reperfusion injury, injection of FGF-2 protects against myocardial injury and 
contractile dysfunction [195]. In vivo, FGF-2 overexpression in transgenic mice 
increased myocyte viability and reduced infarct size [196].   
In contrast to its cardioprotective actions, recent studies have established a 
role of FGF-2 in the cardiac hypertrophic response. In vitro, FGF-2 increases both 
fibroblast and myofibroblast proliferation, and is associated with cardiomyocyte 
growth and reexpression of fetal gene contractile proteins [197]. Mice lacking the 
FGF-2 gene subjected to aortic coarctation had reduced left ventricular mass, wall 
thickness and cardiomyocyte cross-sectional area compared to wild-type mice [198]. 
In neonatal cardiomyocytes, Ang-II binding to AT1R and subsequent activation of 
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ERK1/2 and p38 MAPKs can increases GATA4 binding activity to the FGF-2 
promoter and upregulate the expression of FGF-2 [199]. Ang-II induced hypertensive 
mice lacking FGF-2 do not develop hypertrophy and MAPK (ERK, p38, JNK) 
activation appeared to be reduced [200].  
 
1.10 Intracellular RAS: Implications in 
Cardiovascular Remodelling 
Traditionally, the RAS hormonal pathway was viewed as a circulatory and 
tissue specific system. However, recent studies support the notion of intracellular or 
intracrine RAS, defined by the presence of complete and functional RAS within a 
single cell. Internalization of non-glycosylated prorenin, a biosynthetic precursor of 
renin, in adult cardiomyocytes, results in a significant increase in intracellular Ang-II 
(iAng-II) levels [201]. iAng-II production in neonatal rat ventricular myocytes (NRVM), 
using recombinant adenoviral and plasmid expression vectors, induces cytoskeletal 
reorganization, augments cellular [3H]leucine incorporation, and increases cardiac 
levels of c-jun, IGF-1 and TGF-β mRNA. Furthermore, injection of adenoviral vectors 
constructed to express Ang-II intracellularly in adult mouse heart resulted in 
biventricular cardiac hypertrophy and administration of the AT1R inhibitor, losartan, 
had no influence on the induction of hypertrophy [202]. In diabetic patients, iAng-II 
levels are increased in cardiomyocytes by 3.4 fold and in endothelial cells by 3.1 fold 
compared to non-diabetics. An additional 2-fold increase of iAng-II was observed in 
diabetic hypertensive patients compared to diabetic non-hypertensive patient group 
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[203]. When exposed to high glucose, NRVMs synthesize and retain intracellular Ang-
II with redistribution of the peptide to the nucleus, via renin and chymase dependant 
enzyme pathways. Similarly, exposure of neonatal rat ventricular fibroblasts to high 
glucose-exposure induces the production of iAng-II, which is correlated, with 
increased levels of collagen-1 and TGF-β [204,205]. Diabetes, triggered in adult rats 
by streptozotocin, dramatically increases iAng-II concentrations in cardiac cells, 
leading to increases in oxidative stress, apoptosis and fibrosis [206]. In the latter 
study the AT1R blocker, candesartan, or the ACE inhibitor, benazepril, didn’t provide 
clear beneficial effects [206]. Intracellular administration of Ang-II by microinjection in 
isolated cardiomyocytes reduces inward calcium current (ICa), increases gap 
junctional resistance and favours the generation of re-entrant arrhythmias [207]. 
Similarly, injection of Ang-II in cardiomyocytes isolated from cardiomyopathic failing 
hearts induces an alteration in action potential duration, resting potential and 
refractoriness [208,209]. Intracellular delivery of Ang-II using a liposomal delivery 
system in A7r5 vascular smooth muscle cells promotes cell growth and modulates 
Ca2+ homeostasis [210,211]. Many of the observed intracellular Ang-II actions are not 
inhibited by traditional ARBs, most probably because of their inability of penetrating 
inside the cell. These observations further support the clinical outcomes that current 
ARBs and ACEi do not offer anticipated benefits in high-risk cardiovascular conditions 
[212].     
 
 
  
48 
 
1.11 Thesis Rationale  
  Despite many new advances in diagnosis, therapy and cardiac assist devices, 
heart failure remains a leading cause of death worldwide. The progression of heart 
failure is attributable largely to cardiac remodelling due to maladaptive alterations in 
cardiomyocyte properties and cardiac architectures. The process of cardiac 
remodelling is influenced enormously by activation of the phylogenetically ancient 
renin-angiotensin neurohormonal system. The status of the RAS has evolved into a 
complex hormonal cardiovascular regulatory system since the original discovery of 
renin, the rate-limiting enzyme of the RAS, more than a century ago. Since the RAS is 
involved in many components of the cardiovascular remodelling system, improved 
targeting of the RAS by more specific inhibition of selected components might help to 
reduce cardiovascular risk. The intracellular RAS in cardiac myocytes and fibroblasts 
is poorly understood; a better knowledge of its role may allow for the development of 
new and hopefully better anti-remodelling strategies. The main objective of this thesis 
is therefore to elucidate the role of intracellular RAS in cardiac cells, with a view to 
aiding in the design and synthesis of novel RAS inhibitors to prevent remodelling and 
improve outcome.    
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CHAPTER 2 – Subcellular distribution 
of Ang-II receptors in ventricular 
cardiomyocytes and their role in mediating 
transcriptional responses. 
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Linking Statement and Author Contribution 
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via discrete signalling systems.  
Tadevosyan A, Maguy A, Villeneuve LR, Babin J, Bonnefoy A, Allen BG, Nattel 
S. Nuclear-delimited angiotensin receptor-mediated signaling regulates 
cardiomyocyte gene expression. J Biol Chem. 2010 Jul 16;285(29):22338-49. 
A.T., B.G.A. and S.N. participated in conception and experimental design. A.T. 
carried out all of the cellular fractionations, biochemical/pharmacological assays, de 
novo RNA transcription experiments, immunohistochemistry, microinjections, calcium 
recordings, performed statistical analysis and wrote the first draft of the manuscript 
(Figures 1-9). A.M. provided technical assistance for biochemical assays. L.V. 
acquired all of the immunocytochemistry images. J.B. and A.B. provided help with the 
endocytosis experiments. B.G.A and S.N. supervised the project, provided intellectual 
input and edited the final manuscript. 
 51 
 
 
Nuclear-Delimited Angiotensin Receptor-Mediated Signaling 
Regulates Cardiomyocyte Gene Expression 
 
 
Artavazd Tadevosyan1,3, Ange Maguy3, Louis R. Villeneuve3, Judith Babin1,3, 
Arnaud Bonnefoy1,3,4, Bruce G. Allen1,2,3,5*, and Stanley Nattel1,3,5* 
 
 
From the Department of Medicine1, Department of Biochemistry2, Montreal Heart 
Institute and Université de Montréal3; INSERM U743 Université de Montréal4; and 
Department of Pharmacology and Therapeutics5, McGill University, Montreal, 
Quebec, Canada 
 
 
*Co-senior authors. 
Running head:  Nuclear envelope angiotensin receptors 
 
 
Address correspondence to:  Stanley Nattel, 5000 Belanger Street East, Montreal, 
Quebec, H1T 1C8, Canada.  Tel.: 514-376-3330; Fax: 514-376-1355;  
 
 
 
 
 
 
 
 52 
 
Abstract 
Angiotensin-II (Ang-II) from extracardiac sources and intracardiac synthesis 
regulates cardiac homeostasis, with mitogenic and growth-promoting effects largely 
due to altered gene-expression. Here, we assessed the possibility that angiotensin-1 
(AT1R) or angiotensin-2 (AT2R) receptors on the nuclear envelope mediate effects 
on cardiomyocyte gene-expression. Immunoblots of nucleus-enriched fractions from 
isolated cardiomyocytes  indicated the presence of AT1R and AT2R proteins that 
copurified with the nuclear-membrane marker nucleoporin-62 and histone-3, but not 
markers of plasma (calpactin-I), Golgi (GRP-78) or endoplasmic-reticulum (GM130) 
membranes. Confocal microscopy revealed AT1R and AT2R proteins on nuclear 
membranes. Microinjected Ang-II preferentially bound to nuclear sites of isolated 
cardiomyocytes. AT1R- and AT2R-ligands enhanced de novo RNA synthesis in 
isolated-cardiomyocyte nuclei incubated with [α32P]UTP (e.g. 36.0±6.0 cpm/ng DNA 
control vs. 246.4±15.4 cpm/ng DNA Ang-II, 390.1±15.5 cpm/ng DNA L-162313 (AT1), 
180.9±7.2 cpm/ng DNA CGP42112A (AT2), P<0.001). Ang-II application to 
cardiomyocyte nuclei enhanced NF-κB mRNA-expression, a response that was 
suppressed by co-administration of valsartan and/or PD123177. Dose-response 
experiments with Ang-II applied to purified cardiomyocyte nuclei vs. intact 
cardiomyocytes showed greater increases in NFκB mRNA levels at saturating 
concentrations with ~2 fold greater affinity upon nuclear application, suggesting 
preferential nuclear signaling. AT1R- but not AT2R-stimulation induced 
cardiomyocyte nuclear-preparation [Ca2+]-rises. Inositol-1,4,5-trisphosphate receptor 
block by 2-aminoethoxydiphenyl-borate prevented AT1R-mediated Ca2+-release and 
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attenuated AT1R-mediated transcription-initiation responses. We conclude that 
cardiomyocyte nuclear membranes possess angiotensin-receptors that couple to 
nuclear signaling-pathways and regulate transcription. Signaling within the nuclear 
envelope (e.g. from intracellularly synthesized Ang-II) may play a role in Ang-II-
mediated changes in cardiac gene-expression, with potentially-important mechanistic 
and therapeutic implications. 
 
Key Words:  angiotensin II, angiotensin receptor subtypes, nuclear envelope, gene 
regulation, transcription, remodelling 
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Introduction 
Angiotensin-II (Ang-II) is implicated in the regulation of cardiac contractility, cell 
proliferation and communication through the activation of specific heptahelical 
membrane-spanning G-protein coupled receptors (GPCRs).  Blockers of the renin-
angiotensin system (RAS) are widely used in the treatment of hypertension and heart 
failure (1-3).  There is increasing evidence that RAS components can act 
intracellularly (4-6).  Extracellular signaling peptides could operate internally following 
internalization.  Alternatively, intracellular action could occur via production of Ang-II 
within target cells. 
Neonatal cardiomyocyte stimulation by high concentrations of glucose or 
isoproterenol results in the intracellular synthesis and nuclear trafficking of Ang-II (7).  
Serum-deprived cardiomyocytes release Ang-II into the culture medium and Ang-II 
concentrations increase 100-fold upon mechanical stretch (8).  Internalization of pro-
renin into cardiomyocytes leads to the generation of intracellular Ang-II independently 
of glycosylation (9).  Introduction of Ang-II inside the cell has important effects on 
transmembrane Ca2+-currents, on cardiomyocyte conductance and potentially on the 
pathogenesis of cardiac arrhythmias (10).  Intracellular Ang-II binding sites have been 
imaged in renal and hepatocyte nuclei, but whether those receptors represent 
internalized plasma membrane receptors or a genuine new class of Ang-II receptors 
(ATRs) remains unclear (11,12).  Despite Ang-II’s fundamental role in the regulation 
of heart function and gene expression, direct demonstrations of functional ATRs 
inside cardiac cells are lacking.  Accordingly, the current study investigated the 
subcellular distribution of type 1 and 2 ATRs (AT1Rs, AT2Rs respectively) in native 
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ventricular cardiomyocytes, with particular attention to the nuclear envelope, and 
assessed evidence for coupling of such intracellular receptors to Ang-II-mediated 
transcriptional responses.   
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Materials and Methods 
Reagents and antibodies 
 The following antibodies were used for immunoblotting:  AT1R, AT2R from Santa 
Cruz (Santa Cruz, CA) and Alomone Labs (Jerusalem, Israel); calpactin-I, GM130, 
GRP-78 from BD Biosciences (Franklin Lakes, NJ); histone from Cell Signaling 
(Danvers, MA) and nucleoporin 62 from ABCAM (Cambridge, MA) (see on line Table 
I for more details).  All the secondary antibodies used for Western and 
immunostaining were from Jackson ImmunoResearch Laboratories (West Grove, 
PA).  Candesartan was kindly provided by AstraZeneca (Mississauga, Ontario) and 
valsartan by Novartis (Dorval, Quebec).  The primers for quantitative real-time 
polymerase chain reaction (qPCR) assays were purchased from SuperArray 
(Frederick, MD)/Invitrogen (Burlington, Ontario).  Unless otherwise specified, all 
reagents were of molecular biology grade and obtained from Fisher (Ottawa, Ontario) 
or Sigma-Aldrich (Oakville, Ontario).  
 
Isolation of cardiomyocytes 
Male Wistar adult rats (200-300 g) were anesthetized with a combination of 
ketamine/xylazine (10 mg/kg body weight i.p.) and treated with heparin (1.0 U/kg 
body wt).  All animal-handling procedures were approved by the Animal Research 
Ethics Committee of the Montreal Heart Institute and the procedures complied with 
guidelines established in the Guide for the Care and Use of Laboratory Animals (NIH 
Publication 65-23, revised 1996). Hearts were exposed via sternotomy, rapidly 
excised, and immersed in ice-cold Tyrode solution containing: 140 mM NaCl, 5.5 mM 
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KCl, 1 mM MgCl2, 0.3 mM KH2PO4, 10 mM dextrose, 5 mM HEPES, 2 mM CaCl2, 
adjusted  to pH 7.5 with NaOH. Left-ventricular cardiomyocytes were isolated using a 
Langendorff-perfusion system.  The hearts were cannulated via the ascending aorta 
and in situ retrograde perfusion of the coronary arteries was started with 200 μM Ca2+ 
in modified Tyrode solution (140 mM NaCl, 5.5 mM KCl, 1 mM MgCl2, 0.3 mM 
NaH2PO4, 5 mM HEPES and 10 mM dextrose adjusted to pH 7.5 with NaOH).  After 
perfusion for 3 min at 6 ml/min, the hearts were perfused with calcium-free Tyrode 
solution for an additional 5 minutes.. Subsequently, hearts were enzymatically 
digested by recirculation with Ca2+-free Tyrode solution containing 0.5 mg/ml type II 
collagenase for approximately 45 min.  When the heart softened, the left ventricle was 
minced into small pieces in Kraftbruhe medium (20 mM KCl, 10 mM KH2PO4, 10 mM 
glucose, 40 mM mannitol, 70 mM L-glutamic acid, 10 mM β-hydroxybutyric acid, 20 
mM taurine, 10 mM EGTA and 0.1% albumin; pH 7.5, NaOH).  To promote cell 
dissociation, the solution and tissue fragments were resuspended with a transfer 
pipette and the suspension was filtered through a 200 µm nylon mesh. 
Cardiomyocytes were separated from non-cardiomyocyte cells by sedimentation 
(3x200 g, 3 minutes), the supernatant was discarded or used for fibroblast isolation, 
and the final cardiomyocyte pellet was resuspended in Joklik’s Minimal Essential 
Medium (25 mM NaHCO2, 1.2 mM MgSO4, 1 mM DL-carnitine, 1 mM CaCl2, adjusted 
to pH 7.5 with NaOH). All solutions were constantly aerated with 5% CO2-95% O2, 
and solutions and cells were kept at 37°C throughout the isolation process.  Ca2+-
tolerant, rod-shaped ventricular cardiomyocytes (75 to 90% of all cells) were used on 
the day of isolation or snap-frozen at -80°C for subsequent biochemical studies. 
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Nuclei from total cardiac tissue were isolated in a similar general fashion- details are 
provided in the on-line supplement. 
  
Isolation of cardiomyocyte nuclei 
Cardiomyocytes, isolated as described above, were washed 4 times with phosphate 
buffer before the isolation of myocardial nuclei. Cells were suspended in a hypo-
osmotic buffer (10 mM Tris, 1 mM MgCl2, 10 mM NaCl, 5 mM CaCl2; adjusted to pH 
7.4 with HCl) for 30 minutes at 4ºC. The cells were sedimented at 1000xg for 10 
minutes and then resuspended in 20 ml of hypo-osmotic buffer and sonicated for 90 
seconds in a Branson 3200 sonifier. Triton X-100 (TX-100) was added to the 
sonnicated preparation to a final concentration of 0.1% and then the preparation was 
centrifuged at 1,000 x g for 10 minutes. The supernatant containing the membrane 
and cytoplasmic fractions was kept as a control for biochemical analysis. The 
resulting pellet was resuspended in 15 ml of MC buffer (2.2 M sucrose, 10 mM Tris, 1 
mM MgCl2, 0.1 mM PMSF; adjusted to pH 7.4 with HCl). This suspension was 
transferred to high-resistance centrifugation tubes underlaid with 2.5 ml of MC buffer 
and centrifuged at 100,000 x g for 60 minutes. The pellet containing the nuclear 
fraction was resuspended in buffer containing 20 mM Na-HEPES, 25% 
(volume/volume) glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM 
EGTA, 0.5 mM PMSF, 0.5 mM DTT, 25 μg/ml leupeptin, 0.2 mM Na3VO4, with a final 
pH of 7.4 (NaOH) or 1x transcription buffer (see below), and either used freshly or 
aliquoted, snap-frozen with liquid nitrogen, and stored at -80°C. Membrane proteins 
were separated from cytoplasmic proteins by centrifugation at 100,000 x g (Beckman 
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TLA 100.3 rotor) for 60 minutes. The membrane-protein containing pellets were re-
suspended in extraction buffer containing 25 mM. Tris-HCl (pH 7.4), 5 mM EGTA, 5 
mM EDTA, 1 mM Na3VO4, 0.5 mM AEBSF, 1 mM iodoacetamide, 1 mM β-2-
mercaptoethanol, 10  μg/mL aprotinin, 10 μg/mL leupeptin and 1 μg/mL pepstatin, 
supplemented with 1% Triton X-100 and stored at -80°C. Protein concentrations were 
determined by Bradford assay using a NanoDrop ND-1000 Spectrophotometer 
(Wilmington, DE).  
 Non-cardiomyocyte cell and tissue extracts used to test selectivity of the 
cardiomyocyte-isolation procedure. The purity of isolated cardiomyocytes was 
assessed by Western blot, using protein extracts prepared from cardiomyocytes, 
fibroblasts, smooth muscle cells, endothelial cells and brain rat homogenates. For the 
isolation of fibroblasts, the supernatant obtained from the cardiomyocyte isolation was 
centrifuged at 2,500 × g for 10 minutes. The pellet was resuspended in Dulbecco's 
minimal essential medium (DMEM) containing 10% fetal calf serum (FCS, Biochrom), 
1% penicillin/streptomycin and plated on 58-cm2 dishes. Four hours later, the media 
were changed and adherent cells were washed free of debris and non-attached cells. 
Smooth muscle and endothelial cells were obtained by a previously described method 
(13). The rat brain homogenate protein fraction was a gift from Dr Ling Xiao. 
  
Immunoblot analysis   
Samples were separated by sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) on 8% (w/v) acrylamide running gels with 4% (w/v) 
acrylamide stacking gels.  Proteins were transferred onto PVDF membranes at 300 
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mA and 4°C for 60 min in a transfer buffer consisting of 25 mM Tris-base, 192 mM 
glycine and 20% (v/v) ethanol.  Membranes were blocked for 120 min with a solution 
of skimmed milk powder 5% (w/v) and 0.1% (v/v) Tween 20 in PBS at ambient 
temperature.  Following blocking, membranes were incubated with the primary 
antibody (on-line Table I) overnight at 4°C with continuous mixing.  The following day, 
membranes were washed (4x12 min) with a solution containing 0.5% (w/v) skimmed 
milk powder and 0.1% (v/v) Tween 20 in PBS, then incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody (60 min at room 
temperature).  Membranes were thoroughly washed with PBS-Tween 20 (4x12 min) 
and immunoreactive bands revealed using Enhanced Chemiluminescence Reagent in 
conjunction with Bio-Max MR film (PerkinElmer Life Sciences, Waltham, MA).  
Preliminary experiments were performed to establish exposure times that avoided film 
saturation and permitted quantification.  To ensure equal protein loading, blots were 
stripped and stained using Ponceau S (0.5% Ponceau S, 1% glacial acetic acid, in 
deionized water).  Immunoblots were scanned (1200 dpi) and band intensities 
quantified with Quantity One 1D analysis software (Bio-Rad Laboratories, Hercules, 
CA).  
  
Confocal microscopy and deconvolution 
Freshly-isolated cardiomyocytes were plated on 18-mm laminin (10 µg/ml)-coated 
coverslips for 60 min (37ºC, 95% O2-5% CO2), fixed with 2%-paraformaldehyde for 20 
min and permeabilized with blocking buffer comprising 2% normal donkey serum 
(NDS) and 0.2% (v/v) TX-100 in PBS for 60 min.  After extensive washing to remove 
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the excess serum, cells were incubated overnight at 4ºC with the primary antibody 
diluted in PBS containing 1% NDS and 0.05% TX-100.  Coverslips were then rinsed 
several times with PBS and incubated for 60 min at room temperature with secondary 
antibody (Alexa 488 conjugated anti-rabbit antibody or Alexa 555-conjugated anti-
mouse antibody diluted in 1% NDS and 0.05% TX-100).  After a final wash with PBS, 
coverslips were mounted and fixed on glass slides with drop of a mixture containing 
0.1% diazabicyclo(2.2.2)octane (DABCO)/glycerol.  Fluorescence images were 
acquired using a Zeiss LSM 510 confocal fluorescence microscope (Carl Zeiss, 
Oberkochen, Germany).  Composite images were created using Zeiss LSM510 
software.  For every secondary antibody, control experiments were performed 
omitting the primary antibody to confirm the specificity of the primary antibody.  Nuclei 
were visualized using Hoechst 33342 or DRAQ5 nucleic acid stain.  Image stacks 
were digitally deconvolved (0.01% threshold, lowest background and real signal/noise 
values) for 25 iterations to reduce out-of-focus light using the Maximum Likelihood 
Estimation algorithm and the appropriate experimentally-determined point spread 
function with Huygens Professional software (version 3.1.0p1, Scientific Volume 
Imaging, Hilversum, The Netherlands).  Files were stored in ICS format and exported 
to PowerPoint (Microsoft, Redmond, WA).  
 
[α-32P]UTP RNA transcription initiation assay 
Transcription initiation assays were performed using freshly isolated cardiomyocyte 
nuclei as previously described (14).  Briefly, a mixture of nuclei (treated with ligand 
where indicated), 1x transcription buffer (50 mM Tris, 0.15 M KCl, 1 mM MnCl2, 6 mM 
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MgCl2, 1 mM ATP, 2 mM DTT, 1 U/µl RNAse inhibitor, pH adjusted to 7.4 with NaOH) 
and [α-32P]UTP were incubated for 30 min at 30ºC.  CTP and GTP were omitted to 
prevent chain elongation.  Following treatment with DNase (10 U/μl), nuclei were 
solubilized (10 mM Tris-HCl, pH 8.0, 10 mM EDTA and 1% SDS), aliquots transferred 
onto Whatman GF/C glass fibre filters (Sigma-Aldrich, Oakville, Ontario, Canada), 
washed with 5% trichloroacetic acid (TCA), and air-dried.  32P-incorporation was 
measured by Cerenkov counting in a β-counter.  The DNA concentration was 
determined spectrophotometrically and 32P-incorporation is expressed as dpm/ng 
DNA.  
 
RNA extraction, Reverse transcription, and qPCR 
Total RNA was extracted from cardiomyocyte nuclei using the TRIzol method 
(Invitrogen) after homogenization with a motor-driven mixer.  The concentration, 
quality and purity of total RNA were determined using a BioAnalyzer (Genome 
Innovation Center, Montreal, Quebec).  Total RNA was treated with DNase 1 (10 U 
for 15 min at 37ºC) to remove potential contamination by genomic DNA.  cDNA 
templates for PCR amplification were synthesized from 1 µg of total RNA with a 
reverse transcriptase kit (SuperArray).  
Quantitative PCR (qPCR) was performed using SuperArray SYBR Green PCR kits 
and a Stratagene MX3000P qPCR system.  Quantitative measurements were 
performed in triplicate and normalized to the average of three housekeeping internal 
controls (glyceraldehyde-3-phosphate dehydrogenase, β2-macroglobin, and heat 
shock protein 90-kDa α, class B member 1).  All reactions included 2 µl of cDNA and 
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0.5 µM primers.  Standard curves were made from 10-fold serial dilutions of cDNA 
pools containing high concentrations of the gene of interest.  Data was collected and 
analyzed using MX3000P software.  Relative gene expression was calculated using 
the comparative threshold cycle (Ct) method (15).  The sequences of primers used for 
qPCR are shown in on-line Table II.  
 
Ca2+-imaging 
Ca2+ concentration ([Ca2+]) was measured in isolated nuclei with the ratiometric 
calcium indicator Fura-2/AM (Sigma-Aldrich). Fura2/AM was prepared daily as a 5mM 
stock solution in dimethylsulfoxide (DMSO). Right after the isolation, freshly isolated 
cardiomyocyte nuclei were resuspended in 0.5 ml of loading buffer containing 25 mM 
HEPES, 100 mM KCl, 2 mM K2HPO4 and 4 mM MgCl2. Fura-2/AM was added to the 
suspension of isolated nuclei for a final concentration of 7.5 µM and incubated on ice 
for 45min. After an initial loading period, nuclei were washed of extracellular Fura-
2/AM by centrifugation (2700 x g for 5 min, 4 ºC) to remove non-incorporated Fura-
2/AM and were then added with 1000 µl of loading buffer containing 800 nM CaCl2 
onto fluorodish.  Ang-II, the AT1 agonist L162313, the AT2 agonist CGP42112A, IP3 
or vehicle (DMSO) were added, directly in the bath, close to a single nuclei, pre-
treated or free of selective blockers (candesartan, PD123177 or 2-
aminoethoxydiphenyl-borate (2-APB)) to make a final concentration of 10 µM.    A 
microspectrofluorimeter (IonOptix, Milton, MA) was used for fluorescence 
measurements.  Excitation wavelengths were 340 and 380 nm.  Fluorescence 
emission was detected at 509 nm and was expressed as the ratio of the two 
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excitation wavelengths (F340/F380).  The amplitudes of Ca2+-transients were 
calculated by subtraction of the baseline F340/F380 ratio from peak values.  Ca2+-
concentrations were determined by calibrating the fluorescent signal by sequential 
addition of 9 µM ionomycin plus 1 mM CaCl2 to obtain the maximal fluorescence ratio 
(Rmax) and 4 mM EGTA to obtain the minimum fluorescence ratio (Rmin).  
Autofluorescence was determined by subtracting fluorescence from non-loaded nuclei 
and from the fluorescence produced by fura-2-loaded nuclei. 
 
Assessment of intracellular components of angiotensin synthesis system 
Cardiomyocytes were lysed by sonication in ice-cold 1 M acetic acid containing a 
protease/inhibitor mixture (Sigma S8820). The lysate was sedimented at 15,000 × g 
for 15 min, and the supernatant was dried in a vacufuge, followed by reconstitution in 
1% acetic acid. The samples were applied to a conditioned DSC-18 column 
(Supelco), washed, and eluted with methanol. The eluted samples were dried and 
reconstituted in PBS for enzyme-linked immunosorbent assay (ELISA, Peninsula 
Labs). Ang-II was measured by quantitative competitive ELISA, using a specific anti-
Ang-II antibody (Peninsula Labs), which was previously validated by high-
performance liquid chromatography chip/mass spectrometric analysis (7). ELISA was 
performed on anti-Ang-II antibody-coated 96-well dishes. Competitive binding of 
synthetic biotinylated Ang-II, in the presence of the extracted peptide, was detected 
with streptavidin-horseradish peroxidase conjugate. A standard curve, generated from 
binding of a constant amount of biotinylated Ang-II with increasing concentrations of 
non-biotinylated synthetic Ang-II, was used to calculate the concentration of the 
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peptide in the sample. The concentration of Ang-II in the cell lysates is expressed as 
femtomoles per milligram of protein. Components of the Ang-II biosynthetic pathway 
(angiotensinogen, renin, angiotensin converting enzyme, and cathepsin) were 
quantified in cardiomyocyte lysates by qRT-PCR, as described above. 
 
Statistical analysis 
Data are expressed as mean ± S.E.M. ANOVA with Tukey’s post-hoc test was used 
for statistical comparison.  A P-value <0.05 was considered statistically significant. 
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Results 
 
Endogenous AT1 and AT2 Receptors Localize to Nuclei Isolated from 
Cardiomyocytes and Cardiac Tissue 
To examine the intracellular localization of AT1 and AT2 receptors, we isolated 
membrane, cytosolic, and nuclear fractions from isolated cardiac myocytes and from 
whole adult rat hearts. In initial studies, we characterized nuclear AT1 and AT2 
receptors from intact cardiac tissue preparations. However, to be sure that 
biochemical results applied specifically to cardiomyocytes, we developed a nucleus-
enriched preparation from isolated cardiomyocytes. All results shown in this paper 
were obtained from cardiomyocyte nuclei, whereas the results from cardiac tissue 
preparations are provided under supplemental data. The specificity of the isolated 
cardiomyocyte preparation was characterized by immunoblot with antibodies to 
various tissue-selective protein markers and cell populations (supplemental Fig. S1A). 
Isolated cardiomyocytes showed strong immunoreactive signals for myosin heavy 
chains, and no signals for Van Willebrand factor, neuron-specific enolase, discoidin 
domain receptor 2, or α-smooth muscle actin, which were found in the expected non-
cardiomyocyte samples. 
 
Cellular fractionations were validated by Western blots for calpactin-I (cell membrane, 
38 kDa), GRP-78 (endoplasmic reticulum, 78 kDa), Nup62 (nuclear pore central plug, 
62 kDa), histone-3 (cell nuclei, 17 kDa), and GM130 (Golgi cisternae, 130 kDa), 
respectively (Fig. 1A and supplemental Fig. 2A). Both AT1R (∼43 kDa) and AT2R 
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(∼47 kDa) immunoreactivity was detected in the membrane or crude cell fraction A, 
as were calpactin I, GRP-78, and GM130. After further purification steps, the final 
nuclear fraction or fraction D was enriched in nucleoporin 62 (Nup62), histone-3, 
AT1R, and AT2R immunoreactivity. In contrast, fraction D was significantly depleted 
of calpactin-I, GRP-78, and GM130 immunoreactivity. Both N (Alomone) and C 
(Santa Cruz) terminal antibodies recognized AT1R and AT2R in the nuclear fraction 
(D); results shown are with the Santa Cruz antibody. Fig. 1B shows mean intensities 
of the various bands in cytosolic (fraction B) and nuclear (fraction D) fractions as a 
ratio of calpactin-I immunoreactivity in the membrane (fraction A), and demonstrates 
a substantial reduction in non-nuclear markers (GRP-78 and GM130) and increase in 
nuclear markers (Nup62 and histone-3), along with AT1R/AT2R, in nuclear-enriched 
preparations. The morphological properties of rat cardiomyocyte nuclei were analyzed 
as shown in Fig. 1C, and similar to those of nuclei obtained from cardiac tissue 
(supplemental Fig. S2C). Phase-contrast microscopic imaging (lower panel) reveals 
the integrity of the nuclei, with an intact nuclear envelope surrounding each nucleus. 
The freshly isolated nuclei were stained by DNA interactive agents DRAQ5 (Fig. 1C) 
or Hoechst 33342 dye (supplemental Fig. S2C). Finally, very high concentrations of 
DNA were found in the isolated nuclei (e.g. nuclear 909 ± 46 μg/ml, versus 
cytoplasmic supernatant 114 ± 17 μg/ml, p < 0.001, n = 8/group; Fig. 1D). The data in 
Fig. 1 confirm that both AT1R and AT2R are present in cardiomyocyte nuclei.  
 
To further investigate the subcellular localization of ATRs, we used confocal 
immunofluorescence microscopy with deconvolution to image isolated adult rat 
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ventricular cardiomyocytes decorated with antibodies against AT1R and AT2R, as 
illustrated in Fig. 2. AT1R and AT2R antibodies revealed a striated pattern consistent 
with the presence at the T-tubular network (Fig. 2, Aa and Ba). Immunofluorescence 
was also observed around the nucleus. Fig. 2, Ab and Bb, show the same 
cardiomyocytes stained for Nup62. Fig. 2, Ac and Bc, indicate extensive 
colocalization, more clearly evident in the higher magnification images in the insets. 
Phase-contrast reference images of the same cells are shown in Fig. 2, Ad and Bd. 
Similar results to those shown in Fig. 2 were obtained in all 40 cardiac cells from 10 
rats examined for AT1R and all 30 cells from 10 rats studied for AT2R. No signal was 
observed in cells where the primary antibodies were omitted. 
 
 
Differential Subcellular Trafficking of Ang-II: Extracellular Versus Intracellular 
Injection 
Fig. 3 shows in vitro fluorescence imaging of intracellular Ang-II distribution after 
extracellular administration of Ang-II labeled with FITC to freshly isolated 
cardiomyocytes. High resolution images were then acquired by confocal microscopy 
at 5-min intervals. A 60-min time course confirmed the trafficking of Ang-II inside the 
cell, without any clear specificity for the nucleus. FITC-labeled Ang-II trafficking was 
significantly changed by the AT1R antagonist valsartan (10 μM), indicating that 
binding to cell membrane AT1R receptors is important for Ang-II internalization (Fig. 
3B). (For corresponding dark-field images, see supplemental Fig. S3.) The absence 
of nuclear Ang-II in Fig. 3A argues against endocytosis as the mechanism for ATR 
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localization and suggest that ATRs in the nuclear membrane are most likely a result 
of intracellular synthesis and trafficking. 
 
We then microinjected fluorescently labeled Ang-II into the cytoplasm of single 
cardiomyocytes to analyze the intracellular distribution of Ang-II (Eppendorf Femtojet; 
1 nM Ang-II in 50 to 75 fl per cell), as shown in Fig. 4A. Although FITC-Ang-II rapidly 
diffused throughout the cytoplasm, the fluorescence was enriched or sequestered in 
the perinuclear region of injected cells 10–20 s after microinjection. The fluorescence 
decreased rapidly after 20 s but a clear signal at the nucleus (colocalization with 4′,6-
diamidino-2-phenylindole) remained at 30 s and disappeared within 30 s thereafter. At 
no time was fluorescence detected in cells neighboring the microinjected cell, 
suggesting that the distribution observed in injected cells was due to intracellularly 
injected FITC-Ang-II and not extracellular diffusion. Similar results were obtained in 
10 microinjected cells. Cells that were microinjected with valsartan (100 nM) prior to 
FITC-Ang-II showed little or no nuclear Ang-II fluorescence (Fig. 4B). The data in Fig. 
4 suggest that nuclei have a higher density of Ang-II binding sites than do other 
subcellular structures. 
 
 
Nuclear Ang-II Receptors Regulate Transcription Initiation 
β-Adrenergic receptors were recently shown to stimulate [32P]UTP incorporation in 
isolated nuclei (16). To determine whether nuclear ATRs are able to control 
transcription, freshly isolated cardiomyocyte (Fig. 5) or cardiac tissue (supplemental 
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Fig. S4) nuclei were incubated with [α-32P]UTP in addition to ATR ligands and 
antagonists. Ang-II, L162,313 (AT1R-selective agonist), PD123177 (AT2R-selective 
agonist), candesartan (AT1R-selective antagonist), and PD123177 (AT2R-selective 
antagonist) were added directly to the incubation medium (Fig. 5A). Both non-
selective and subtype-specific agonists increased the synthesis of RNA, although 
stimulation with an AT1R agonist produced a greater response than with the AT2R 
agonist (390 ± 16 cpm/ng of DNA versus 181 ± 7 cpm/ng of DNA, n = 4/group, p < 
0.001). Both AT1R and AT2R antagonists significantly reduced the ability of Ang-II to 
enhance transcription. 
 
To determine whether the activation of heterotrimeric G proteins are involved in 
coupling ATRs within the nuclear membrane to transcription, freshly isolated nuclei 
were pre-treated for 120 min with pertussis toxin. Pretreatment of isolated 
cardiomyocyte nuclei with pertussis toxin blocked the ability of Ang-II to increase de 
novo RNA synthesis (Fig. 5B). Thus, Gi is involved in coupling Ang-II receptors to 
transcription. 
 
Ribosomal RNA (rRNA) constitutes the most abundant form of RNA. To determine 
whether stimulation of ATRs on nuclear membranes alters the abundance of rRNA 
following stimulation of isolated nuclear preparations, total RNA was resolved on 2% 
agarose gels and visualized by staining with ethidium bromide. Ang-II increased rRNA 
levels (Fig. 5C). Overall, Ang-II increased the signal strength (18 and 28 S) to 2.09 ± 
0.08 OD, compared with 1.02 ± 0.02 OD in control (n = 4/group, p < 0.001). The Ang-
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II effect was attenuated by valsartan and PD123177, which reduced the signal 
strength to 1.21 ± 0.04 OD and 1.11 ± 0.07 OD (n = 4/group, p < 0.001), respectively. 
Responses in total cardiac nuclear preparations (supplemental Fig. S4) were 
qualitatively similar to results from isolated cardiomyocyte nuclei (Fig. 5). 
 
 
Nuclear Ang-II Receptors Regulate NFκB Gene Expression 
Studies have shown that Ang-II is implicated in the activation of various nuclear 
transcription factors, including NFκB, and control of NFκB gene transcription is a 
potentially important regulatory mechanism (17). To assess the possible role of 
nuclear ATRs in the control of NFκB transcription, we treated isolated cardiomyocytes 
and purified nuclei with different concentrations of Ang-II. Following RNA isolation, the 
expression of NFκB was assessed by qPCR and normalized to the average of three 
housekeeping genes, β2-microglobulin, glyceraldehyde-3-phosphate dehydrogenase, 
and heat shock protein 90-kDa α, class B member 1. The primer sequences are 
provided in supplemental Table S2. Ang-II produced clear concentration-response 
curves, both when applied to intact cells and to nuclei isolated from cardiac tissues 
(supplemental Fig. S5A). Fig. 6A shows dose-response results obtained from 120-min 
applications of Ang-II to isolated intact cardiomyocytes (extracellular) or to nuclear 
preparations isolated from cardiomyocytes. At higher concentrations, there was a 
significantly greater increase in NFκB mRNA expression following Ang-II application 
to cardiomyocyte-nuclear preparations versus extracellular application to isolated 
cardiomyocytes. Preincubation of nuclei with valsartan (10−6 M) or PD123177 (10−6 
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M) prior to Ang-II administration reduced the Ang-II-induced increase in NFκB mRNA 
abundance (49 and 39% inhibition, respectively, versus Ang-II alone; n = 4/group, p < 
0.001, Fig. 6B), whereas pretreatment with both antagonists abolished the NFκB 
mRNA expression response to Ang-II (n = 4, p = NS versus control). 
 
 
Nuclear AT1R Stimulation Induces Nuclear [Ca2+] Responses via IP3R-mediated 
Mechanisms and Thereby Influences Transcription Initiation 
The nuclear envelope serves as a pool for calcium and has been proposed to 
regulate nuclear Ca2+ signals (18). Several mechanisms for generating Ca2+-
transients in the nucleus have been identified (19). The effect of ATR agonists on 
nuclear Ca2+ concentration was examined in freshly isolated nuclei using the 
ratiometric fluorescent Ca2+ indicator, Fura-2/AM. Exposure to vehicle alone did not 
alter nuclear Ca2+ signals (supplemental Fig. S6). Exposure of nuclei to Ang-II (10 
μM) produced a prompt increase in [Ca2+]. In the example shown in Fig. 7A, [Ca2+] in 
nuclei isolated from cardiomyocytes rose from a baseline value of 111 to 243 nM, 
followed by a return to baseline values. The AT1R-selective agonist L162,313 (10 
μM) also caused an intranuclear [Ca2+] response (Fig. 7B), and the Ang-II response 
was prevented by co-administration with the AT1R inhibitor candesartan (10 μM) (Fig. 
7C). Unlike AT1R-selective agonists, the AT2R agonist CGP42112A (10 μM) failed to 
elicit a nuclear [Ca2+] response (Fig. 7D) and the AT2R antagonist PD123177 (10 μM) 
was unable to prevent an Ang-II-mediated Ca2+ rise (Fig. 7E). Overall mean data (n = 
4/group) are summarized in Fig. 7F, indicating a significant increase in nuclear [Ca2+] 
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with AT1R agonists, which is blocked by an AT1R antagonist. AT2R selective 
agonists produced no significant change in [Ca2+], nor did antagonism of AT2R 
significantly attenuate the response to Ang-II. Similar results were obtained in nuclei 
isolated from whole hearts (supplemental Fig. S7). 
 
IP3 is an important mediator of nuclear Ca2+ mobilization via nuclear envelope Ca2+ 
stores (20). We therefore tested the hypothesis that Ang-II regulates nuclear [Ca2+] 
via IP3-dependent Ca2+ release. As shown in Fig. 8A, IP3 (10 μM) caused a transient 
increase of [Ca2+] in nuclei isolated from cardiomyocytes, whereas the application of 
IP3 after pre-treatment with the IP3R blocker 2-APB (10 μM) failed to increase 
nuclear [Ca2+] significantly (Fig. 8B). Pretreatment of nuclei with 2-APB suppressed 
the nuclear [Ca2+] responses induced by Ang-II (Fig. 8C). Overall mean ± S.E. [Ca2+] 
response amplitudes are summarized in Fig. 8D. Similar results were seen for nuclei 
isolated from whole hearts (supplemental Fig. S8). 
 
To examine the potential role of the AT1R-mediated nuclear Ca2+ rise in the AT1R-
induced transcription response, we pretreated cardiomyocyte nuclei with various 
concentrations of 2-APB prior to stimulation with Ang-II, L-162,313 (AT1R agonist), or 
CGP42112A (AT2R agonist). At a threshold concentration of 1 μM, 2-APB 
significantly decreased transcription initiation by Ang-II (Fig. 9A, n = 4/condition, p < 
0.05) and by the AT1R agonist L-162,313 (Fig. 9B, n = 4/condition, p < 0.01). 
Maximum inhibition with 200 μM APB suppressed but did not eliminate Ang-II and L-
162,313 responses, pointing to Ca2+-dependent and Ca2+-independent components. 
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Consistent with the lack of nuclear [Ca2+] response to AT2R stimulation, 2-APB failed 
to alter CGP42112A-induced transcription initiation (Fig. 9C, n = 4/condition). Similar 
results were obtained with nuclei isolated from intact cardiac tissues (supplemental 
Fig. S9). 
 
 
Assessment of Intracellular Components of Angiotensin Synthesis System 
We found by ELISA that lysates prepared from isolated cardiomyocytes contain Ang-
II at concentrations of 32.7 ± 4.1 fmol/mg of protein in the free cytosol. In addition, we 
found by qPCR that components required to produce Ang-II such as angiotensin 
converting enzyme, renin, angiotensinogen, and cathepsin are present inside 
cardiomyocytes (supplemental Fig. 1B). 
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Discussion 
 
Main Findings 
In the present study, we examined the subcellular localization of Ang-II 
receptors and their functionality in adult rat ventricular cardiomyocytes. Our data 
indicate that both AT1R and AT2R localize to and signal at the nuclear envelope, and 
that this localization is not a result of post-endocytotic trafficking. We also found that 
nuclear AT1Rs and AT2Rs mediate de novo RNA synthesis, affecting the abundance 
of both rRNA and NFκB mRNA, and that Gi availability is essential for this Ang-II 
effect. Ang-II signaling via AT1Rs induces [Ca2+] responses in isolated nuclei via 
IP3R-dependent pathways, which participate in AT1R-induced de novo RNA 
synthesis. 
 
Relation to Previous Studies of GPCR Nuclear Receptors 
Classically, GPCRs, which comprise the largest protein superfamily in the 
human genome, are thought to induce intracellular effects via downstream signaling 
pathways from the plasma membrane (21, 22). In recent years, we and others have 
confirmed that endothelin (15), β- and α-adrenergic (17, 23), prostaglandin E2 (24) 
receptors, in addition to the signaling molecules associated with many GPCRs, 
including adenylate cyclase (25), G-protein coupled receptor kinases (GRK) (26, 27), 
phospholipase proteins (22), Gi, Gs, and Gq, are present on the nuclear/perinuclear 
membranes in a constitutive manner, independent of agonist stimulation. Determining 
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the subcellular localization of proteins provides crucial information concerning their 
function and interaction with other molecules in a specific microenvironment, and thus 
represents a critical step in genome annotation. 
The data in the present paper suggest that Ang-II stimulates cardiomyocyte 
nuclear receptors to induce transcriptional responses in a Gi-dependent manner, 
similar to previous observations for cardiac nuclear β-adrenoceptors (17). We found 
that Ang-II increases [Ca2+]i in nuclear-enriched preparations via AT1Rs. Intracellular 
Ang-II increases nuclear [Ca2+] in vascular smooth muscle cells, an effect that is 
blocked by intracellular but not extracellular AT1R blockade (28). Intracellular 
application of Ang-II increases cell [Ca2+]i in A7r5 vascular smooth muscle cells 
lacking extracellular ATRs, an effect prevented by AT1R, but not AT2R blockers (29). 
Nuclear Ca2+ signaling appears to be an important regulator of gene transcription, 
particularly in neurons (30), and IP3 receptors are involved in nuclear Ca2+ signaling 
in a muscle cell line (31). Our observation of nuclear AT1R-selective effects to 
increase nuclear [Ca2+] suggests a potential role for AT1R-mediated nuclear Ca2+ 
changes in transcriptional responses. The degree of [32P]UTP incorporation 
enhancement was greater with nuclear preparation application of the AT1R agonist L-
162,313 than with the AT2R agonist CGP42112A (Fig. 5A), consistent with the notion 
that AT1R-related Ca2+-dependent nuclear signaling may participate in transcriptional 
responses. However, clearly the Ang-II-induced transcriptional response does not 
depend solely on increased nuclear [Ca2+], because Ang-II-induced rRNA (Fig. 5C) 
and NFκB (Fig. 6B) RNA expression changes were sensitive to both AT1R and AT2R 
blockade, and selective AT2R stimulation with CGP42112A-induced transcriptional 
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responses. Further work will be needed to characterize in detail how Ang-II induces 
nuclear [Ca2+] responses and to define nuclear [Ca2+]-sensitive and -insensitive 
transcriptional control pathways. 
 
Evidence for a Role of Intracellular Ang-II Signaling 
The involvement of an intracellular renin-angiotensin system in biological 
responses has long been debated. We found significant expression of the 
components needed to produce Ang-II in cardiomyocyte lysates, and measured 
cytoplasmic Ang-II concentrations of over 30 fmol/mg of protein, of the same order as 
reported by Singh et al. (5). Ichihara et al. (32) demonstrated the existence of 
nonproteolytically activated intracardiac prorenin and elevated tissue Ang-II 
concentrations in genetically hypertensive rats, which produced end organ damage 
despite prevention of systemic renin-angiotensin activation. By contrast, the 
prevention of intracellular prorenin activation fully prevented cardiac fibrosis, despite 
the maintenance of systemic renin-angiotensin activation and severe hypertension 
(32). Mice engineered to lack intracardiac angiotensinogen lack cardiac hypertrophy 
and fibrosis despite hypertension comparable with similarly hypertensive control mice 
(33). In a rat vascular smooth muscle cell line (A7r5) devoid of plasma membrane 
ATRs, intracellular (liposome-based) Ang-II delivery enhances cell proliferation, 
whereas extracellular Ang-II has no effect, with intracellular Ang-II responses 
suppressed by intracellular application of AT1R or AT2R blockers (29). Independent 
of systemic hemodynamic effects, local cardiac Ang-II may cause deleterious 
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myocardial remodeling and functional deterioration post-myocardial infarction (34). In 
summary, there is evidence for a role of intracellular Ang-II signaling in cardiovascular 
remodeling. Our data, which indicate that AT1Rs and AT2Rs are present on 
cardiomyocyte nuclei and that Ang-II induces AT1R- and AT2R-mediated 
transcriptional responses in purified nuclear preparations, suggest that nuclear ATRs 
may be important mediators of intracellular Ang-II effects on the heart. 
 
Potential Role of Nuclear AT1 and AT2 Receptors in Cardiac Remodeling 
Ang-II is an important signaling molecule for cardiac remodeling, although 
there remains uncertainty over whether cardiac Ang-II signaling alone is enough to 
induce remodeling or whether Ang-II actions conspire with stressors (like 
hypertension and excess hemodynamic load) to induce remodeling (35). 
Overexpression of AT1Rs is a much more potent stimulus to cardiac remodeling than 
Ang-II overproduction, suggesting that receptor density may be the limiting factor for 
Ang-II-related remodeling (35). It has long been known that radiolabeled Ang-II 
preferentially localizes in the perinuclear regions of cardiomyocytes following 
intraventricular injection (36). The presence of nuclear Ang-II receptors has been 
demonstrated in the liver (11, 12) and kidneys (37). Similar to our findings, direct 
application of Ang-II to isolated renal-cortical cell nuclei enhances in vitro transcription 
of a variety of genes (37). Ang-II activates several nuclear transcription factors and is 
implicated in the pathogenesis of vascular damage through NFκB (18). NFκB 
increases the expression of cytokines, enzymes, and adhesion molecules, as well as 
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other products involved in inflammation, proliferation, and hypertrophy (38). Our 
observations raise the interesting possibility that direct nuclear receptor signaling may 
be an important mediator of the action of Ang-II to promote cardiac remodeling via 
altered gene transcription. 
 
Novel Elements and Potential Implications 
Our work is the first demonstration, to our knowledge, that cardiomyocytes 
express nuclear envelope Ang-II receptors that can induce changes in cardiac gene 
transcription, that Ang-II stimulation of nuclear receptors can induce nuclear [Ca2+] 
responses via IP3-mediated pathways in an AT1R-specific fashion, and that blockade 
of IP3R-mediated nuclear [Ca2+] changes suppress the AT1R-mediated effect on 
cardiac gene transcription. To demonstrate the properties of the nuclear angiotensin 
system in cardiomyocytes, we developed and applied a novel nucleus-enriched 
preparation from isolated cardiomyocytes, to our knowledge for the first time in the 
literature. Our findings provide mechanistic insights into observations suggesting that 
Ang-II acts through intracellular receptors to regulate cardiomyocyte growth and 
induce cardiac remodeling (39). 
There is growing interest in the development of intracrine pharmacology, small 
molecule compounds designed to modulate intracellular signaling systems mediated 
by compounds synthesized within the target cell (40). Lipid-soluble renin inhibitors 
and angiotensin converting enzyme inhibitor prodrugs are particularly effective in 
inhibiting ATR-related glioblastoma (41) and neuroblastoma (42) cell growth, pointing 
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to the potential importance of blocking intracellular Ang-II signaling. Further 
information about the nature, role, and significance of cardiomyocyte nuclear ATRs 
should contribute to the development of rationally based intracrine pharmacology for 
cardiac remodeling prevention. 
 
Potential Limitations 
Transmembrane receptors can exist in monomeric, homodimeric, or 
heterodimeric states, and the multimeric state of the receptor may alter its 
pharmacological properties. AT1 and bradykinin B2 receptors form stable 
heterodimers, increasing G-protein activation (43). The dimerization status of the 
nuclear membrane ATRs could have important implications for the intracrine 
physiology of the renin-angiotensin system, but is beyond the scope of the present 
study. We have not investigated the specific molecular properties of nuclear ATRs, 
and it remains to be determined whether they are identical to cell-membrane 
receptors that are simply targeted to the nucleus, or whether a subset of ATRs with 
specific molecular compositions are selectively targeted to nuclear membranes. 
Angiotensin-receptor blockers are known to suppress angiotensin-related cardiac 
remodeling. To act via nuclear angiotensin-receptor inhibition they would have to 
achieve significant intracellular concentrations. The extent to which commercially 
available agents cross the plasma membranes of heart cells is incompletely known, 
although telmisartan, a lipid-soluble agent, has been shown to achieve 10-fold 
concentration in the intracellular compartment versus culture medium (44). 
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Conclusions  
The current study provides novel insights into cardiac intracellular Ang-II signaling by 
demonstrating the existence of nuclear AT1Rs and AT2Rs that are coupled to RNA 
transcription and nuclear Ca2+ signaling in cardiomyocytes. Ang-II acts via AT1Rs to 
induce Ca2+ mobilization in cardiomyocyte nuclear preparations via IP3 receptor-
mediated mechanisms. A better understanding of the nature and role of nuclear Ang-
II receptors will help to provide a better appreciation of the molecular basis for cardiac 
remodeling and hopefully lead to the development of improved pharmacological 
interventions for cardiac disease prevention and therapy. 
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Figure Legends 
 
Figure 1.  Immunoreactivity of angiotensin II receptor subtypes 1 and 2 in purified 
cardiomyocyte nuclei.  A, Western blots showing expression of various markers on 
cardiomyocyte fractions. Isolated cardiomyocytes were fractionated into three 
fractions: membrane, cytosolic, and nuclear.  Aliquots (40 μg) of each fraction were 
separated by SDS-PAGE and transferred onto PVDF-membranes.  After blocking, 
membranes were incubated with antisera specific for calpactin-I, GRP-78, GM130, 
histone-3, Nup62, AT1 or AT2.  Immunoreactive bands were visualized by ECL.  B, 
Mean±SEM expression levels for GRP-78, GM130, histone-3, Nup62, AT1, AT2 
normalized to calpactin-I. (N=6/antibody/fraction) **P<0.01, ***P<0.001 vs. respective 
cytosolic fraction.  C, Representative images of a purified nuclear preparation. Top: 
DNA-staining with DRAQ 5; Bottom: Corresponding phase-contrast image.  D, 
Mean±SEM DNA content (μg/ml) of cytoplasmic or nuclear fraction (N=8/group). 
***P<0.001 vs. cytoplasmic. 
 
Figure 2.  Subcellular distribution of AT1 and AT2 receptors in adult rat ventricular 
cardiomyocytes.  A, Panels a-d show representative results from a single cell.  Panel 
a is a confocal image demonstrating the nuclear localisation of AT1R (green), b 
shows nuclear staining with nucleoporin p62 (red), c is a superimposed confocal 
image showing the colocalization of AT1R with Nup 62, coincident signals appear in 
yellow (Merge), d is a phase contrast image of the same cell.  Data are representative 
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of 40 cells from 10 rats.  B, Panels a-d show representative results from a single cell.  
Panel a is a confocal image demonstrating the nuclear localisation of AT2R (green), b 
shows nuclear staining with nucleoporin p62 (red), c is a superimposed confocal 
image showing the colocalization of AT2R with Nup 62, coincident signals appear in 
yellow (Merge), d is a phase contrast image of the same cell.  Data are representative 
of 30 cells from 10 rats.  
 
Figure 3.  Endocytosis and intracellular trafficking of Ang-II. A, FITC-Ang-II (1 nM) 
was applied extracellularly to the bathing medium. Images are shown immediately 
after Ang-II application (0 min) and then 30 and 60 min later.  Merged images are 
superimposed fluorescent images.  B, cells were preincubated with valsartan (10 μM, 
for 25 min) prior to administration of Ang-II. Hoechst 33342 was used as a nuclear 
marker.  Z-stacks were acquired every 5 min using a Zeiss LSM-510 confocal 
microscope. (N=6/group) 
 
Figure 4.  Subcellular localization of intracellularly applied FITC-Ang-II.  A, phase 
contrast image showing myocyte immediately prior to injection. FITC-Ang-II (1 nM) 
was microinjected into freshly isolated cardiomyocytes and fluorescence visualized at 
10, 20 seconds post-injection.  B, Cells were microinjected with valsartan (100 nM) 
prior to FITC-Ang-II injection.  DAPI was used as a nuclear marker.  No fluorescence 
was observed in adjacent cells at any time. (Results similar to those in A and B were 
obtained for 10 microinjected cells from 10 rats each.) 
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Figure 5.  AT1R and AT2R in nuclear membranes regulate cardiomyocyte 
transcription initiation.  A, De novo RNA synthesis.  Isolated cardiomyocyte nuclear 
preparations were stimulated with Ang-II, L 162,313 (a non-peptide AT1R-selective 
agonist), CGP 42112A (an AT2R-selective agonist), candesartan plus Ang-II, or 
PD123177 plus Ang-II (all at 10-μM), as indicated. Following the addition of 
antagonists candesartan (Cand) and PD123177, nuclei were preincubated for 30 min 
prior to the addition of Ang-II. ***P<0.001 vs. control; +P<0.05, +++P<0.001  vs. Ang-
II.  B, Cardiomyocyte nuclei were treated with PTX 5 μg/ml for 2 hours and then 
stimulated with Ang-II.  Data represent mean ± SEM of at least five separate 
experiments performed in triplicate and normalized to control. ***P<0.001 vs. control; 
N.S. = non-significant vs. control. C, Representative 2% agarose gel electrophoresis 
of RNA extracted from purified cardiomyocyte nuclei of 2 separate experiments 
stained with ethidium bromide (GTP and CTP not omitted) under the following 
conditions: non-stimulated (lane 1 and 2); stimulated with Ang-II (10 μM, lane 3 and 
4); stimulated with Ang-II in the presence of valsartan (10 μM, lane 5 and 6); 
stimulated with Ang-II in the presence of PD123177 (10 μM, lane 7 and 8). Results in 
lanes 1, 3, 5, and 7 are from one experiment, lanes 2, 4, 6, and 8 from another. 1 μg 
of each sample was loaded. Bottom panel shows mean±SEM results as arbitrary 
optical density (O.D.) units from 4 different experiments/condition. ***P<0.001 vs. 
control, ++P<0.01 vs. Ang-II. 
 
Figure 6.  Regulation of cardiomyocyte nuclear NF-κB mRNA expression by nuclear 
ATRs.  Isolated nuclei were treated for 2 hours with Ang-II at different concentrations.  
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NF-κB mRNA was quantified by qPCR. A, Data are presented as NF-κB mRNA 
expression relative to an average of three housekeeping genes 
(N=6/concentration/group).  *P<0.05 **P <0.01, ***P<0.001 vs. intact cells.  B, 
Valsartan (10 μM) or PD123177 (10 μM) significantly reduced the Ang-II (10 μM) 
induced NF B a ctivity,          
antagonists completely abolished the NF-κB gene expression-response.  Results are 
expressed as mean±SEM ***P<0.001 vs. Ang-II.  
 
Figure 7.  Coupling of ATRs to Ca2+ entry in cardiomyocyte nuclear enriched 
preparations.  FURA-2/AM-loaded freshly isolated cardiomyocyte nuclei were seeded 
onto glass slides and nuclear Ca2+ concentration [Ca2+] was measured with an 
IonOptix microspectrofluorimeter (λex = 340 and 380 nm; λem = 509 nm).  Typical 
recordings of internal Ca2+ are shown, with recordings from all preparations studied 
shown in insets, after administration of: A, Ang-II (10 μM); B, L-162,313 (10 μM); C, 
candesartan (10 μM) plus Ang-II (10 μM); D, CGP 42112A (10 μM); E, PD123177 (10 
μM) plus Ang-II (10 μM).  F, Summary of mean±SEM [Ca2+] transient amplitudes 
(N=4/group/condition) ***P<0.001 vs. control, N.S. = non-significant vs. control; 
arrows in A-E indicate the time of drug application.  
 
Figure 8.  IP3-dependent Ca2+ signals from isolated cardiomyocyte nuclei.  Isolated 
nuclei were exposed to A, IP3 (10 μM).  B, the IP3R blocker 2-APB (10 μM) followed 
by exposure to IP3. C, the IP3R blocker 2-APB (10 μM) followed by exposure to Ang-
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II (10 μM).  D, summary of [Ca2+] transient amplitudes, mean±SEM 
(N=5/group/condition) **P<0.01 ***P<0.001; arrows indicate the time of drug 
application in A-C.   
 
Figure 9. Role of IP3R-signaling for AT1R-mediated transcription initiation. Isolated 
nuclei were pre-treated with various concentrations of 2-APB for 30 minutes and 
incubated with: A, Ang-II B, L-162,313 or C, CGP42112A (all at 10 μM) and de novo 
RNA synthesis was measured by 32P-UTP incorporation. ***P<0.001, **P<0.01 or 
*P<0.05 vs. agonist alone (Ang-II or L-162,313); #P<0.05 vs. 2 APB (50 μM), DMSO 
or H2O alone in A and B; N.S = non-significant from each other. 
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Supplemental Materials 
 
Isolation of heart nuclei.  
Nuclear isolation was performed according to a modified version of a 
previously-described method (13). Briefly, rat hearts were manually ground into a 
powder under liquid nitrogen, resuspended in cold phosphate-buffered saline (PBS) 
(137 mM NaCl, 10 mM phosphate, 2.7 mM KCl with a final pH of 7.4, NaOH) and 
homogenized with a Polytron. The total extract was labelled Fraction A. The 
subsequent steps were carried out on ice or in a cooling cabinet at 4°C. 
Homogenates were centrifuged at 1400 × g for 15 min and the supernatant, denoted 
Fraction B, was diluted 1:1 with buffer A (10 mM K-HEPES, 1.5 mM MgCl2, 10 mM 
KCl, 1 mM DTT, 25 μg/ml leupeptin, 0.2 mM Na3VO4 with a final pH of 7.4, NaOH), 
incubated for 10 min on ice and re-centrifuged at a higher speed (3500 x g) for 15 
min. The resulting supernatant was discarded and the pellet, containing crude nuclei 
(designated Fraction C) was resuspended in buffer B (0.3 M K-HEPES, 1.5 M KCl, 
0.03 M MgCl2, 25 μg/ml leupeptin, 0.2 mM Na3VO4 with a final pH of 7.4, NaOH), 
incubated on ice for 10 min, and centrifuged for 30 min at 5000 × g. The pellet, 
comprising a nuclear-enriched fraction (designated Fraction D), was resuspended in 
buffer C (20 mM Na-HEPES, 25% (volume/volume) glycerol, 0.42 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM 
DTT, 25 μg/ml leupeptin, 0.2 mM Na3VO4 with a final pH of 7.4, NaOH) or 1× 
transcription buffer (see below) and either used freshly or aliquoted, snap-frozen with 
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liquid nitrogen, and stored at -80°C. Protein concentrations were determined by 
Bradford assay using a NanoDrop ND-1000 Spectrophotometer (Wilmington, DE). 
 
1. Xiao, L., Coutu, P., Villeneuve, L.R., Tadevosyan, A., Maguy, A., Le Bouter, S., 
Allen, B.G., and Nattel, S. (2008) Circ Res 103(7), 733-742 
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On-line Table I  
Primary Antibody Information 
 
Secondary Antibody Information 
Antibody Description Company Catalogue 
Number 
Dilution 
Donkey anti-rabbit IgG Jackson 711-005-152 1:10000 
Donkey anti-mouse IgG Jackson 711-005-150 1:15000 
Donkey anti-goat IgG Jackson 711-005-003 1:10000 
 
 
 
 
 
 
 
Protein Isotype Company Catalogue 
Number 
Dilution 
AT1 (43kDa) Rabbit-polyclonal Alomone labs ZZR-011-AN01 1:400 
AT1-c18 Goat-polyclonal Santa Cruz Sc-31181 1:500 
AT2(47kDa) Rabbit-polyclonal Alomone labs AAR-012-AN01 1:400 
AT2-c18 Goat-polyclonal Santa Cruz Sc-7420 1:500 
Calpactin-I (36kDa) Mouse-monoclonal BD 
Biosciences 
610068 1:2000 
DDR2 (98kDa) Rabbit-polyclonal Abcam Ab5520 1:200 
GM-130 (130kDa) Mouse-monoclonal BD 
Biosciences 
610823 1:250 
GRP78 (75kDa) Rabbit-polyclonal Abcam Ab21685 1:1000 
Histone 3 (17kDa) Rabbit-polyclonal Cell Signaling #9715 1:1000 
MyHC (223kDa) Mouse-monoclonal Abcam Ab15 1:1000 
NSE (47kDa) Rabbit-polyclonal Abcam Ab16873 1:2000 
Nup-62 (62kDa) Mouse-monoclonal BD 
Biosciences 
610498 1:1000 
VWF (130, 190kDa) Goat-polyclonal Santa Cruz Sc-8068 1:100 
αSMA (42kDa) Mouse-monoclonal Sigma A5228 1:2000 
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On-line Table II 
Primers Information 
 
 
 
 
 
 
Primers Description Sequences RefSeq 
mRNA 
Ace 
Angiotensin-
converting 
enzyme 
F: CCTGATCAACCAGGAGTTTGCAGAG 
R: GCCAGCCTTCCCAGGCAAACAGCAC NM_012544.1 
Agt Angiotensinogen 
F: GACCGCGTATACATCCACCCCTTTCATCTC 
R: 
GTCCACCCAGAACTCATGGAGCCCAGTCAG 
NM_134432.2 
B2m 
Beta-2 
microglobulin 
 
F: GAATTCAGTGTGAGCCAGGATG 
R:  CAAGTGTACTCTCGCCATCCAC 
 
NM_012512.1 
Cts Cathepsin F: GGGGGAAATCTACAAAAATG R: AAAGACTCCTATCTGCCTCACT NM_022597.2 
GAPDH 
 
Glyceraldehyde-
3-phosphate 
dehydrogenase 
 
F: TACATGTTCCAGTATGACTC 
R: TGTGAGGGAGATGCTCAGTG 
NM_017008 
 
Hspcb 
Heat shock 
protein 90kDa 
alpha, class B 
member 1 
F: TGTTTCTTCACCACCTCCTTGA 
R: CCTACCTGGTGGCAGAGAAAGT NM_001004082 
NFκB1 
 
Nuclear factor of 
kappa light 
polypeptide 
gene enhancer 
in B-cells 1 
 
F: CTGCGATACCTTAATGACAGCG 
R: AATTTGGCTTCCTTTCTTGGCT 
 
XM_342346.3 
 
Ren Renin F: CTGGGAGGCAGTGACCCTCAACATTACCAG R: GAGAGCCAGTATGCACAGGTCATCGTI’CCT NM_012642.4 
 105 
 
On-line Figure Legends 
 
Figure 1. Assessment of cardiomyocyte preparation and expression of renin-
angiotensin components in cardiomyocytes. A, The purity of isolated cardiomyocytes 
was assessed by Western blot, with aliquots (40 μg each) of proteins isolated from 
cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and whole-brain. 
Proteins were separated by SDS-PAGE and transferred onto PVDF. After blocking, 
membranes were incubated with antisera specific for Van Willebrand’s Factor (VWF), 
neuron-specific enolase (NSE), discoidin domain receptor 2 (DDR2), α-smooth 
muscle actin (αSMA), myosin heavy chain (MyHC) and GAPDH. Immunoreactive 
bands were visualized by ECL (examples of Western blots are illustrated, we 
performed 4 separate experiments/antibody/fraction) B, The expression of renin-
angiotensin components were confirmed with RNA isolated from the cytosol of 
cardiac myocytes, by qRT-PCR with primers for angiotensinogen (AGT), angiotensin 
converting enzyme (ACE), cathepsin and renin, data are presented as mRNA 
expression relative to an average of three housekeeping genes (N=8/primer) 
 
Figure 2. Immunoreactivity of angiotensin II receptor subtypes 1 and 2 in purified 
cardiac nuclei. A, Rat hearts were fractionated into four fractions: total extract (A), 
supernatant (B), crude nuclear (C) and enriched nuclear (D) fractions. Aliquots (30 
μg) of each fraction were separated by SDS-PAGE and transferred onto PVDF. After 
blocking, membranes were incubated with antisera specific for Calpactin I, GRP78, 
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Nup62, GM130, AT1 or AT2 (examples of Western blots are illustrated, 
N=6/antibody/per fraction). Immunoreactive bands were visualized by ECL. B, 
Mean±SEM expression levels for GRP78, GM130, Nup62, AT1, AT2 normalized to 
Calpactin I. *P<0.05, **P<0.01 vs. respective fraction in B. C, Representative images 
of a purified nuclear preparation. Left: DNA-staining with Hoechst 33342; Right: 
Corresponding phase-contrast image. D, Mean±SEM DNA content (μg/ml) of 
cytoplasmic or nuclear fractions (N=10/group). ***P<0.001 vs. cytoplasmic. 
  
Figure 3. Endocytosis and intracellular trafficking of Ang-II. A, FITC-Ang-II (1 nM) 
was applied extracellularly to the bathing medium. Images are shown immediately 
after Ang-II application (0 min) and then 30 and 60 min later. Merged images are 
superimposed fluorescent images. B, cells were preincubated with valsartan (10 μM, 
for 25 min) prior to administration of Ang-II. Hoechst 33342 was used as a nuclear 
marker. Z-stacks were acquired every 5 min using a Zeiss LSM-510 confocal 
microscope. (N=6/group) 
  
Figure 4. AT1R and AT2R in nuclear membranes regulate transcription initiation. A, 
De novo RNA synthesis. Isolated nuclear preparations were stimulated with Ang-II, L 
162,313 (a non-peptide AT1R-selective agonist), CGP 42112A (an AT2R-selective 
agonist), candesartan plus Ang-II, or PD123177 plus Ang-II (all at 10 μM), as 
indicated. Following the addition of antagonists candesartan (Cand) and PD123177, 
nuclei were preincubated for 30 min prior to the addition of Ang-II. ***P<0.001 vs. 
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control; ++P<0.01 vs. Ang-II. B, Nuclei were treated with PTX 5 μg/ml for 2 hours and 
then stimulated with Ang-II. Data represent mean ± SEM of at least five separate 
experiments performed in triplicate and normalized to control. ***P<0.001 vs. control; 
N.S. = non-significant vs. control. C, representative 2% agarose gel electrophoresis of 
RNA extracted from purified nuclei stained with ethidium bromide (GTP and CTP not 
omitted) under the following conditions: non-stimulated (lane 1); stimulated with Ang-II 
(10 μM, lane 2); stimulated with Ang-II in the presence of valsartan (10 μM, lane 3); 
stimulated with Ang-II in the presence of PD123177 (10 μM, lane 4). 1 μg of each 
sample was loaded. Bottom panel shows mean±SEM results as arbitrary optical 
density (O.D.) units from 6 different experiments/condition. **P<0.01 vs. control, 
++P<0.01 vs. Ang-II. 
 
Figure 5. Regulation of nuclear NFκB mRNA expression by nuclear ATRs. Isolated 
nuclei were treated for 2 hours with Ang-II at different concentrations. NFκB mRNA 
was quantified by qPCR. A, Data are presented as NFκB mRNA expression relative 
to an average of three housekeeping genes (N=6/concentration/group). ***P<0.001 
vs. intact cells, N.S. = non-significant. B, Valsartan (10 μM) or PD123177 (10 μM) 
significantly reduced the Ang-II (10 μM) induced NFκB activity, while pretreatment of 
nuclei with both AT1 and AT2 antagonists completely abolished the NFκB gene 
expression-response. Results are expressed as mean±SEM *P<0.05 vs. control, 
+P<0.01 vs. Ang-II, #P<0.01 vs. valsartan, N.S: non significant vs. control 
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Figure 6. Vehicle control for calcium transients. Typical recordings of intracellular 
Ca2+ are shown, with recordings from isolated nuclei preparations shown in insets, 
after administration of DMSO 
 
Figure 7. Coupling of ATRs to Ca2+ entry in nuclear enriched preparations. FURA-
2/AM-loaded freshly isolated cardiac nuclei were seeded onto glass slides and 
nuclear Ca2+ concentration [Ca2+] was measured with an IonOptix 
microspectrofluorimeter (λex = 340 and 380 nm; λem = 509 nm). Typical recordings 
of intracellular Ca2+ are shown, with recordings from each preparation studied shown 
in insets, after administration of: A, Ang-II (10 μM); B, L-162,313 (10 μM); C, 
candesartan (10 μM) plus Ang-II (10 μM); D, CGP 42112A (10 μM); E, PD123177 (10 
μM) plus Ang-II (10 μM). F, Summary of mean±SEM [Ca2+] transient amplitudes 
(N=6/group/condition) *P<0.05 vs. control, N.S. = non-significant vs. control; arrows in 
A-E indicate the time of drug application. 
 
Figure 8. IP3-dependent Ca2+ signals from isolated nuclei. Isolated nuclei were 
exposed to A, IP3 (10 μM). B, the IP3R blocker 2-APB (10 μM) followed by exposure 
to IP3. C, the IP3R blocker 2-APB (10 μM) followed by exposure to Ang-II (10 μM). D, 
summary of [Ca2+] transient amplitudes, mean±SEM (N=5/group/condition) 
***P<0.001; arrows indicate the time of drug application in A-C. 
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Figure 9. Role of IP3R-signaling for AT1R-mediated transcription initiation. Isolated 
nuclei were pre-treated with various concentrations of 2-APB for 30 minutes and 
incubated with: A, Ang-II B, L-162,313 or C, CGP42112A (all at 10 μM) and de novo 
RNA synthesis was measured by 32P-UTP incorporation. ***P<0.001 or **P<0.01 vs. 
agonist alone (Ang-II or L-162,313); ##P<0.01 or #P<0.05 vs. DMSO or 2-APB alone 
(15 μM); N.S: non-significant. 
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CHAPTER 3 – Synthesis and 
characterisation of novel photoreleasable 
angiotensin II analogs to probe intracellular 
actions with spatial and temporal precision 
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characterized cell-permeable photolabile caged Ang-II analogues. These compounds 
are biologically inert precursors of Ang-II that release active Ang-II intracellularly 
when exposed to ultraviolet light.  
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Abstract 
Several lines of evidence suggest that intracellular angiotensin II (Ang-II) 
contributes to the regulation of cardiac contractility, renal salt reabsorption, vascular 
tone and metabolism; however, work on intracrine Ang-II signalling has been limited 
to indirect approaches because of a lack of selective intracellularly-acting probes.  
Here, we aimed to synthesize and characterize cell-permeable Ang-II analogues that 
are inactive without uncaging, but release active Ang-II upon exposure to a flash of 
ultraviolet light, as novel tools to study intracrine Ang-II physiology.  We prepared 
three novel caged Ang-II analogues, [Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and 
[Tyr(DMNB)4]Ang-II-ODMNB, based upon the incorporation of the photolabile moiety 
4,5-dimethoxy-2-nitrobenzyl (DMNB).  Compared to Ang-II, the caged Ang-II 
analogues showed 2-3 orders of magnitude reduced affinity toward both angiotensin 
type-1 (AT1R) and type-2 (AT2R) receptors in competition binding assays, and 
greatly-reduced potency in contraction assays of rat thoracic aorta.  Following 
ultraviolet irradiation, all three caged Ang-II analogues released Ang-II and potently 
induced contraction of rat thoracic aorta.  [Tyr(DMNB)4]Ang-II showed the most rapid 
photolysis upon ultraviolet irradiation and was the focus of subsequent 
characterization.  Whereas Ang-II and photolysed [Tyr(DMNB)4]Ang-II increased 
ERK1/2 phosphorylation (via AT1R) and cGMP production (AT2R), caged 
[Tyr(DMNB)4]Ang-II did not.  Cellular uptake of [Tyr(DMNB)4]Ang-II was 4-fold greater 
than that of Ang-II and significantly greater than uptake driven by the positive-control 
HIV TAT(48-60) peptide.  Intracellular photolysis of [Tyr(DMNB)4]Ang-II induced an 
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increase in nucleoplasmic Ca2+ ([Ca2+]n), and initiated 18S rRNA and NF-κB mRNA 
synthesis in adult cardiac cells.  We conclude that caged Ang-II analogues represent 
powerful new tools to selectively study intracrine signalling via Ang-II. 
 
Keywords: Intracrine signalling; Biochemistry and metabolism; Angiotensin converting 
enzyme; Angiotensin receptors  
 
Abbreviations  AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 
receptor; ACE, angiotensin-converting enzyme; DMNB, 4,5-dimethoxy-2-nitrobenzyl 
group; PACAP(28-38), peptide corresponding to amino acids 28-38 of the pituitary 
adenylyl cyclase-activating polypeptide; TAT(48-60), peptide corresponding to amino 
acids 48-60 of the HIV-1 TAT protein; UV, ultraviolet. 
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Introduction 
The renin-angiotensin system (RAS) is critically involved in controlling 
functions at various levels, from cells to tissues to the entire organism.  The 
physiological actions of RAS and its blockade have been translated into clinical 
settings, improving both quality and duration of life for patients with hypertension, 
heart failure, renal insufficiency, myocardial infarction, and stroke (Kobori et al., 2007; 
Lang & Struthers, 2013).  RAS activation is initiated following cleavage of 
angiotensinogen into angiotensin-I (Ang-I), via renin synthesized in juxtaglomerular 
cells of renal afferent arterioles.  Subsequently, angiotensin-converting enzyme (ACE) 
hydrolyses the inactive decapeptide Ang-I into the biologically active octapeptide 
angiotensin-II (Ang-II), which exerts actions via heterotrimeric G protein-coupled type-
1 (AT1R) and type-2 (AT2R) receptors. 
Although the RAS has been traditionally viewed as an endocrine system, a 
variety of studies point to intracellular (“intracrine”) Ang-II actions.  Angiotensin 
receptors are localized on the nuclear envelope of numerous cell types (Robertson & 
Khairallah, 1971; Haller et al., 1999; Cook et al., 2006).  Exposure of isolated cardiac 
nuclei to Ang-II causes inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+-release and 
de novo RNA synthesis (Tadevosyan et al., 2010; Tadevosyan et al., 2012).  
Hyperglycemia stimulates local Ang-II production in the hearts of diabetic patients and 
is implicated in increased expression of transforming growth factor-β (TGF-β) and 
collagen (Frustaci et al., 2000; Singh et al., 2008). The intracrine actions attributed to 
Ang-II are not prevented by acute extracellular application of angiotensin receptor 
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blockers or ACE inhibitors (Tadevosyan et al., 2010).  As these compounds have a 
limited capacity to cross the plasma membrane, they are unable to abolish the 
cytosolic synthesis of Ang-II or its binding to cognate receptors on the nuclear 
membrane (Schwab et al., 1990; Singh et al., 2007).  Direct demonstration of the 
intracrine effects of Ang-II has been hampered because of difficulty in selectively 
targeting intracellular Ang-II receptors without activating cell-surface receptors; 
therefore, the role of intracellular Ang-II signalling in mediating the effects of RAS 
activation remains poorly understood. 
Better spatial and temporal resolution of biologically active molecules can be 
achieved with the use of “caged compounds”, characterized by the addition of a 
photo-labile group on a substituent essential for receptor recognition (Yu et al., 2010).  
This approach has been used to study cellularly localized actions of a range of 
molecules, including ATP (McCray et al., 1980), GTP (Schlichting et al., 1989), 
endothelin-1, (Bourgault et al., 2007; Merlen et al., 2013), isoproterenol (Muralidharan 
& Nerbonne, 1995; Vaniotis et al., 2013), phenylephrine (Muralidharan et al., 1993), 
γ-aminobutyric acid (Wang & Augustine, 1995), urotensin II (Bourgault et al., 2005), 
endothelin receptor antagonists (Merlen et al., 2013), IP3 (Li et al., 1998; 
Tertyshnikova & Fein, 1998), cofilin (Ghosh et al., 2004), DNA (Monroe et al., 1999) 
and RNA (Chaulk & MacMillan, 1998; Ando et al., 2001). Caged molecules can be 
introduced non-invasively into the cell in an inert form and then subsequently 
uncaged with a focused pulse of ultraviolet (UV) light, allowing downstream effects to 
be monitored without disrupting other aspects of the system (Merlen et al., 2013; 
Vaniotis et al., 2013), a feature not exhibited by conventional reagents. 
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Ang-II displays stringent conformational and dynamic requirements for the amino 
acids at position 4 (tyrosine) and 8 (phenylalanine) for receptor binding (Aumelas et 
al., 1985; Samanen et al., 1989; Bovy et al., 1990; Noda et al., 1995).  Ang-II 
analogues bearing modifications at positions 4 or 8 differentially activate post-
receptor signalling in a biased fashion, thus giving rise to distinct biological outcomes 
(Zimmerman et al., 2012).  To develop a tool with which to study the consequences of 
selective activation of intracellular Ang-II receptors, we synthesized photo-activatable 
caged analogues of Ang-II by adding a photo-labile DMNB residue on the phenolic 
group of tyrosine-4 and/or on the α-COOH of phenylalanine 8, thereby creating three 
“caged” analogues of Ang-II: [Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and 
[Tyr(DMNB)4]Ang-II-ODMNB.  Here, we report for the first time the design, synthesis 
and characterization of these compounds that can be photo-triggered to release Ang-
II.  We go on to show that photoactive [Tyr(DMNB)4]Ang-II demonstrates intracrine 
regulation of cardiomyocyte nuclear calcium content and gene-expression. 
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Materials and Methods 
Cell Culture and AT1R/AT2R Transfection 
Human embryonic kidney 293 (HEK 293) cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 
µg/mL streptomycin, 100 units/mL penicillin, and 2 mM L-glutamine at 37°C in a 
humidified 5% CO2-containing atmosphere.  HEK 293 cells were seeded at a density 
of 4×104 cells per 20 mm well of 24-well plates, 1×105 cells per 35 mm well of 6-well 
plates, or 106 cells per 100 mm culture dish.  For transient expression in HEK 293 
cells, expression vectors encoding AT1R-Venus or AT2R-Venus were transfected into 
cells with polyethylenimine (PEI) at a final concentration of 9 µg/mL (Zhang et al., 
2009).  Radioligand binding assays, immunoblots, or ELISA experiments were carried 
out 48 h after transfection. 
 
Synthesis and Purification of Caged Angiotensin-II Analogues  
All Ang-II analogues were synthesized manually on a 2-chlorotrityl chloride resin (0.7 
mmol/g) using solid-phase peptide synthesis with Fmoc chemistry.  Synthesis of 
Fmoc-Tyr(DMNB)-OH was performed as previously described (Bourgault et al., 2005, 
2007).  Coupling of protected amino acids, monitored with the qualitative ninhydrin-
test, was performed with a 3-equivalent excess of the protected amino acids, based 
on the original substitution of the resins, benzotriazol-1-yl-oxy-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP; 3 equiv) and N,N-
diisopropylethylamine (DIPEA; 6 equiv) in N,N-dimethylformamide (DMF) for 45 min.  
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Fmoc removal was achieved with 20% piperidine in DMF for 20 min.  After 
deprotection, the resin was washed extensively with DMF (1x), methanol (1x), 
methylene chloride (DCM) (1x) and DMF (2x) before starting another cycle for the 
introduction of the next amino acid.  Cleavage of Ang-II and [Tyr(DMNB)4]-Ang-II from 
the resin was performed with a mixture of trifluoroacetic acid 
(TFA)/triisopropylsilane/phenol/water (92/2.5/3/2.5) for 2 h.  Following evaporation of 
the solvent, the crude peptides were precipitated by addition of cold diethyl ether.  
The products were isolated, dissolved in water and freeze-dried.  For C-terminally 
modified peptides Ang-II-ODMNB and [Tyr(DMNB)4]-Ang-II-ODMNB, cleavage from 
the solid support was carried out with AcOH/trifluoroethanol/DCM (1:1:8; v/v/v) to 
produce fully protected peptides with a free carboxy-terminal function.  The C-terminal 
carboxylic acid was reacted with 4,5-dimethoxy-2-nitrobenzyl alcohol (DMNBA), as 
described by Bourgault et al. (Bourgault et al., 2007)  C-terminally caged Ang-II 
analogues were obtained by stirring the protected peptides bearing a C-terminal 
DMNB ester group with TFA/triisopropylsilane/phenol/water (92/2.5/3/2.5).  Similarly, 
to obtain fluorescein-conjugated peptides, a N-protected ε-amino acid spacer (Fmoc-
aminohexanoic acid-OH; Fmoc-Ahx-OH) was coupled to peptidyl-resins using the 
BOP reagent condensation methodology (see above).  After Fmoc removal, the free 
amino group was allowed to react overnight with fluorescein isothiocyanate (FITC; 1.2 
equiv) in a DMF/DCM mixture (1:1), in presence of triethylamine (20 equiv) (Jullian et 
al., 2009).  TFA cleavage (TFA/triisopropylsilane/phenol/water; 92/2.5/3/2.5; 2 h) 
produced the expected ﬂuorescent peptides.  Crude peptides were purified by 
preparative reverse phase high performance liquid chromatography (RP-HPLC) using 
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a Phenomenex C18 column (300 Å pore size, 15 µm bead diameter, 250 mm x 21.2 
mm) at a flow rate of 20 mL/min.  Peptides were eluted with a linear gradient of 0-
100% solution B over 2 h (solution A: 0.06% TFA/H2O, solution B: 40% CH3CN in 
0.06% TFA/H2O).  The absorbance was monitored at 229 nm (A229).  To confirm the 
purity and mass of the purified products, aliquots of the collected fractions were (1) 
resolved by analytical RP-HPLC using a CSC-Kromasil C18 column (100 Å pore size, 
5 µm bead diameter, 250 mm x 4.6 mm) connected to a Beckman 128 pump and 
Beckman 168 PDA detector, at a flow rate of 1 mL/min, and (2) assessed by matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry 
(Voyager DE system).  Fractions from preparative HPLC found to have the expected 
m/z value and be >95% pure were pooled, lyophilized and stored at -20°C. 
 
Competition Binding Assays 
Purified Ang-II (10 µg) was radiolabeled with Na125I (0.3 mCi) using chloramine-T (5 
µg) in 0.05 M phosphate buffer (pH 7.4) at room temperature for 60 s.  The reaction 
was stopped by addition of 10 mM sodium metabisulfite and then applied to a Sep-
Pak C18 cartridge (Waters Corp, Milford, MA, USA).  [125I]Ang-II was eluted with a 
60% CH3CN/H20 0.1% TFA solution and stored at -20°C until use.  Competition 
binding assays employed concentrations of unlabelled ligands (Ang-II, 
[Tyr(DMNB)4]Ang-II, Ang-II-ODMNB, [Tyr(DMNB)4]Ang-II-ODMNB) ranging from 10-
10 M to 10-5 M.  HEK 293 cells transfected transiently with AT1R-Venus or AT2R-
Venus were plated in 24-well plates, gently washed twice with phosphate-buffered 
saline (PBS), and incubated for 45 min at 37°C in binding buffer (DMEM, 0.1% BSA) 
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containing [125I]Ang-II (50,000 cpm/well) plus the indicated concentrations of 
unlabelled ligand.  At the end of the incubation period, buffer was removed by suction 
and cells were washed twice with ice-cold PBS, before being treated with 0.5 M 
NaOH for 10 min at room temperature (Bosnyak et al., 2011).  The material in each 
well, corresponding to bound radioligand, was quantified using a Wallac WizardTM 
1470 γ-counter.  Non-specific binding was measured in the presence of 1 µM 
unlabelled Ang-II.  The statistical fit of the data with one- or two-site models was 
initially evaluated with Akaike’s information criteria and extra sum-of-squares F test 
comparisons of model fits, and both AT1 and AT2 data were best fitted by a single-
site binding model.  To determine the pIC50 values for each Ang-II analogue, data 
were fit by one-site non-linear regression model using Graphpad Prism 6.0c for Mac 
OS X (GraphPad Software, La Jolla California USA).  
 
Preparation of Rat Thoracic Aortic Rings and Measurement of Contraction 
Strength  
Aortic rings were prepared from male Sprague Dawley rats (250-300 g) euthanized 
with CO2 asphyxiation.  All animal care and handling procedures were performed in 
accordance with the Canadian Council for the Care of Laboratory Animals and were 
approved by the Institutional Animal Research Ethics Committee, Institut National de 
la Recherche Scientifique - Institut Armand-Frappier and by the Montreal Heart 
Institute.  The descending thoracic aorta was excised, transferred to a Petri dish 
containing Krebs bicarbonate buffer (118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 
mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, pH 7.4), and cleaned 
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of connective tissue.  The endothelium was removed from aortic rings by gently 
rubbing the luminal surface and the vessel was cut into 4 mm rings.  Single aortic 
rings were mounted in 5 mL organ baths (37°C) filled with Krebs solution aerated with 
carbogen gas (95% O2, 5% CO2).  Isometric force-displacement transducers 
connected to a Grass 7E polygraph were used to measure changes in contraction.  
Aortic rings were allowed to equilibrate for 1 h under a resting tension of 1 g with 
buffer changes every 15 min.  Once the tension was stable, a reference contractile 
response was obtained by stimulating with 40 mM KCl.  Aortic rings were then 
washed multiple times, and the contractile response to Ang-II or the caged Ang-II 
analogues was determined as cumulative concentration-response curves.  For each 
ring preparation, the contractile response was expressed as a percentage of the 
change in tension induced by 40 mM KCl. 
 
 
ERK 1/2 Phosphorylation 
HEK 293 cells seeded in uncoated 6-well plates were transfected with either AT1R-
Venus or AT2R-Venus as described above.  Cells were serum-starved for 24 h prior 
to stimulation.  On the day of the experiment, cells were washed twice with serum-
free DMEM and the assay was initiated by adding the indicated ligands and incubated 
at 37°C.  To terminate the incubation, cells were placed on ice, the medium was 
removed, and then cells were washed twice with ice-cold PBS.  They were then 
scraped into ice-cold lysis buffer (25 mM Na HEPES (pH 7.4), 150 mM NaCl, 25 mM 
NaF, 10 mM MgCl2, 1 mM EGTA, 1 mM Na3VO4, 0.025% sodium deoxycholate, 10% 
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glycerol (v/v), 10 μg/mL leupeptin, 10 μM benzamidine, 0.5 μM microcystin, 1% Triton 
X-100 (v/v), 0.1 mM phenylmethylsulfonyl fluoride and 5 mM dithiothreitol).  After a 30 
min incubation on ice, lysates were cleared by centrifugation at 10000×g for 10 min, 
and the supernatants retained.  The protein concentration of each lysate was 
determined, before being denatured using Laemmli sample buffer, and resolved by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE, precast 10% acrylamide gels, 
Bio-Rad Laboratories).  Proteins were transferred onto polyvinylidene difluoride 
membranes, probed with a phospho-ERK1/2-specific antibody (Cell Signalling 
Technology) and then, after stripping the membranes with Re-blot Plus mild antibody 
stripping solution (Millipore), re-probed using an ERK1/2-specific antibody (Abcam) to 
assess the total ERK immunoreactivity.  Horseradish peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch Inc.) were used and 
immunoreactive bands were revealed by chemiluminescence and quantified using the 
Quantity One 1-D analysis software (Bio-Rad Laboratories). 
 
Assessment of Angiotensin Receptor Expression in Thoracic Aorta   
HEK 293 cells, HEK 293-AT1R, HEK 293-AT2R or an isolated thoracic aorta were 
lysed by homogenizing samples in cold 300 mM Sucrose, 60 mM KCl, 0.5 mM EGTA, 
2 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM MgCl2•6H2O, 50 mM HEPES, 20 mM 
NaF, 0.2 mM Na3VO4, 20 mM β-glycerophosphate, 0.5 mM AEBSF, 25 µg/ml 
leupeptin, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µM microcystin, 0.1% NP40, pH 
7.4. Samples were then sonicated with two 10-s pulses, and intact cells, nuclei and 
cell debris were removed by centrifugation (500×g for 10 min). The supernatant was 
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centrifuged (80,000×g for 60 min) to pellet the membrane fraction, the supernatants 
discarded and 50 µg of each membrane fraction was resolved on SDS-PAGE. 
Following transfer, membranes were probed with AT1R (Alomone Labs), AT2R 
(Alomone Labs) or N-cadherin (BD Bioscience) specific antibodies.   
 
Live-Cell Fluorescence Imaging 
To assess the cell permeability of [Tyr(DMNB)4]Ang-II, fluorescein-conjugated 
derivatives of Ang-II, [Tyr(DMNB)4]Ang-II, TAT(48-60), and PACAP(28-38) were 
synthesized and accumulation of fluorescein-conjugated peptides in HEK 293 cells 
examined.  HEK 293 cells (non-transfected) were grown on glass coverslips, 
incubated for 60 min at 37°C with the fluorescent peptide in HEPES-Krebs-Ringer 
(HKR) buffer (5 mM HEPES, 2.68 mM KCl, 137 mM NaCl, 2.05 mM MgCl2, 1.8 mM 
CaCl2 and 1 g/L glucose, pH 7.4), washed extensively, and then incubated for 5 min 
with Cell Mask (1:1000; Invitrogen) and DRAQ5 (1:1000; BioStatus) to label the 
plasma membrane and nucleus, respectively.  Fluorescence was then visualized with 
an Olympus FluoView FV1000 inverted confocal microscope.  Separate channels 
were employed for each fluorophore (i.e. FITC, Cell Mask, DRAQ5) and the emission 
channels scanned sequentially to minimize crosstalk between overlapping emission 
spectra.  Cells were imaged by serial z-stack progressive scans, background 
fluorescence subtracted, and fluorescence values quantified using FluoView Software 
(FV10-ASW).  
To visualize changes in nucleoplasmic Ca2+ concentration ([Ca2+]n), freshly isolated 
canine ventricular cardiomyocytes were plated at 37°C for 60 min on laminin-coated 
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35 mm glass bottom culture dishes in Tyrode’s physiological buffer.  Cells were 
loaded with 5 µM Fluo-4AM (Invitrogen; from a 2.5 mM Fluo-4AM/10% Pluronic 
F125/DMSO stock) for 30 min in 10 mM HEPES (pH 7.4), 134 mM NaCl, 6 mM KCl, 
10 mM glucose, 2 mM CaCl2, 1 mM MgCl2, and in the absence or presence of 
[Tyr(DMNB)4]Ang-II, as described previously (Merlen et al., 2013).  Cardiomyocytes 
were washed three times, stained with a live-cell-permeant DNA dye (DRAQ5; 1 µM) 
and used for Ca2+ imaging within 1 h.  Images were obtained using a Zeiss LSM 7 
Duo microscope (combined LSM710 and Zeiss Live systems) with a 63x/1.4 oil Plan-
Apochromat objective.  Fluo-4AM was excited using a 488 nm/100 mW diode (1-5% 
laser intensity) and fluorescence emitted between 495 nm and 550 nm was collected.  
Cells were scanned at 30 fps in bi-directional mode.  The pixel size was set at 0.2 µm 
and the pinhole at 1.5 Airy units.  After establishing a baseline, [Tyr(DMNB)4]Ang-II 
was photolysed by a 70 µW pulse of UV-light using a 405-nm/30 mW diode. The 
power output from the 405-nm diode was measured at the level of the stage using an 
EC Plan-Neofluar 10x/0.3 objective lens using an X-Cite XR2100 optical power 
measurement system (Lumen Dynamics Group Inc).  DRAQ5 emissions were used to 
focus the UV-laser into a 60-µm2 rectangular region overlapping the nucleus.  The 
microscope stage (Zeiss Observer Z1) was equipped with a BC 405/561 dichroic 
mirror that permitted simultaneous photolysis of [Tyr(DMNB)4]Ang-II (LSM 710 405 
nm laser) and image acquisition (Zeiss Live).  Intranuclear Ca2+ levels were 
expressed as a percentage of fluorescence intensity relative to basal fluorescence 
(∆[Ca2+]Nuc(F/F0;%)); basal fluorescence is the fluorescence intensity acquired 1 s 
prior to uncaging the [Tyr(DMNB)4]Ang-II.  
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Flow Cytometry 
Uptake of peptides into HEK 293 cells was quantified by flow cytometry.  HEK 293 
cells were incubated for 60 min at 37°C in the presence of the fluorescein-conjugated 
derivatives of Ang-II, [Tyr(DMNB)4]Ang-II, TAT(48-60), or PACAP(28-38) in HKR 
buffer.  Following multiple washes with an isotonic acidic aqueous solution (200 mM 
glycine, 100 mM NaCl, pH 4.0) and PBS to remove extracellular fluorescein-peptides, 
cells were detached by trypsinization, centrifuged at 1000×g for 5 min, and 
resuspended in PBS.  To identify non-viable cells, propidium iodide (PI; 0.5 μg/mL) 
was added prior to analysis.  A minimum of 10,000 viable cells per sample were 
analyzed using a Becton Dickinson FACScan system.  The mean fluorescence 
intensity of the live cell population was used for further analysis using the FlowJo 
software. 
 
Canine Cardiomyocyte Isolation 
Cardiac cell isolation was performed by perfusion with Tyrode’s solution containing 
collagenase (100 U/mL, Worthington, type II) as previously described (Tadevosyan et 
al., 2015). 
 
Quantitative PCR 
RNA from cardiac cells was extracted with Trizol (Life Technologies) following the 
manufacturer’s protocol.  cDNA was synthesized from 1 µg RNA with the use of a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  qPCR assays 
were performed as described previously (Dawson et al., 2012) using the following 
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TaqMan probes and primers (Applied Biosystems): eukaryotic 18S rRNA (Assay ID: 
Hs03003631_g1), NFkB (Assay ID: Cf02622547_m1), HPRT1 (Assay ID: 
Cf02626255_g1).  HPRT1 was used as an internal standard.  Each RNA was 
assessed in duplicate and analyzed with the delta-CT method. 
 
Statistical Analysis 
Data from radioligand binding and functional assays were from a minimum of 3 
independent experiments and are presented as mean ± SEM.  EC50, pEC50, IC50 
and pIC50 values were determined by fitting experimental data by non-linear 
regression with GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, La 
Jolla California USA).  Student's t-tests (for single 2-group comparisons) , 1-way or 2-
way ANOVA with Bonferroni post hoc test (multiple groups with a common control) 
were used for statistical comparisons and P<0.05 or less was considered to be 
statistically significant. 
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Results 
Design and Synthesis of Photoactivable Caged Ang-II Analogues 
Previous structure-function studies have shown that Ang-II activates AT1 and AT2 
receptors through an induced-fit mechanism; for which the aromatic Tyr4 moiety and 
the α-COOH group of Phe8 are crucial for biological activity (Aumelas et al., 1985; 
Bovy et al., 1990; Noda et al., 1995; Samanen et al., 1989)  Accordingly, we designed 
and synthesized three Ang-II analogues incorporating the photo-labile nitrobenzyl 
substituent (4,5-dimethoxy-2-nitrobenzyl; DMNB) on either the phenolic function of 
Tyr4, the terminal α-COOH group, or both (Fig. 1A-D).  The caging substituent was 
stable when exposed to 1) 20% piperidine in DMF during removal of the Fmoc N-
protecting group and 2) 100% trifluoroacetic acid (TFA) during peptide cleavage from 
the resin used in solid phase synthesis.  Each Ang-II analogue eluted from RP-HPLC 
as a single major product.  The purity of each fraction was assessed and confirmed 
by analytical HPLC.  Analysis of Ang II, [Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and 
[Tyr(DMNB)4]Ang-II-ODMNB by mass spectrometry revealed a major peak 
corresponding to the calculated molecular mass (Table I).  Computational structural 
analysis using PyMol molecular visualization software predicted that the addition of 
the DMNB group induces conformational changes, including alterations in both main 
chain torsion angles and side chain orientation (Fig. 1A-D).   
In order to be used in studying intracrine Ang-II signalling in intact cells, a caged Ang-
II analogue must possess the following characteristics (relative to unmodified Ang-II): 
1) reduced affinity for ATR1 and ATR2 binding, 2) reduced affinity and efficacy for 
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ATR1 and ATR2 activation, 3) rapid uncaging without inducing cell damage and 
release of the original unmodified form of the ligand upon uncaging, 4) increased cell 
permeability, 5) physiological activity of the intracellular form under conditions in 
which extracellular activation is excluded.  What follows is a characterization of 
[Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and [Tyr(DMNB)4]Ang-II-ODMNB according to 
these criteria.  
 
Pharmacological Characterization of the Caged Ang-II Analogues  
Radioligand binding assays showed a strong rightward shift in the displacement curve 
for all three analogues compared to Ang-II (Fig. 1E and 1F).  The shift indicated 
between 100- and 1000-fold reduced binding affinity.  Unmodified Ang-II displaced 
[125I]Ang-II binding to AT1R or AT2R with IC50 values of 3.2 nM and 32 nM, 
respectively.  In contrast, the caged analogues displaced [125I]Ang-II with much higher 
IC50 values, indicating affinity-reductions of 2-3 orders of magnitude: for AT1R and 
AT2R respectively: [Tyr(DMNB)4]Ang-II, 1.1 µM and 1.6 µM; Ang-II-ODMNB, 0.91 µM 
and 0.47 µM; [Tyr(DMNB)4]Ang-II-ODMNB, 1.1 µM and 1.9 µM (Table I). 
The ability of the caged Ang-II analogues (in the absence of uncaging) to activate 
cell-surface angiotensin receptors was evaluated by concentration-response curve 
bioassays using rat thoracic aortic ring preparations (Figs. 2A-D), which expresses 
both AT1R and AT2R (Fig. 2E).  Ang-II evoked a concentration-dependent 
contraction with a pEC50 of 8.10±0.15 and a maximal efficacy (Emax) of 134%±11% 
(N=7).  All caged Ang-II analogues were far less potent than Ang-II (Fig. 2F) and 
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induced no detectable vasoconstriction at concentrations of the order (10-8 M) used 
to study intracrine signalling.  
 
Photorelease Kinetics and Action of Caged Ang-II Analogues 
Photorelease kinetics of the caged Ang-II analogues (10-8 M) upon exposure to UV-
light were examined by mass spectroscopy (Figs. 3A-C).  UV-irradiation (100 W) 
caused a time dependent decrease in the abundance of each caged Ang-II analogue 
(indicating its photolysis), with a concomitant increase in free Ang-II (corresponding to 
Ang-II release via cleavage of the photolabile group).  Mass spectrometry revealed 
that no significant side reactions releasing products other than Ang-II occurred during 
photolysis.  Of the three caged Ang-II analogues, [Tyr(DMNB)4]Ang-II showed the 
fastest rate of release (Fig. 3D).  The time-course of changes in concentration of the 
caged compound ([Tyr(DMNB)4]Ang-II) and the free Ang-II product of photolysis was 
independently confirmed with 3 different UV-exposure durations (1 second, 1 minute 
and 3 minutes) by HPLC (Fig. 3E).   
We next sought to verify that photolysis resulted in the release of physiologically 
functional Ang-II.  After assessing their contractile response to 40 mM KCl as a 
reference, we incubated aortic rings with caged Ang-II analogues at concentrations 
(10-8 M) that were inactive in the absence of photolysis, and then photolysis was 
induced by UV-irradiation while monitoring tension.  UV-irradiation in the absence of 
caged Ang-II did not increase tension (Fig. 4A).  In contrast, in the presence of the 
caged compounds UV-irradiation induced time-dependent increases in tension of 
aortic ring preparations, following an initial ~2-3 minute delay.  The rate of rise of the 
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tension varied among the compounds (note differences in time-scales of Fig. 4B-D).  
Photolysis of [Tyr(DMNB)4]Ang-II induced the fastest-rising response (Fig. 4B D).  Fig. 
4E shows a quantification of the response from its onset for each probe, with results 
expressed as percentage of maximal 40 mM KCl-response (mean±SEM values for all 
experiments with each agent).  The fastest-appearing response was clearly seen with 
[Tyr(DMNB)4]Ang-II, consistent with its rapid uncaging rate in Fig. 3D.  Thus, the 
caged Ang II analogues described here show very limited ability to bind to and 
activate ATRs in the absence of photolysis; upon photolysis, they release 
pharmacologically active Ang-II.  Because [Tyr(DMNB)4]Ang-II displayed minimal 
intrinsic activity, rapid photolysis, and clear biological activity following UV-irradiation, 
we focused on the evaluation of [Tyr(DMNB)4]Ang-II for further study of intracrine 
Ang-II signalling in live cells. 
 
Photolysis of [Tyr(DMNB)4]Ang-II activates AT1R-mediated ERK signalling  
To further examine the biological activity of Ang-II photoreleased from caged 
analogues, we examined an AT1R-specific response to extracellular Ang-II.  
Extracellular signal-regulated kinases (ERKs)-1/2 are activated by mitogenic signals, 
including AT1R-stimulation.  Accordingly, we examined the effects of extracellular 
[Tyr(DMNB)4]Ang-II and Ang-II via AT1R activation by assessing ERK1/2 
phosphorylation in HEK 293 cells transiently transfected with AT1R. Ang-II (5 min, 
37°C) increased ERK phosphorylation in a concentration-dependent manner that was 
half-maximal at ~10-8 M (Fig. 5A).  At a concentration as high as 10-6 M, 
[Tyr(DMNB)4]Ang-II did not induce ERK1/2 phosphorylation in the absence of 
 
 
142 
 
photolysis (Fig. 5B).  In contrast, upon photolysis [Tyr(DMNB)4]Ang-II induced a 
concentration-dependent increase in ERK1/2 phosphorylation (Fig. 5C) with a 
maximum level of ERK1/2 phosphorylation similar to Ang-II (Fig. 5D).  Consistent with 
AT1R-mediated ERK activation in HEK 293 cells, Ang-II-induced ERK 
phosphorylation was inhibited by AT1R blockade with valsartan (Figs. 5E and 5F).  
UV-irradiation alone did not increase ERK1/2 phosphorylation.  Hence, 
[Tyr(DMNB)4]Ang-II is unable to activate AT1R-induced ERK-phosphorylation at 
concentrations as high as 1 µM, but upon photolysis shows full pharmacological 
activity. 
 
Photolysis of [Tyr(DMNB)4]Ang-II activates AT2R-mediated cGMP signalling 
We then proceeded to examine the AT2-R mediated biological activity of extracellular 
Ang-II photoreleased from caged analogues.  AT2R-dependent cardiac-vessel 
vasodilation is mediated by the NO/cGMP pathway (Tsutsumi et al., 1999).  
Therefore, we examined the effects of extracellular [Tyr(DMNB)4]Ang-II  and Ang-II on 
AT2R activation by measuring cGMP levels by ELISA (Thermo Scientific) in HEK 293 
cells transiently transfected with AT2R.  cGMP production in Ang-II-treated cells (10 
nM, 45 min) was 2-fold greater than vehicle-treated cells (3.63±0.43 versus 1.80±0.22 
pmol/mg protein) (Fig. 6).  At the same concentration, [Tyr(DMNB)4]Ang-II had no 
effect on the cGMP levels (2.24±0.04 versus 2.17±0.24 pmol/mg protein for cells 
exposed to UV-light alone).  Upon uncaging by UV-irradiation, [Tyr(DMNB)4]Ang-II (10 
nM) increased the cellular cGMP content by 2-fold (4.51±0.33 versus 2.17±0.24 
pmol/mg protein for cells exposed to UV-light alone).  The effects of both Ang-II and 
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irradiated [Tyr(DMNB)4]Ang-II were abolished by preincubation with the AT2R-
selective antagonist, PD 123319.  Similarly, preincubating HEK 293 cells with the 
non-selective NO synthase inhibitor L-NAME markedly attenuated the increase in 
cGMP induced by both Ang-II and irradiated [Tyr(DMNB)4]Ang-II.  Hence, 
[Tyr(DMNB)4]Ang-II (10 nM) alone is unable to activate AT2R but upon photolysis, it 
shows strong AT2R-mediated activity. 
 
Cell Permeability of [Tyr(DMNB)4]Ang-II 
To test the ability of [Tyr(DMNB)4]Ang-II to cross the plasma membrane, we 
synthesized fluorescein-labelled derivatives of caged (fluorescein-
[Ahx0,Tyr(DMNB)4]Ang-II) and uncaged (fluorescein-[Ahx0]Ang-II) angiotensin-II.  The 
uptake of Ang-II and [Tyr(DMNB)4]Ang-II was compared to that of fluorescein-
[Ahx0]TAT(48-60), a cell permeable peptide derived from the HIV transactivating 
regulatory protein TAT, and fluorescein-[Ahx0]PACAP(28-38), a highly basic segment 
of pituitary adenylyl cyclase-activating polypeptide previously characterized as having 
no cell-penetrating properties (Doan et al., 2012).  Non-transfected HEK 293 cells 
were employed to minimize receptor-mediated endocytosis of Ang-II.  Cells were 
treated with either fluorescein-[Ahx0]Ang-II, fluorescein-[Ahx0,Tyr(DMNB)4]Ang-II, 
fluorescein-[Ahx0]PACAP(28-38) or fluorescein-[Ahx0]TAT(48-60) and the cellular 
uptake of the fluorescent peptides was analyzed by both confocal fluorescence 
microscopy and flow cytometry (Figs 7A and 7B).  CellMask™ orange and DRAQ5 (a 
DNA-binding dye) were used to delineate the plasma membrane and nucleus, 
respectively.  After acidic washes to remove peptides non-specifically bound to the 
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extracellular surface, images of cellular fluorescence were acquired with a confocal 
microscope.  Fluorescein-[Ahx0]TAT(48-60) (2936±410) produced a clear intracellular 
fluorescence signal, whereas almost no intracellular fluorescence was observed with 
fluorescein-[Ahx0]PACAP(28-38) (186±61).  Overall, we observed significantly greater 
intracellular fluorescence intensity with fluorescein-[Ahx0,Tyr(DMNB)4]Ang-II 
(3475±338) than with fluorescein-[Ahx0]Ang-II (726±74) (Fig. 7C).  Further analysis 
with flow cytometry revealed that cells preincubated with fluorescein-
[Ahx0,Tyr(DMNB)4]Ang-II displayed a much greater mean fluorescence signal (77±2) 
than with fluorescein-[Ahx0]Ang-II (24±6) and even greater than the cell-permeable 
standard fluorescein-[Ahx0]TAT(48-60) (60±3) (Fig. 7D).  Thus, Tyr(DMNB)4]Ang-II is 
a potent cell-penetrating peptide that permits both 1) delivery of a caged Ang-II 
analogue into intact live cells and 2) spatial and temporal control of ligand release.  
 
Photolysis of [Tyr(DMNB)4]Ang-II Inside Cardiac Cells Increases Nuclear 
Calcium, 18S rRNA and NF κB mRNA levels  
Nuclear Ca2+ regulates essential cellular processes, including transcription, growth 
and apoptosis.  Ang-II is a potent promoter of Ca2+ release but, so far, tools have 
been lacking to discriminate the contribution from organelle-localized versus cell-
surface ATRs.  Both AT1R and AT2R are expressed on nuclei of numerous cell 
types, including cardiomyocytes (Tadevosyan et al., 2012).  Here, using live-cell 
confocal fluorescence microscopy, we examined the effect of intracellular 
[Tyr(DMNB)4]Ang-II photolysis on nucleoplasmic Ca2+ ([Ca2+]n) and cytoplasmic Ca2+ 
([Ca2+]c) indices in adult canine cardiomyocytes (Figs 8 A-C).  Changes in [Ca2+]n and 
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[Ca2+]c  were visualized using the cell-permeable Ca2+ dye Fluo-4 AM.  Following 
exposure to 20 nM [Tyr(DMNB)4]Ang-II, cells were thrice-washed to ensure removal 
of the extracellular moiety.   
Photolysis of [Tyr(DMNB)4]Ang-II caused a significant increase in [Ca2+]n whereas 
non-photolyzed [Tyr(DMNB)4]Ang-II did not (Figs. 8A and B).  To ensure that the 
photoactivated compound does not act via diffusion out of the cell followed by 
surface-receptor interaction, cells loaded with [Tyr(DMNB)4]Ang-II were both pre-
treated for 20 min with, and photolyzed in the presence of, 1 µM valsartan.  Valsartan 
did not reduce the magnitude of the increase in  [Ca2+]n at 400 s post-photolysis of 
[Tyr(DMNB)4]Ang-II, but the increase in [Ca2+]n was more rapid in the presence of 
valsartan. Hence, following photolysis, Ang-II does not increase [Ca2+]n by leaving the 
cell and acting on cell-surface receptors; however, there may be cross-talk between 
cell surface and nuclear ATRs.  Cells exposed to 100 µM 2-APB to block inositol 
trisphosphate (IP3) receptors (the principal angiotensin-dependent nuclear Ca2+-entry 
pathway (Tadevosyan et al., 2010)) displayed a significant decrease in [Ca2+]n  
accumulation following photolysis.  Sham-loaded cardiomyocytes (i.e. without 
[Tyr(DMNB)4]Ang-II in the loading buffer) displayed no change in [Ca2+]n in response 
to UV-irradiation (Fig. 8B).  Extracellular application of 20 nM Ang-II caused a slow 
and limited increase in [Ca2+]n, relative to that induced by intracellular photolysis of 
[Tyr(DMNB)4]Ang-II, and this effect was abolished when cells were pretreated with 1 
µM valsartan.  The changes in [Ca2+]c in response to photolysis of [Tyr(DMNB)4]Ang-
II were generally similar to that of [Ca2+]n, but the increases in fluorescence intensity 
were smaller for [Ca2+]c  (Figs 8B and C).  To compare directly the [Ca2+]n response 
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with the [Ca2+]c response, we normalized each to their respective baseline values (Fig 
8D).  The [Ca2+]n response occurred with or before the [Ca2+]c response, making it 
very unlikely that the [Ca2+]n increases are secondary to the change in [Ca2+]c.  
Figure 8E indicates the mean response in each group by showing mean baseline 
(t=10 seconds) versus post-photolysis (t=400 seconds) values. 
We have shown previously that Ang-II increases the transcription of ribosomal RNA 
(rRNA) and NF-κB mRNA in nuclei isolated from rat adult cardiomyocytes 
(Tadevosyan et al., 2010).  Similarly, photolysis of [Tyr(DMNB)4]Ang-II (cAng-II) 
increased 18S rRNA and NF-κB mRNA, compared to the more slowly photolysed 
Ang-II-ODMNB, in intact cardiomyocytes (Figs 9A and 9B).  Therefore, selective 
activation of intracellular ATRs in cardiomyocytes increases [Ca2+]n and regulates 
gene transcription. 
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Discussion 
The intracrine RAS has been suggested to control intracellular Ca2+-fluxes, 
generation of reactive oxygen species, junctional conductance, cell volume, 
chromatin solubility, gene transcription and posttranslational histone modifications 
(Re & Cook, 2011).  The presence of functional Ang-II receptors on the nuclear 
membrane, along with the nuclear localization of carboxy-terminal sequence of the 
AT1R (Lee et al., 2004), provided additional support for the idea that classical 
receptor signalling occurs on intracellular membranes (Morinelli et al., 2007).  To 
further examine this concept and develop a tool for exploring it, we synthesized novel 
caged, cell-permeable Ang-II analogues, [Tyr(DMNB)4]Ang-II being the most effective, 
allowing spatio-temporal control of ATR activation within intact cells.  Furthermore, we 
have shown that photolysis of [Tyr(DMNB)4]Ang-II inside intact cardiomyocytes 
increases [Ca2+]n, as well as 18S rRNA and NF-κB mRNA levels.  
A variety of approaches, each with its own challenges and technical limitations, 
have been applied in vitro and in vivo to study the role of the intracrine RAS.  Redding 
et al. bred transgenic mice that expressed a construct comprising Ang-II fused in-
frame to the cyan fluorescent protein (ECFP), linked by a small spacer arm, under 
control of the mouse metallothionein promoter (Redding et al., 2010).  This construct 
was developed in a manner that ensures that ECFP-Ang-II is synthesized but 
retained intracellularly as it was unable to access the secretory pathway.  Although 
this transgene resulted in changed diastolic and systolic blood pressure, as well as 
thrombotic renal microangiopathy, its expression was ubiquitous rather than 
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intracellularly targeted.  Similarly, Li et al. used the sgtl2 gene promoter to selectively 
drive expression of ECFP-Ang-II in proximal renal tubules; however, this construct 
was delivered using an adenovirus and, hence, the effect was transient (Li et al., 
2011).  Furthermore, in vivo delivery to other organs might have been hampered by 
host immune responses.  There have been several reports in which liposomes were 
used to deliver hormones intracellularly.  Filipeanu et al. demonstrated that liposomal 
delivery of Ang-II into A7r5 cells induced cell growth through activation of the 
phosphoinositide 3-kinase and MAPK/ERK pathways (Filipeanu et al., 2001).  
However, during liposomal delivery only a small fraction (7.2±0.2%) of the 
administered Ang-II was actually taken up into target cells.  Additional disadvantages 
of the liposomal delivery strategy include inability to target the cargo to a specific cell 
type, biological instability due to the amphiphilic character of liposomes, interactions 
with lipoproteins, and interactions with common degradation pathways.  De Mello 
used microinjection to introduce Ang-II into ventricular cardiomyocytes and observed 
increased inward Ca2+ current (ICa) and altered myocardial contractility (De Mello, 
1998).  Similarly, Haller et al. reported that microinjection of Ang-II into vascular 
smooth muscle cells (VSMCs) induced a rise in [Ca2+] within the injected cell and also 
in adjacent cells (Haller et al., 1996).  It was concluded that Ang-II stimulated a cluster 
of VSMCs via release of diffusible intracellular second messengers from the injected 
cell.  Nevertheless, the possibility that observed effects were due to outflow of the 
peptide that eventually activated neighbouring cell-surface receptors could not be 
excluded.  Moreover, although microinjection provides a way to introduce an agonist 
(or antagonist) into a cell, it can only be applied realistically to single cell experiments 
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and, therefore, like liposomal delivery, it is not amenable to biochemical analysis of 
intracrine effects.  
The development of caged, cell-permeable Ang-II analogues will permit the 
study of the molecular pharmacology and physiological function of endogenous ATRs 
in a broad range of primary cells and possibly ex vivo tissue preparations.  Insights 
into the structural interactions involving Ang-II and its receptors guided the design of 
caged peptide analogues to selectively interfere with receptor binding and activation 
(Chaulk & MacMillan, 1998; Monroe et al., 1999; Ando et al., 2001).  The photolabile 
4,5-dimethoxy-2-nitrobenzyl group (DMNB) exhibits maximal absorption in the near 
UV-range (λ=365 nm), excellent solubility in aqueous solution, and is compatible with 
sensitive biological preparations.  In the present study, DMNB was introduced at the 
phenolic hydroxyl group of Tyr4 and/or at the carboxyl function of Phe8 of Ang-II 
(Figs. 1A-D).  The addition of DMNB enhanced the lipophilicity of Ang-II, allowing 
[Tyr(DMNB)4]AngII to cross plasma membranes efficiently, while remaining water 
soluble.  Cell permeability was so effective that the intracellular accumulation of 
[Tyr(DMNB)4]AngII was greater than that of a potent cell-penetrating peptide derived 
from the HIV-1 trans-activating protein, TAT (Fig. 7A-D).  All three synthetic caged 
analogues i.e. [Tyr(DMNB)4]Ang-II, Ang-II-ODMNB and [Tyr(DMNB)4]Ang-II-ODMNB) 
showed greatly decreased ability to bind and activate ATRs in the absence of 
photolysis.  [Tyr(DMNB)4]Ang-II was the best suited for live-cell studies because of its 
rapid photolysis kinetics.  This characteristic allows the study of events occurring on a 
rapid time scale and minimizes exposure of target-cells to UV-irradiation.  Rapid 
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photolysis also permits evaluation of the effects of acute ligand application in either 
single cells or a cell population, an experimental condition that cannot be achieved 
with liposomes or microinjection.  The temporal and spatial control of Ang-II release 
upon UV-irradiation provides a versatile tool for studying the functional and molecular 
pharmacology of intracrine Ang-II signalling.  We examined the effects of 
[Tyr(DMNB)4]Ang-II in isolated tissue preparations, cultured HEK 293 cells, and 
isolated adult cardiomyocytes.  Studies in these systems confirmed the reduction in 
intrinsic affinity and activity of [Tyr(DMNB)4]Ang-II, in comparison with Ang-II, and its 
capacity to demonstrate substantial pharmacological potency and efficacy upon 
photolysis.  
Although we previously demonstrated the mobilization of nuclear Ca2+ (which 
could be blocked by 2-APB) and de novo mRNA synthesis upon exposure to Ang-II in 
isolated nuclei (Tadevosyan et al, 2010), the physiological significance remained 
unclear in the absence of convincing evidence in an intact cell system. Here, we used 
photorelease of Ang-II from a caged analogue to show intracellular Ang-II dependent 
mobilization of nuclear Ca2+, along with de novo RNA synthesis, in intact 
cardiomyocytes.  This effect was suppressed by 2-APB, potentially implicating IP3 
receptors, whereas extracellular valsartan did not alter the response. Thus, the caged 
compound allowed us for the first time to show convincingly that intracellular Ang-II 
increases nucleoplasmic and cytosolic [Ca2+] in intact cardiomyocytes, with 
pharmacological evidence suggesting that this action is independent of extracellular 
receptors and that IP3 receptors might play an important role.  Further work is needed 
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to clarify the precise mechanisms underlying [Ca2+] changes in various subcellular 
compartments produced by intracellular Ang-II.  In principle the probes developed 
here could be used to study the role of intracellular Ang-II not only in cardiomyocytes, 
but in any cell-type. 
In summary, we have revealed the effectiveness of incorporating a 
photosensitive 4,5 dimethoxy-2-nitrobenzyl (DMNB) blocking group on the tyrosine-4 
side chain of Ang II in creating a cell-permeable, photoactivable Ang-II analogue.  The 
corresponding caged Ang-II analogue, [Tyr(DMNB)4]Ang-II, was stable, 
pharmacologically inactive within the required concentration range, rapidly released 
upon exposure to UV-light, and rapidly releases active Ang-II upon photolysis.  
Furthermore, when loaded into live cells, uncaging [Tyr(DMNB)4]Ang-II with a 
localized pulse from a UV-laser produces spatial and temporal release of Ang-II that, 
unlike other means of delivery, allows both pharmacological and functional studies of 
the intracrine Ang-II system in both primary and cultured cells. 
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Figure Legends 
 
Figure 1.  Structures of the caged Ang-II analogues and competitive displacement of 
[125I]Ang-II by caged Ang-II analogues. (A) Angiotensin-II (B) Ang-II-ODMNB (C) 
[Tyr(DMNB)4]Ang-II (D) [Tyr(DMNB)4]Ang-II-ODMNB.  The position of the photo-
sensitive 4,5-dimethoxy-2-nitrobenzyl moiety is indicated in brackets and was added 
either on the side chain of the tyrosine at position 4, the C-terminal carboxylic function 
of phenylalanine-8, or at both sites.  Red and blue surfaces describe negative and 
positive electrostatic potentials (-3.5 kBT, +3.5 kBT), respectively.  Three-dimensional 
structures were generated using the PyMol visualization software.  The electrostatic 
potentials were calculated using the Adaptive Poisson-Boltzmann Solver with the 
PyMol tool.  (E) and (F), Competitive displacement of [125I]Ang-II by Ang-II or caged 
Ang-II analogues (n=6/condition) in HEK 293 cells transfected with AT1R or AT2R.  
Data are percentage of specific radioligand binding in absence of competitors.  Non-
specific binding was determined in presence of 1 µM Ang-II. 
 
Figure 2.  Concentration-dependent responses of rat thoracic aortic rings to various 
analogues without uncaging.  Contraction-recordings were obtained with a curvilinear 
pen recorder for (A) Ang-II, (B) Ang-II-ODMNB (C) [Tyr(DMNB)4]Ang-II, and (D) 
[Tyr(DMNB)4]Ang-II-DMNB.  (E) Immunoblotting for AT1R, AT2R and N-cadherin 
(positive control) in membranes isolated from rat thoracic aorta as well as HEK 293, 
HEK 293-AT1R and HEK 293-AT2R cells.  (F) Overall results expressed as 
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percentage of contractile response induced by 40 mM KCl.  Data are mean±SEM of 
at least 5 experiments/group performed on tissues isolated from separate animals for 
each experiment.  Descending arrows on original recordings indicate baseline 
adjustment. 
 
Figure 3.  Photolysis kinetics of various analogues.  Photolysis (100-W UV-lamp) of a 
10-8 M solution of (A) [Tyr(DMNB)4]Ang-II, (B) Ang-II-ODMNB and (C) 
[Tyr(DMNB)4]Ang-II-ODMNB was performed in Krebs-Henseleit buffer and analyzed 
by mass spectrometry (n=3/group).  (D) Caged peptide concentration over time 
following UV-irradiation.  (E) Signal-intensity (Y-axis) versus wavelength (X-axis) and 
HPLC elution-time (Z-axis) at different times after photorelease of [Tyr(DMNB)4]Ang-II 
as analyzed by analytical HPLC.  
 
Figure 4.  Contractile responses of rat thoracic aortic rings following photolysis of 
various analogues.  Isometric aortic tension recording was obtained with a curvilinear 
pen recorder after 15-min incubation in the presence of caged analogues (10-8 M) 
followed by in situ photolysis with 30-W UV-lamp.  (A) Control (B) [Tyr(DMNB)4]Ang-II, 
(C) Ang-II-ODMNB and (D) [Tyr(DMNB)4]Ang-II-DMNB.  (E) Overall results as 
percentage of contractile response induced by 40 mM KCl.  Data are mean±SEM 
(n=4 independent preparations from each of 4 animals/group). 
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Figure 5.  AT1R-dependent ERK-phosphorylation following photolysis of 
[Tyr(DMNB)4]Ang-II.  Effects of (A) Ang-II, (B) [Tyr(DMNB)4]Ang-II, (C) UV-irradiated 
[Tyr(DMNB)4]Ang-II on serum starved HEK 293 cells transfected with AT1R.  
Phosphorylated ERK1/2 (p-ERK) and total ERK1/2 (ERK) immunoreactivity was 
determined on cell-lysates.  (D) pERK immunoreactivity normalized to total ERK 
immunoreactivity (mean±SEM).  (E) p-ERK and ERK immunoreactivity in AT1R 
transfected HEK 293 cells treated with vehicle, in the presence or absence of 10-nM 
Ang-II or [Tyr(DMNB)4]Ang-II (cAng-II), or valsartan (Val; 1 µM, 30 min) with or 
without UV-irradiation (1 min).  (F) Mean±SEM data corresponding to experiment in 
(E), N=3/concentration. **P<0.01, ***P<0.001, ns=non-significant.  
 
Figure 6.  AT2R-dependent cGMP production following photolysis of 
[Tyr(DMNB)4]Ang-II.  cGMP was measured in serum-starved HEK 293 cells 
transfected with AT2R following incubation with vehicle (control), Ang-II (10 nM) or 
[Tyr(DMNB)4]Ang-II, 10 nM), in the presence of PD123319 (PD, 1 µM), L-NAME (1 
mM), and UV-irradiation, as indicated.  Data shown mean±SEM, n=3/condition, 
***P<0.001, ##P<0.01 or ###P<0.001 vs. Ang II, §§§P<0.001 vs. [Tyr(DMNB)4]Ang-
II, ns=non-significant. 
 
Figure 7.  Cellular uptake of fluorescein-[Ahx0,Tyr(DMNB)4]Ang-II.  (A) Intracellular 
distribution of fluorescein-[Ahx0]Ang-II, fluorescein-[Ahx0,Tyr(DMNB)4]Ang-II, 
fluorescein-[Ahx0]PACAP(28-38) and fluorescein-[Ahx0]TAT(48-60) upon confocal 
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microscopy in live non-permeabilized HEK 293 cells.  Cell Mask and DRAQ5 were 
used to delineate the plasma membrane and nuclei, respectively.  (B) Intracellular 
fluorescence intensity (mean±SEM, ***P<0.001).  (C) Representative uptake 
efficiency of fluorescein-conjugated PACAP(28-38), TAT(48-60), Ang-II and 
[Tyr(DMNB)4]Ang-II in HEK 293 cells upon flow cytometry; quantified (D) with 
fluorescence-activated cell sorting analysis software FlowJo (Mean±SEM, 
n=3/condition, *P<0.05, ***P<0.001). 
 
Figure 8.  Response of nucleoplasmic and cytosolic [Ca2+] to photolysis of 
intracellular [Tyr(DMNB)4]Ang-II.  A) Nucleoplasmic and cytosolic [Ca2+] recorded in 
canine cardiomyocytes before (t=10 s) and after (t=400 s) photolysis in cells loaded 
with vehicle (control), 20 nM [Tyr(DMNB)4]Ang-II (cAng-II), 20 nM cAng-II + 1 µM 
valsartan, 20 nM cAng-II + 100 µM 2-APB, 1 µM valsartan  alone or extracellularly 
administered 20 nM Ang-II with or without 1 µM Valsartan.  Photolysis was induced by 
a pulse of UV-light (2-5 s, 70 µW) from a 405 nm/30 mW diode.  (B) Nucleoplasmic 
(C) Cytosolic[Ca2+] recorded in ventricular cardiomyocytes before and after photolysis 
in cells preincubated with [Tyr(DMNB)4]Ang-II, vehicle (Ctl), valsartan, 2-APB along 
with non-photolysed [Tyr(DMNB)4]Ang-II or vehicle.  Dotted bracket: UV irradiation.  
DRAQ5 fluorescence was used to select the area corresponding to the nucleoplasm.  
Signals are presented as background-subtracted normalized fluorescence (%F/F0), 
where F is the fluorescence intensity and F0 is the resting fluorescence in the same 
cell prior to photolysis. (D) [Ca2+] fluorescence in nucleus and cytosol normalized to 
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respective baseline (t=10 s) values. Nuclear changes are shown by dashed lines and 
cytosolic by solid lines.  (E) For each condition (n=8-12 cells), mean nuclear Fluo-4 
fluorescence at baseline (t=10 s; hatched bars) or after stimulation (t=400 s) was 
quantified.  Data are mean±SEM, ***P<0.000, n.s.=nonsignificant. 
 
Figure 9.  Photolysis of intracellular [Tyr(DMNB)4]Ang-II regulates gene-transcription.  
(A) 18S rRNA and (B) NF-κB mRNA quantified by qPCR.  A stimulation-control (scr) 
condition was performed where cardiomyocytes were loaded with a slowly-
photolysing Ang-II analogue, Ang-II-ODMNB.  Myocytes were incubated with 
[Tyr(DMNB)4]Ang-II or Ang-II-ODMNB (10 nM) for 30 min at room temperature.  
Following incubation, cells were washed, placed on ice, and exposed to a UV-lamp 
(30 W Pen-Ray lamp) for 1 min.  In addition, cells were examined following treatment 
with buffer (Ctl) or extracellular Ang-II (Ang-II; 10 nM).  Cells were then incubated at 
37°C for 4 h prior to RNA extraction.  Data are mean±SEM, *P<0.05, **P<0.01, 
***P<0.0001. 
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Table 1.  Physicochemical and binding properties of Ang-II and its photolabile 
analogues, as evaluated by competition binding assays using HEK 293-AT1 and HEK 
293-AT2 transfected cells 
Compound Name 
aMScalc  
(g.mol-1) 
bMSfound 
(g.mol-1) 
cPurity 
Binding 125I-Ang-II 
(HEK293-AT1R) 
Binding 125I-Ang-II 
(HEK293-AT2R) 
IC50 
(nM) 
pIC50 n 
IC50 
(nM) 
pIC50 n 
Ang-II 1046.18 1047.10 ≥95% 3.2 8.58±0.10 8 32 7.65±0.18 6 
[Tyr(DMNB)4]Ang-II 1241.35 1241.52 ≥95% 1110 6.01±0.11 6 1640 6.88±0.61 6 
Ang-II-ODMNB 1241.35 1242.43 ≥95% 915 6.13±0.27 6 470 6.45±0.28 5 
[Tyr(DMNB)4]Ang-
II-ODMNB 
1436.52 1437.52 ≥95% 1140 6.31±0.27 6 1930 6.54±0.52 6 
 
aTheoretical monoisotopic molecular weight as calculated with ChemDraw Ultra 7.0.1.  
bM/z value assessed by MALDI-TOF-MS.  cPercentage of purity determined by HPLC 
using the eluent system:  A = H2O containing 0.06% TFA and B = 40% CH3CN in 
aqueous 0.06% TFA, with a gradient of 1% B/min and a flow rate of 1 ml/min on a 
Jupiter C18 column.  Detection at 229 nm.  
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
 
 
 
CHAPTER 4 – Nuclear 
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Receptor Signaling in Cardiac Fibroblasts 
Governs de Novo RNA Expression, 
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Abstract 
 
Introduction: Cardiac fibroblasts are the most abundant cell type in the heart and 
govern cardiac structural remodeling. Recent findings indicate that the activation of 
the intracellular renin-angiotensin system (iRAS) in cardiomyocytes changes cell 
communication and alters cardiac excitability, but the functional importance of iRAS in 
cardiac fibroblasts is unknown.  
Objective:  To characterize intracellular Ang-II binding-sites and their functional role in 
atrial cardiac fibroblasts. 
Methods and Results:  Immunoblots of subcellular fractions obtained from isolated 
canine atrial fibroblast indicated the presence of nuclear AT1R and AT2R. AT1R was 
predominantly found on the inner nuclear membrane, whereas AT2R 
immunoreactivity localised to the inner nuclear membrane as well as the 
nucleoplasm. Ang-II-FITC binding assays and immunohistochemical analysis further 
confirmed the nuclear localization of AT1R and AT2R. AT1R mRNA and nuclear 
immunoreactivity- levels were significantly increased in atrial fibroblasts isolated from 
a canine heart failure (HF) model. In contrast, AT2R mRNA levels remained 
unchanged and nuclear AT2R was glycosylated. Nuclear expression of G proteins 
Gαq/11, Gαi/3, and Gβ was confirmed by immunoblotting and confocal microscopy. 
[α-32P]UTP incorporation showed that nuclear AT1R and AT2R regulate de novo RNA 
synthesis via inositol trisphosphate receptor (IP3R)- and nitric-oxide (NO)-dependant 
pathways. In intact cultured fibroblasts, intracellular Ang-II release lead to IP3R-
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dependant increases in nucleoplasmic Ca2+ concentration with IP3R3 being the 
predominant isoform detected. Intracellular Ang-II regulated fibroblast proliferation 
([3H]thymidine incorporation), collagen mRNA levels and collagen 1A1 secretion.  
Conclusions: AT1R and AT2R are present on fibroblast nuclei. Nuclear AT1R are 
upregulated whereas AT2R are glycosylated in HF. Nuclear AT1R and AT2R, acting 
through NO and IP3R, regulate fibroblast transcription and intracellular Ang-II 
regulates fibroblast proliferation and ECM synthesis. Fibroblast nuclear AT1R/AT2R 
may play a key role in heart structural remodeling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Intracrine angiotensin system, nuclear receptors, cardiac fibroblasts, 
fibroblast regulation, remodeling  
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Introduction  
Cardiac fibroblasts are the most predominant cell type of the myocardium and 
play a fundamental role in regulating the structural, mechanical and electrical 
properties of the heart [1, 2]. Fibroblast proliferation, which results in excessive 
extracellular matrix synthesis and cardiomyocyte uncoupling, leads to tissue fibrosis 
and myocardial remodeling. Many of the functional effects of cardiac fibroblasts are 
mediated by proinflammatory cytokines, vasoactive peptides and hormones [3].  
The renin-angiotensin system (RAS) through primary reactive vasoconstrictor 
angiotensin-II (Ang-II) regulates fibroblast homeostasis [4]. Ang-II leads to 
progressive collagen production within the myocardium in a dose-dependent manner 
and has emerged as a key candidate promoting the development of myocardial 
fibrosis [5]. The classical RAS was considered for decades as a circulatory system in 
which the octapeptide Ang-II is delivered to target tissue or cells.  Evidence is now 
available that independently of traditional RAS, cardiac cells can synthesize Ang-II 
intracellularly. Exposure of fibroblasts to isoproterenol or high glucose results in 
increased intracellular Ang-II levels [6]. Similarly, cardiomyocytes isolated from 
diabetic rats contains higher Ang-II concentrations compared to healthy animals [7]. 
Microinjection of Ang-II into cardiomyocytes changes physiological properties such as 
cell volume, cell communication and activation of ion channels [8].         
In the present study we sought to assess in atrial fibroblasts the subcellular 
distribution of Ang-II type 1 (AT1R) and type 2 receptors (AT2R), to characterize the 
underlying subtype-specific signalling mechanisms and define potential functional 
 
 
181 
 
significance using a novel caged Ang-II analog, [Tyr(DMNB)4]Ang-II [9]. We 
investigated atrial fibroblasts because of their important role in atrial fibrillation 
secondary to structural remodeling [2, 3]. A canine model of heart failure (HF) 
induced by ventricular tachypacing (VTP) was used to study the potential role of the 
iRAS in HF-related atrial arrhythmogenic remodeling as well as the effects of HF on 
Ang-II intracrine signalling [2, 3]. 
 
Materials and Methods 
Heart Failure (HF) Animal Model 
All animal protocols were approved by the institutional animal research ethics 
committee and were in accordance with the guidelines of the National Institutes of 
Health. Adult mongrel dogs were anesthetized with ketamine (5.0 mg/kg IV), 
diazepam (0.25 mg/kg IV) and halothane (1.5% PI). A unipolar pacing lead was 
inserted under fluoroscopy via the left internal jugular vein into the right ventricular 
apex and connected to an electronic pacemaker implanted in a subcutaneous pocket 
in the neck. After 24-hour post-operative recovery, the ventricular pacemaker was 
programmed to pace the ventricles at 240 bpm and an electrophysiological study was 
performed at the end of the VTP period.  
  
Atrial Fibroblast Isolation 
Adult mongrel dogs of either sex (20-30 kg) were anesthetized with morphine 
(2 mg/kg subcutaneous injection), α-chloralose (120 mg/kg intravenous), and heparin 
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(10,000 U). The heart was placed into 500 ml of ice-cold Tyrode solution (136 mM 
NaCl, 5.4 mM KCl, 1 mM MgCl2 · 6H2O, 2 mM CaCl2, 0.33 mM NaH2PO4 · H2O, 5 mM 
HEPES, 10 mM glucose, pH 7.4 at room temperature. Following cannulation of the 
left circumflex coronary artery and ligation of all leaks from arterial branches with silk 
to assure adequate perfusate pressure, the atria was perfused for 10 min with Ca2+ 
free Tyrode solution. The digestion of the atria was performed with constant recycling 
of collagenase solution containing 100 U/mL collagenase type II, 0.1 % bovine serum 
albumin (BSA) in Ca2+-free Tyrode’s solution. Digested tissue was sliced into small 
pieces and triturated with a transfer pipette to dissociate cell clumps in Dulbecco's 
modified eagle medium (DMEM). Debris was removed by filtration through a 500 μm 
nylon cell strainer and cells were centrifuged at 50 x g for 5 minutes, with slow 
deceleration, to pellet cardiomyocytes. The supernatant was centrifuged at 850 x g for 
15 minutes to pellet cardiac fibroblasts. Cells were immediately frozen in liquid 
nitrogen (freshly isolated cells) or plated in T-75 culture flask and transferred to an 
incubator at 5% CO2/95%-humidified air (37°C) in DMEM supplemented with 10% 
fetal bovine serum (FBS) and 2% penicillin/streptomycin. The medium was changed 2 
hours after plating to remove dead and non-attached cells and every 24 hours 
thereafter 
 
Cellular Fractionation and Western Blots 
Cultured or freshly isolated cardiac fibroblasts were washed in ice-cold 
phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 4.2 mM Na2HPO4 · 
H2O, 1.8 mM KH2PO4, pH 7.4 at room temperature. Cells were then placed on an 
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orbital shaker for 20 min at 4°C and semi-permeabilized in a lysis buffer: 150 M NaCl, 
0.2 mM EDTA, 20 mM Hepes-NaOH, 2 mM DTT, 2 mM MgCl2, 40 µg/ml digitonin, 
supplemented with protease/phosphatase inhibitor cocktail just before use. The 
homogenate was then diluted with equal volume of lysis buffer without digitonin and 
transferred to a Dounce homogenizer. To further disrupt the cells and free the nuclei, 
10 strokes with the tight pestle (‘B’) were performed. Freshly isolated nuclei are 
obtained after centrifugation at 850 x g for 15 min at 4°C in a swinging-bucket rotor 
(Sorvall 75-006-434 rotor). The supernatants are transferred to new tubes and further 
centrifuged at 80000 x g for 60 min 4°C (Beckman, TLA-100.3 rotor) to separate 
membrane and cytosolic fractions.   
Membrane, cytosolic or nuclear cell extracts were diluted with Laemmli sample 
buffer and denatured by heating at 100°C for 5 min, and then protein was quantified 
by the Bradford assay. Fixed amounts of protein was separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (7.5-12%) and 
electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. 
Membranes were blocked for 1 hour at room temperature and probed with primary 
antibodies overnight at 4°C. After extensive washing, membranes were further 
incubated with the appropriate secondary antibody conjugated to horseradish 
peroxidase and immunoreactive bands were detected by enhanced 
chemiluminescence (ECL). After stripping in ReBlot-plus strong antibody solution, 
membranes were blocked and re-probed with additional primary and secondary 
antibodies.  
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To detect secreted collagen, 50 µl of culture media collected from constant 
quantities of cells was mixed with Laemmli sample buffer, heated, and separated on 
precast 7.5% SDS-PAGE gels. Following migration, proteins were transferred 
electrophoretically onto nitrocellulose membranes and blocked in 3% bovine serum 
albumin (BSA) in PBS on a rotator overnight at 4°C. Membranes were probed with 
the primary antibodies for 1 hour at room temperature, then washed and incubated 
with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room 
temperature. Signals were detected with the ECL reagent and band intensities were 
quantified with Bio-Rad Quantity One software.  
 
Nuclear Fractionation 
Freshly isolated nuclei were suspended in 0.25 M sucrose, 50 mM Tris-HCl, 10 
mM MgCl2, 1 mM dithiothreitol. (pH 7.4) containing protease/phosphatase inhibitor 
cocktail and incubated for 30 min at 4 °C with 1% (w/v) sodium citrate. The nuclear 
suspension was centrifuged for 15 min at 500 x g and the supernatant, containing the 
outer nuclear membrane (ONM)-enriched fraction, was collected. The remaining 
pellet was re-suspended in 0.3 M sucrose, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM 
dithiothreitol. (pH 7.4). DNase (200 µg/ml) was added and samples were digested 
overnight at 4 °C on a rotating mixer. The homogenate was centrifuged for 2 h at 10 
000 x g and the supernatant, containing the nucleoplasmic (NP) fraction, was 
collected. The pellet, containing the inner nuclear membrane (INM), was further 
purified using sucrose density (0.25 M/ 1.6 M / 2.4 M) gradients (20 min at 100000 x 
g).   
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RNA extraction and Quantitative Polymerase Chain Reaction (qPCR) 
Total RNA was extracted using a kit from Macherey-Nagel, following the 
manufacturer’s protocol. The concentration and purity of extracted RNA were 
assessed with a NanoDrop ND-1000 spectrophotometer. Single-stranded cDNA was 
synthesized from 1 µg of pure RNA with a High Capacity cDNA Reverse Transcription 
Kit. qPCR was performed with TaqMan probes and primers using a Stratagene 
Mx3000P system. Samples were assayed in duplicate and the results expressed 
relative to an internal housekeeping standard (HPRT).  
 
[3H]Thymidine Incorporation 
Cultured atrial fibroblasts were plated in 24-well plates at 30,000 cells/well and 
serum-starved for 24 hours. Parallel series of cells were treated with various drugs 
and incubated for an additional 48 hours. DNA synthesis was assessed by adding 1 
µCi/well of [3H]thymidine 6 hours prior to the end of the treatment period. Cells were 
washed twice with ice-cold PBS, 5% trichloroacetic acid (TCA) was added, and then 
cells were kept for 1 hour at 4°C to precipitate DNA. The precipitate was then washed 
with ice-cold PBS, lysed with 0.5 M NaOH and resuspended in scintillation fluid. 
[3H]Thymidine incorporation was determined using a beta-counter.  
 
[α-32P]UTP -Transcription Initiation Assay 
Freshly isolated fibroblast nuclei were resuspended in 50 mM Tris, 0.15 M KCl, 
1 mM MnCl2, 6 mM MgCl2, 1 mM ATP, 2 mM DTT, 1 U/μL RNAse inhibitor, pH 7.9 at 
room temperature, and incubated in the presence of agonist/antagonists and 10 μCi 
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[α-32P]UTP (3,000 Ci/mmol) at 30°C for 30 min. Reactions were terminated by 
digestion with DNase and nuclei were lysed with 10 mM Tris–HCl 10 mM EDTA, 1% 
SDS, pH 8.0 at room temperature. Samples were then transferred onto Whatman 
GF/C glass microfiber-filter discs, washed twice with ice-cold 5% TCA containing 20 
mM sodium pyrophosphate, and air-dried. Filters were then placed in vials containing 
scintillation fluid, and 32P-incorporation was determined using a beta counter. The 
DNA content of each sample was determined spectrophotometrically using a 
NanoDrop ND-1000 spectrophotometer and [α-32P]UTP incorporation was expressed 
as cpm/ng DNA. 
  
Immunohistochemistry 
Cardiac atrial fibroblasts plated in 18-mm coverslips were fixed for 20 min with 
2% paraformaldehyde in PBS, pH 7.3, at room temperature, to preserve cell 
morphology. The cells were then incubated with the blocking/permeabilizing buffer 
(0.1% Triton X-100, 1% normal donkey serum (NDS), 1% BSA, pH 7.4) for 1 hour and 
then incubated overnight at 4°C with primary antibody diluted in 0.05% Triton X-100, 
0.5% NDS, 0.5% BSA, pH 7.4. After three 5-min washes with PBS, cells were 
incubated at room temperature for 1 hour in a foil-covered plate with the appropriate 
Alexa-conjugated secondary antibodies diluted in 0.05% Triton X-100, 0.5% NDS, 
0.5% BSA, pH 7.4. Cells were then carefully washed (3 x 5 min) with PBS, excess 
water was removed with a tissue and cells were placed onto a microscope slide 
containing a drop of 1,4-diazabicyclo[2.2.2]octane (DABCO) anti-quenching mounting 
medium (0.2% DABCO in glycerol) and the edges of the coverslip were sealed with 
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nail polish. Images were acquired with an Olympus FluoView FV1000 confocal laser-
scanning microscope equipped with a 40X/1.3 oil immersion objective. For 
multichannel image acquisition, excitation and emission collection were carried out in 
a sequential mode for each channel. Acquisition parameters were tuned to optimize 
detection sensitivity and minimize photobleaching.  
 
Fluorometric Nitric Oxide Assay 
Isolated nuclei were preincubated with the fluorescent NO specific indicator 
4,5-diaminofluorescein (DAF-2, 5 µg/ml) in a buffer containing 140 mM NaCl, 14 mM 
glucose, 4.7 mM KCl, 2.5 mM CaCl2, 1.8 mM MgSO4, 1.8 mM KH2PO4, and 0.1 mM 
L-arginine (pH 7.4) for 30 min at 37°C. Nuclei were washed 3 times with HEPES 
buffer (20 mM HEPES, 115 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 
13.8 mM glucose, pH 7.4) to remove any unbound fluorescent dye and then 
incubated with various agonist/antagonists at 37°C. Samples were transferred to a 
96-well microplate and the DAF-2 fluorescence was measured with a Biotek Synergy 
2 microplate reader (excitation λ=488 nm, emission λ=510 nm) 
 
[Tyr(DMNB)4]Ang-II uncaging and intracellular Ca2+ measurement 
To monitor changes in intracellular calcium concentration, freshly isolated 
cardiac fibroblasts cultured directly in FluoroDishes were loaded with 5 µM Fluo-4AM 
in DMEM in the presence or absence of [Tyr(DMNB)4]Ang-II and placed into an 
incubator for 30 min at 37°C. Cells were washed three times with indicator-free 
medium and incubated for an additional 15 min to allow complete de-esterification of 
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AM-esters. DRAQ5, a membrane-permeable fluorescent dye with high affinity for 
double-stranded DNA, was used to stain the nucleus and to focus the UV-laser on a 
rectangular intracellular region overlapping the nucleus. Images were acquired using 
a Zeiss LSM 7 Duo microscope (combined LSM710 and Zeiss Live systems) with 
Zeiss Plan-Apochromat 63x/1.4 oil DIC objective lens equipped with a BC 405/561 
dichroic mirror. Fluo-4AM was excited with an argon laser at 488 nm/100 mW diode 
(1-5% laser intensity) and fluorescence produced between 495 nm and 550 nm was 
measured. Cardiac fibroblasts were scanned in bi-directional mode at 30 fps, with 
pixel size set at 0.2 µm and the pinhole at 1.5 Airy units.  After establishing a stable 
baseline, [Tyr(DMNB)4]Ang-II was uncaged by a 70 µW pulse of UV-light using a 405-
nm/30 mW diode. An X-Cite-optical power measurement system (XR2100) was used 
to monitor the optical power output at the stage level. Intracellular Ca2+ 
measurements were expressed as a percentage of fluorescence intensity relative to 
resting fluorescence prior to photolysis (∆[Ca2+] (F/F0;%)). 
  
Statistical Analysis 
Densitometric analyses were performed with Quantity One Bio-Rad software.  
Statistical analyses were performed with GraphPad Prism version 5.0 for Windows 
with one-way or two-way analysis of variance, as appropriate, with Bonferroni post 
hoc tests. All data are presented as mean±SEM.  A two-tailed P≤0.05 was considered 
statistically significant. 
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Results  
Endogenous Ang-II Receptors Localize to the Nucleus in Atrial Cardiac 
Fibroblasts 
To assess the subcellular distribution of AT1R and AT2R in atrial cardiac 
fibroblasts, we isolated membrane, cytosolic and nuclear fractions. The fractionation 
was validated using organelle specific markers including pan-cadherin (membrane), 
HSP70 (cytosol) and lamin B (nuclei). Immunoblotting with subtype-specific 
antibodies revealed AT1R and AT2R immunoreactivity in all three fractions but band 
intensity was greatest in membrane and nuclear fractions (Figure 1A). To further 
examine the nuclear compartmentalization of AT1R and AT2R, we performed a 
nuclear subfractionation and isolated the ONM, INM and NP with minimal cross-
contamination as defined by nesprin, emerin and HDAC2 immunoreactivity. AT1R 
immunoreactivity was detected more prominently on INM, whereas the AT2R 
immunoreactivity was observed in both INM and NP (Figure 1B). Ang-II binding was 
examined in intact nuclei using the fluorescently-labeled Ang-II analog (Ang-II-FITC) 
along with the DNA dye DRAQ5. Fluorescent labeling was detected at the nuclear 
envelope and to some extent in the nucleoplasm. Ang-II-FITC (100 nM) binding was 
displaced by both the AT1R selective antagonist, valsartan (1 μM) and the AT2R 
selective antagonist, PD 123,177 (1 μM). Pre-incubation with both valsartan and PD 
123,177 completely inhibited Ang-II-FITC binding to isolated nuclei (Figure 1C-D). To 
further investigate the intracellular distribution of Ang-II receptors, permeabilized atrial 
fibroblasts cultured for three days were exposed to primary AT1R or AT2R 
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andtibodies and then incubated with secondary Alexa Fluor-conjugated fluorescent 
dyes. Immunofluorescence confocal microscopy was performed, with TOPRO-3 was 
used to delineate the nucleus and vimentin to show the intact fibroblast cytoskeleton 
(Figure 2A-B). These experiments revealed clear nuclear localisation for AT1R and 
AT2R.       
 
Intracellular Ang-II Levels, Nuclear AT1R and Glycosylated Nuclear AT2R are 
Upregulated in HF 
We studied changes in AT1R and AT2R mRNA expression as a function of 
VTP duration (control, 24 h and 2 week ventricular pacing). AT1R mRNA levels were 
significantly upregulated only after 2 weeks of VTP whereas AT2R mRNA levels 
remained unchanged (Figure 3A-B). Intracellular Ang-II concentrations, measured by 
competitive quantitative ELISA, were also upregulated at 2 week VTP (Ctl: 5.2±1.8 
vs. CHF: 17.9±1.4 pmol/mg protein P<0.01) (Figure 3C). At the protein level, plasma-
membrane AT1R immunoreactivity remained unchanged at 2-week VTP, whereas 
nuclear AT1R immunoreactivity was significantly increased (Figure 3D-E). Contrary to 
AT1R, AT2R immunoreactivity, both in membrane and nuclear fractions, were 
unaffected at 2-week VTP. However, we observed increased abundance of a higher 
molecular mass band of AT2R immunoreactivity in the nuclear fraction. To determine 
if the slower-migrating band corresponds to a glycosylated form of AT2R, we 
incubated the isolated membrane and nuclear fractions with peptide N-glycosidase F 
(PNGase F), which catalyzes the cleavage of N-linked oligosaccharides from N-linked 
glycoproteins [35]. PNGase F-digested samples showed a complete disappearance 
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of the higher mass AT2R band compared to non-treated groups (Figure 3F). The 
lower mass band that appeared in the treated group most likely represents the 
receptor in its totally deglycosylated form. These results suggest that at 2-week VTP 
the glycosylation status of nuclear AT2R has been altered whereas its abundance 
has not been changed    
  
Nuclear AT1R and AT2R Regulate de Novo RNA Synthesis through NO and 
IP3R Signaling 
To assess the potential functional role of nuclear AT1R and AT2R, we 
employed immunoblotting and immunofluorescence to localize downstream 
heterotrimeric G protein signaling partners (Figures 4A-B). Both Gαq/11 and Gαi/3 
were present in the nuclear fraction and colocalized with TOPRO-3. Gαs was 
detected only in cytosolic fractions: no nuclear immunofluorescence was observed. 
Gβ immunoreactivity was also detected in nuclear fractions and immunofluorescence 
revealed intense staining of the nuclear membranes. Thus, Gα and Gβ subunits, 
known to mediate AT1R and AT2R signalling, are present on atrial cardiac fibroblast 
nuclear membranes.  
To explore the functional consequences of nuclear AT1R and AT2R activation 
more directly, purified nuclei were incubated with [α-32P]UTP to measure de novo 
RNA transcription in response to Ang-II. Ang-II produced a dose-dependent increase 
in de novo RNA transcription reaching statistical significance at 10 nM and plateaued 
at 100 nM (Figure 5A). Pretreated with 1 μM valsartan (AT1R-selective antagonist) or 
1 μM PD 123,177 (AT2R-selective antagonist) prior to Ang-II (100 nM) exposure 
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significantly reduced [α-32P]UTP incorporation (Ang-II: 420±41, Ang-II + valsartan: 
111±14, Ang-II + PD 123,177:  220±1 cpm/ng DNA, N=4/group, P<0.001). RNA 
polymerase II is responsible for transcribing DNA to produce mRNA precursors and 
preincubating nuclei with an RNA polymerase II inhibitor, α-amanitin (5 μg/ml), 
prevented Ang-II from increasing transcription initiation (Figure 5B).  
To determine the mechanisms whereby activating AT1R or AT2R lead to 
changes in gene expression, nuclei were preincubated with an nitric oxide (NO)-
selective fluorescence dye 4,5-diaminofluorescein (DAF-2) and then exposed to Ang-
II. Ang-II (100 nM) increased DAF-2 fluorescence and this increase was abolished by 
PD 123,177 (1 μM) but not by valsartan (1 μM), indicating that AT2R activate NO-
synthase (NOS) in nuclear membranes whereas AT1R do not. Furthermore, the ANG 
II-induced production of NO was abolished when nuclei where pretreated with the 
NOS inhibitor L-NAME (1 mM) (Figure 5C). Immunoblotting subsequently revealed 
the presence of endothelial NOS (eNOS or NOS3) immunoreactivity in the nuclear 
fraction (Figure 5D).  
We have previously demonstrated that cardiomyocyte nuclear AT1R are 
coupled to IP3R activation to increase nuclear Ca2+ concentration [Ca2+]n that, in turn, 
plays a key role in regulating gene expression. To determine if this pathway also 
functions in fibroblast nuclei, we pretreated cardiac fibroblast nuclei with a specific 
AT1R agonist (L-162313, 1 μM) or AT2R agonist (CGP 42112A, 1 μM), in the 
presence or absence of the IP3R blocker 2-APB (100 μM) or L-NAME (1 mM), and 
assessed transcription initiation using [α−32P]UTP incorporation. The results showed 
that the ability of AT1R to increase transcription initiation was reduced significantly by 
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2-APB and not L-NAME, whereas that of AT2R was reduced by L-NAME and not by 
2-APB. These results indicate nuclear AT1R and AT2R regulate transcription via 
different signalling pathways (Figure 5E). 
 
Intracellular Ang-II Mediates IP3R dependant Ca2+ Release  
Here, we examined the ability of Ang-II to alter nuclear Ca2+ activity in intact 
atrial fibroblasts. A photolabile cell-permeable caged Ang-II (cAng-II) analog 
([Tyr(DMNB)4]Ang-II) was employed and changes in [Ca2+] were determined using the 
cell-permeant fluorescent Ca2+ indicator, Fluo-4 AM. DRAQ5 fluorescence was used 
to localize nuclei. In contrast to control cells (Figure 6A), UV irradiation of cAng-II (100 
nM) loaded fibroblasts generated a transient increase in nuclear Fluo4 fluorescence 
(white arrows indicate photobleached cells). Addition of valsartan (1 μM) in the 
extracellular medium failed to block the ability of cAng-II to increase [Ca2+]n (Figures 
6A-b), suggesting that the photolysed Ang-II is acting via intracellular receptors rather 
than being released into the media to act on nearby cells through autocrine or 
paracrine signaling. The addition of 2-APB (100 μM) significantly attenuated, but 
failed to totally block, the ability of photolyzed Ang-II to increase [Ca2+]n. Ang-II added 
directly to the extracellular media produced a rise in nuclear Ca2+ but with lower 
fluorescence intensity than observed upon intracellular photolysis of cAng-II (Figure 
6A-C). Analysis of IP3R isoform expression by qPCR revealed that the IP3R3 isoform 
predominates over IP3R1 and IP3R2 (Figure 6D). Immunoblot analysis of IP3R 
isoforms in nuclear subfractions showed abundant IP3R3 in the INM and weaker 
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immunoreactivity in the ONM, with very weak signals for IP3R1 and IP3R2 (Figure 
6D-E).  
 
Intracellular Ang-II Regulates Fibroblast Proliferation  
Here, we compared the growth stimulus-induced proliferative capacity of atrial 
fibroblasts originally plated at equal density. Stimulation of atrial fibroblast with Ang-II 
resulted in a significant increase in [3H]thymidine incorporation compared to non-
treated fibroblasts. Pretreatment with valsartan (AT1R blocker) and PD 123,177 
(AT2R blocker) prior to the Ang-II treatment returned [3H]thymidine incorporation to 
basal levels (Figure 7A). Fibroblasts loaded with cAng-II were UV-irradiated and 
[3H]thymidine uptake was measured. Compared to basal UV-irradiated levels, 
[3H]thymidine incorporation increased substantially (159.8±9.4 dpm in cAng-II vs 
88.5±5.5 dpm in control). The ability of intracellular, photolyzed cAng-II to increase 
[3H]thymidine incorporation was not prevented by extracellular AT1R and AT2R 
blockers (131±7.4 dpm). A caged, non-photolysable Ang-II analog was unable to 
increase [3H]thymidine incorporation. The [3H]thymidine incorporation in the UV-
irradiated control group (no cAng-II loading) did not differ significantly from the non 
UV-irradiated control group (Figure 7B-C).       
 
Intracellular Ang-II Regulates Collagen Expression 
Finally, we evaluated the effect of Ang-II on collagen synthesis in atrial 
fibroblasts.  Growth-arrested cultures were treated with extracellular Ang-II or loaded 
with cAng-II, alone or in combination with valsartan and PD123,177.  Collagen 1A1, 
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1EX1 and 3A1 expression was determined at the mRNA level and secreted collagen 
1 was measured by immunoblotting. Results are shown in Figure 8. When fibroblasts 
were treated with extracellular Ang-II, collagen 1EX1 and 3A1 mRNA levels were 
increased; collagen 1A1 secretion showed a small, but non-significant, increase. 
Photolysis of intracellular cAng-II resulting in a sustained increase in expression of all 
three collagen isoforms. This increase was not prevented by the addition of 
extracellular AT1R and AT2R blockers. Collagen-1 secretion showed changes similar 
to those in mRNA (Figure 8D,E).  
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Discussion 
 
Main Findings and Significance 
In the present study we have demonstrated: 1) the presence of nuclear AT1R 
and AT2R in atrial cardiac fibroblasts; 2) the upregulation of intracellular Ang-II, 
nuclear AT1R and alterations in the glycosylation of nuclear AT2R in HF; 3) the 
presence of nuclear heterotrimeric G protein subunits; 4) the involvement of NOS and 
IP3R in the activation of nuclear AT1R and AT2R to transcription; 5) intracellular Ang-
II regulates nuclear Ca2+ homeostasis in intact atrial fibroblasts independent of 
plasma membrane AT1R; 6) the control of fibroblast proliferation and collagen-1 
secretion by intracellular Ang-II. These findings suggest that intracellular Ang-II may 
participate in structural remodeling by controlling fibroblast function through activation 
of nuclear AT1R and AT2R.  
 
Relation to Previous Studies of Nuclear Receptors 
Cardiac fibroblasts play a key role in cardiac development, arrhythmogenesis 
and are fundamental in defining heart structure and function [10-12]. Although 
classical seven-transmembrane domain, G protein-coupled receptors (GPCRs) 
including angiotensin receptors (AT1R, AT2R) [13], endothelin receptors (ETA, ETB) 
[14], α-adrenergic receptors (α-1AR) [15], β-adrenergic receptors (β-1AR, β-3AR) [16] 
and urotensin receptors (U-II) [17] have increasingly been detected on cardiac 
nuclear membranes, almost nothing is known about their involvement in cardiac 
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fibroblasts. Most of the aforementioned studies were performed with cardiac 
myocytes or total cardiac nuclei preparations from dissected cardiac tissue, and 
hence could not define a role in fibroblasts. Both AT1R and AT2R were detected in 
adult human atrial fibroblasts [18, 19], dermal fibroblasts, synovial fibroblasts, lung 
fibroblasts [20], and AT1R are upregulated whereas AT2R remain unchanged in the 
left atrial tissue samples obtained from patients with atrial fibrillation [21]. 
Furthermore, earlier studies have identified putative nuclear localization signal (NLS) 
sequences in both AT1R and AT2R [22]. To our knowledge this is the first report to 
show the presence of subcellular Ang-II binding sites within isolated canine atrial 
fibroblasts and more precisely the presence of both AT1R and AT2R on the inner lipid 
bilayer of the nuclear envelope. Trafficking to the INM may occur following 
biosynthesis though a vesicle-mediated pathway, nuclear pore complex-dependent 
and -independent pathways and via diffusion-retention [23]. Furthermore, we have 
demonstrated and increase in nuclear AT1R immunoreactivity and altered 
glycosylation of nuclear AT2R in a model of HF. The upregulation of AT1R in earlier 
studies on chronic atrial fibrillation may reflect, at least in part, changes in AT1R at 
the nuclear level [21]. Our findings of altered AT2R post-translational modification in 
MI are consistent with previous reports in which 5 glycosylation sites in the 
extracellular N-terminal domain of AT2R were identified [24]. As the AT2R does not 
undergo internalization and trafficking, the glycosylated AT2R in the nucleus reflects 
the AT2R that was post-transnationally modified in the Golgi apparatus and trafficked 
to the nucleus [25].  
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Functional Role of Nuclear AT1R and AT2R 
Heterotrimeric G proteins play a central role in GPCR-mediated signal 
transduction and serve as cellular switches to control at the molecular level the 
functional responses to GPCR activation [26]. In our study, Gαq/11, Gαi3, and Gβ 
were detected in the nuclear fraction whereas Gαs was only found in the cytoplasm. 
AT1R signalling is principally via Gαq11 and involves the production of inositol 
trisphosphate and mobilization of intracellular Ca2+. In contrast, AT2R signal through 
Gαi3 to activate the cGMP/NO pathway [27, 28]. We have shown that, In nuclei 
isolated from cardiac atrial fibroblasts, AT2R is responsible for NO production as the 
AT1R selective antagonist, valsartan, had no effect on DAF-2 fluorescence, whereas 
the AT2R selective antagonist PD123,319 significantly reduced DAF-2 fluorescence 
to levels similar to those observed when nuclei were pretreated with NOS inhibitor, L-
NAME. Consistent with previous findings in whole heart nuclei, eNOS 
immunoreactivity was detected in nuclei isolated from fibroblasts [29]. Furthermore, 
consistent with our previous studies on cardiomyocyte nuclei [13, 16, 30, 31], we 
observed a dose-dependent increase in de novo RNA synthesis in nuclei treated with 
Ang-II. We report that AT1R-mediated increase in transcriptional involves activation of 
IP3R whereas AT2R-mediated transcriptional involves NOS activation. IP3Rs are a 
family of Ca2+-channels comprising three isoforms that differ in amino acid sequence 
and predominantly localize to the nuclear envelope. IP3R signalling requires the 
presence of phosphatidylinositol 4,5-bisphosphate, phosphatidylinositol kinases, 
phospholipase C and diacylglycerol kinases: all of these are present in the nuclear 
membrane [32]. Using a cell-permeable photoreleasable Ang-II analog in intact 
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fibroblasts, we demonstrated that intracellular Ang-II generates an IP3R-dependant 
increase in [Ca2+]n that was not prevented by extracellular AT1R blockers   
 
Role of Intracellular Ang-II in Fibroblast Proliferation and ECM Secretion 
Fibroblasts respond to a wide range of neurohormonal stimuli with proliferation 
and increased production and secretion of components of the extracellular matrix, 
leading to pathological remodeling and altered cardiac function [1]. Ang-II-induced 
fibroblast proliferation is mediated through autocrine/paracrine factors [33]. Here, we 
report for the first time a novel regulatory aspect of fibroblast physiology: intracrine 
Ang-II-mediated proliferation and increased collagen synthesis and secretion. 
Extracellular Ang-II alone produced a significant increase in fibroblast number but not 
in collagen-1 synthesis and secretion, whereas intracellular photolysis of cAng-II 
significantly increased both fibroblast proliferation and collagen secretion. In intact 
fibroblasts, the effects of increased intracellular Ang-II were not prevented by the 
presence of valsartan and PD 123319 in the extracellular media, indicating the effects 
of intracellular Ang-II were not mediated by receptors at the cell surface. 
 
Potential Limitations 
Fibroblasts may be affected during enzymatic digestion of cardiac tissue and 
culture. Fibroblasts may lose their morphological and functional properties after 7 
days of culture and may differentiate into myofibroblasts; therefore we used 
fibroblasts cultured for no more than 3-4 days in our experiments. Moreover, in vivo 
fibroblasts may be coupled to cardiomyocytes, hence our in vitro observations may 
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differ from those made using fibroblasts in the physiological in vivo milieu [2]. 
Mitochondrial Ang-II receptors have been recently described. In our cAng-II 
experiments in intact cells we cannot rule out the possibility of contributions from 
mitochondrial or other intracellular endomembrane ATRs [34].  
 
Conclusions  
The current study identifies novel participants in the profibrotic response by 
demonstrating the existence of nuclear AT1R and AT2R that are coupled to 
transcriptional responses through IP3R/NO pathways and regulate nuclear Ca2+ 
signaling and NO generation. Atrial fibroblast ATRs are altered in HF and cardiac 
fibroblasts exposed to intracellular Ang-II proliferate and secrete collagen-1.  The 
identification and characterization of functional intracrine Ang-II signaling opens up 
new avenues of research involving the Ang-II system, with potential implications for 
the development of novel pharmacological interventions. 
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Legends  
Figure 1. Endogenous AT1R and AT2R localize to the nucleus in canine atrial 
fibroblasts. A, Cultured fibroblasts were fractionated by differential centrifugation and 
the purity of membrane, cytosolic and nuclear fractions (50 μg) were validated by 
immunoblotting with pan-cadherin, HSP70 and lamin B antibodies. The presence of 
AT1R and AT2R was determined by immunoblotting. B, Subfractionation of isolated 
fibroblast nuclei was performed to separate ONM, INM and NP. Nesprin, Emerin and 
HDAC2 served as markers of the ONM, INM/lamina and nucleoplasm, respectively. 
Immunoblotting detected AT1R and AT2R in nuclear subfractions. C, Isolated nuclei 
were plated on laminin-coated 18 mm coverslips and then incubated with 100 nM 
Ang-II-FITC at room temperature or preincubated with valsartan (1 µM) and/or 
PD123177 (1 µM) for 30 min prior to the addition of Ang-II-FITC. Nuclei were washed, 
stained with fluorescent DNA dye DRAQ5, and images acquired using an Olympus 
FluoView FV1000 confocal microscope. D, Quantification of Ang-II emitted 
fluorescence. Mean±SEM **P<0.01, ***P<0.001, N=5/condition.  
 
Figure 2. AT1R and AT2R colocalize with TOPRO-3 nucleic acid stain in canine atrial 
fibroblasts. A, Permeabilized cultured atrial fibroblast were stained with AT1R 
conjugated with Alexa Fluor 488 (red), vimentin conjugated with Alexa Fluor 555 
(green), and TOPRO-3 (blue). Merged images indicate the extent of colocalization. 
Bright field images confirm the purity of fibroblast isolation. B, Fibroblast were stained 
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for AT2R as above. Similar observations were obtained from five different canine 
atrial fibroblast preparations.  
 
Figure 3. Ventricular tachypacing increases nuclear AT1R immunoreactivity and 
alters AT2R glycosylation in fibroblasts. A, Expression of AT1R in freshly isolated 
canine atrial fibroblast throughout the VTP time course (12 h, 24 h, 1 wk and 2 wk 
VTP). B, Expression of AT2R during the VTP-time course. C, Ang-II levels of control 
and 2 week VTP isolated fibroblasts. D, Immunoblotting for AT1R, AT2R, pan-
cadherin and lamin-B in membrane and nuclear proteins from freshly-isolated CTL 
and 2 week VTP fibroblasts. E, Quantification (Mean±SEM) of AT1R and AT2R 
immunoreactivity in membrane and nuclear fractions normalized to, respectively, pan-
cadherin and lamin-B. F, PNGase F treatment of nuclear AT2R. Nuclei were 
incubated with PNGase F at 37 °C for 7.5 hours followed by immunoblotting for 
AT2R. Glycosylation Ratio was calculated using non PNGase F treated samples by 
dividing the glycosylated band intensity over the nonglycosylated band. Mean±SEM  
*P<0.05, ***P<0.001  CTL vs. HF; N=4/group. 
 
Figure 4. Presence of G protein subunits in fibroblast nuclei. A, Detection of Gαq/11, 
Gαi/3, Gαs, Gβ in membrane, cytosolic and nuclear subfractions by Western blot. B, 
Representative confocal images demonstrating the distribution of Gαq/11, Gαi/3, Gαs, 
and Gβ in atrial fibroblasts. Superimposed confocal image shows the colocalization of 
G proteins with TOPRO-3 nucleic acid dye. Similar observations were obtained from 
four different canine heart preparations. 
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Figure 5. Nuclear AT1R and AT2R regulate gene expression. A, Transcription 
initiation was measured as [α-32P]UTP incorporation in isolated fibroblast nuclei 
treated with increasing concentrations of Ang-II. B, [α-32P]UTP incorporation was 
measured in fibroblast nuclei treated with Ang-II (100 nM) alone, or pretreated with α-
amanitin (5 μg/ml), Valsartan (1 µM) or PD123177 (1 µM) and then stimulated with 
Ang-II. C, NO production was determined as a measure of DAF-2 fluorescence in 
nuclei stimulated with Ang-II alone, or pretreated with Valsartan (1 µM), PD123177 (1 
µM) or L-NAME (1 mM) and then stimulated with Ang-II. Data represent mean ± SEM 
of at least four separate experiments performed in triplicate and normalized to control. 
***P<0.001 vs. control. D, Immunoblotting for eNOS in cytosolic and nuclear enriched 
fractions. E, [α-32P]UTP incorporation measured in fibroblast nuclei treated with L-
162313 (1 µM), CGP 42112A (1 µM) or in combination with either L-NAME (1 mM) or 
2APB (100 µM). Mean±SEM *P<0.05, **P<0.01, ***P<0.001.  
 
Figure 6. Photolysis of Intracellular cAng-II increases [Ca2+]n. A, Cultured atrial 
fibroblasts were plated on FluoroDishs and changes in nucleoplasmic [Ca2+] were 
recorded using fluorescent calcium dye Fluo4-AM. Cells were incubated with cAng-II 
(100 nM), cAng-II and Valsartan (1 µM), or cAng-II and 2-APB (100 µM). Where 
indicated Ang-II was added directly to the extracellular media. Images shown are 
before (T = 10 s) and after (T = 100 s) flash photolysis. White arrows indicate the cells 
selected for uncaging. B, Representative traces of nucleoplasmic [Ca2+] as measured 
above. C, Mean±SEM of fluorescence signals, presented as background-subtracted 
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normalized fluorescence (%F / F0), where F is the fluorescence intensity, and F0 is 
the resting fluorescence recorded in the same fibroblast under steady-state conditions 
prior to photolysis **P<0.01, ***P<0.001. D, Expression of IP3R1, IP3R2, IP3R3 as 
determined by qPCR. E, Immunoblotting for IP3R1, IP3R2, IP3R3 in nuclear 
subfractions.  
 
Figure 7. Intracellular Ang-II regulates fibroblast proliferation. A, [3H]thymidine 
incorporation in atrial fibroblasts treated with medium alone, Ang-II (100 nM), 
PD123177 (1 µM) and Valsartan (1 µM), or pretreated with PD123177 (1 µM) and 
Valsartan (1 µM) before Ang-II (100 nM) treatment. B, [3H]thymidine incorporation in 
atrial fibroblasts treated with medium alone, cAng-II (100 nM), Scramble (Ang-II-
ODMNB), PD123177 (1 µM) and Valsartan (1 µM), or treated with cAng-II before 
PD123177 (1 µM) and Valsartan (1 µM). C, Percent change of [3H]thymidine uptake 
over applicable basal values. Mean±SEM *P<0.05, **P<0.01, ***P<0.001, N=4/group. 
 
Figure 8. Intracellular Ang-II regulates collagen synthesis and secretion. 
Quantification of A, collagen 1A1 B, collagen 1EX1 and C, collagen 3A1 mRNA in 
cultured fibroblasts treated with control, Ang-II (100 nM), PD123177 (1 µM) and 
Valsartan (1 µM), pretreated with PD123177 (1 µM) and Valsartan (1 µM) before Ang-
II (100 nM) or following photolysis of fibroblasts exposed to cAng-II (100 nM), 
PD123177 (1 µM) and Valsartan (1 µM), treated with cAng-II before PD123177 (1 
µM) and Valsartan (1 µM). D, collagen 1 secretion expression was measured by 
immunoblot analysis of the cell culture media. E, Quantification of collagen 1 
 
 
210 
 
immunoblotting experiments. Band intensities were analyzed by densitometry. 
Mean±SEM *P<0.05, **P<0.01, ***P<0.001, N=4/group, N.S = non-significant from 
control.     
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5.1 Summary and Novel Contributions 
Our understanding of the importance and role of the renin-angiotensin system 
has evolved enormously since the initial discovery of the rate-limiting enzyme, renin, 
by Tigerstedt and Bergman more than a century ago [213]. New frontiers are 
emerging, with the identification of novel components, subsystems, signalling 
transduction mechanisms and functional roles. Traditionally considered as a 
circulating endocrine system, recent experimental data provide evidence of a 
complete and functionally active RAS within cells, termed an ‘intracrine’ or 
intracellular system. Understanding the diversity of RAS signalling may lead to the 
development of novel pharmacological interventions for the prevention of cardiac 
disease and improved therapeutic outcomes. 
In chapter 2, we advanced knowledge regarding intracrine RAS in cardiac cells 
in several ways. We identified, for the first time, the presence of nuclear AT1R and 
AT2R in ventricular cardiomyocytes. This nuclear localization of AT1R and AT2R was 
independent of G protein activation and therefore was not a result of clathrin- 
mediated internalization. Ang-II was detected in cardiomyocyte lysates and 
microinjected Ang-II localized primarily to the nuclear and perinuclear compartments. 
Transcriptomic analysis demonstrated that these intracellular receptors regulate de 
novo RNA synthesis through the activation of G proteins and affect the abundance of 
both ribosomal and messenger RNA. NF-κB mRNA is more abundant when isolated 
nuclei were exposed to Ang-II. Furthermore, nuclear AT1R but not AT2R is coupled to 
IP3R-dependent Ca2+ signalling and governs transcriptional regulation.   
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In chapter 3, we synthesized and pharmacologically characterized, novel cell-
permeant photoreleasable Ang-II analogues to efficiently study for the first time 
intracrine RAS signalling directly in intact cells. In the Laboratory of Molecular and 
Pharmacological Studies on Peptides, we synthesized, using solid-phase peptide 
synthesis with Fmoc chemistry, caged Ang-II analogues by incorporating a 
photocleavable 4,5-dimethoxy-2-nitrobenzyl (DMNB) moiety onto the phenolic group 
of tyrosine-4 and/or the α-COOH of phenylalanine-8 of Ang-II. The incorporation of a 
DMNB residue on the active site of the Ang-II peptide prevents the recognition, 
binding, and subsequent activation of its target receptor (AT1R, AT2R). Our 
synthesized and highly purified Ang-II analogues ([Tyr(DMNB)4]Ang-II, Ang-II-
ODMNB and [Tyr(DMNB)4]Ang-II-ODMNB) showed two to three orders of magnitude 
reduced binding affinity towards both AT1R and AT2R. Similarly, studies in rat 
thoracic aortic ring preparations revealed a similar rightward shift in the concentration-
response curve for contraction. A study of the kinetics of photolysis for each of the 
three caged Ang-II analogues revealed that [Tyr(DMNB)4]Ang-II exhibited the fastest 
rate of release of free Ang-II and therefore was the main focus of subsequent 
functional studies. Whereas [Tyr(DMNB)4]Ang-II itself has no effect, Ang-II or 
photolyzed [Tyr(DMNB)4]Ang-II increases dose dependently ERK phosphorylation in 
HEK 293 cells transfect with AT1R and activate NO/cGMP signalling in HEK 293 cells 
transfected with AT2R. In contrast to Ang-II, [Tyr(DMNB)4]Ang-II is a potent cell 
penetrating peptide, showing similar characteristics to those of the HIV-1 derived TAT 
peptide (TAT48–60), which is regularly used for intracellular delivery of many 
therapeutically active and diagnostic agents. Photolysis of [Tyr(DMNB)4]Ang-II inside 
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cardiomyocytes increases nuclear calcium through IP3R-mediated mechanisms 
which, in turn, regulates 18S rRNA and NF-κB mRNA levels. These findings provide 
further pharmacological evidence in support of the functional intracrine RAS actions in 
cardiac cells. Hence, [Tyr(DMNB)4]Ang-II is a novel pharmacological probe that could 
be used in medical research to investigate the role of intracrine RAS not only in 
cardiac cells, but in any cell type, to delineate specific roles of intracellular Ang-II. 
In chapter 4, we presented the first study characterizing the functional role of 
intracrine RAS signalling in cardiac fibroblasts and investigated its potential 
involvement in HF. We present evidence that AT1R and AT2R are present on 
intracellular organelles and more specifically on the inner nuclear membrane. 
Furthermore, we demonstrate that intracellular Ang-II and nuclear AT1R are 
increased in HF, whereas the glycosylation of nuclear AT2R is altered. G protein 
subunits including Gαq/11, Gαi/3, and Gβ were detected in isolated nuclear fractions. 
Transcription initiation, analyzed by [α-32P]UTP incorporation, showed that nuclear 
AT1R and AT2R regulate de novo RNA synthesis via IP3R and NO signal 
transduction pathways, respectively. Using Tyr(DMNB)4]Ang-II, we demonstrated in 
intact cultured atrial fibroblasts that intracellular photorelease of Ang-II leads to 
increased [Ca2+]n, which is not prevented by extracellular AT1R blockers. The 
increase in [Ca2+]n can be attenuated by an IP3R blocker and we showed for the first 
time that IP3R3 is the predominant IP3R isoform in atrial fibroblast nuclear 
membranes. Furthermore, increasing intracellular Ang-II results in fibroblast 
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proliferation, collagen synthesis and secretion independent of extracellular AT1R and 
AT2R.    
      
5.2 Current Insights and Directions for Future 
Research 
5.2.1 Concepts of Intracellular RAS  
Major milestones in our understanding of RAS included the discovery of 1) 
Ang-II generating secretory proteins: renin and angiotensinogen, 2) membrane-
anchored ACE with catalytic sites located on the extracellular domain, and 3) the fact 
that AT1R and AT2R belong to the GPCR superfamily. The accepted dogma has 
been that in GPCRs localize to the plasma membrane, become functional, and are 
activated in response to agonist binding. Hence, the concept of circulating and 
extracellular RAS dominated our thinking [214]. The intracellular synthesis and 
function of Ang-II was not explored in any detail until recently  
To describe an intracrine RAS, defined by the existence of RAS components 
and the synthesis and actions of Ang-II within a cell, two potential models of the 
intracrine system were considered. First, intracellular RAS may act as a transient 
system where renin, angiotensinogen, and ACE are sorted in secretory vesicles, 
resulting in intravesicular Ang-II generation due to the close proximity of the 
substrates [215]. In support of the proposed model, renin and Ang-II immunoreactivity 
were observed within juxtaglomerular epitheloid granular cells [216]. Using 
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transmission electron microscopy Ang-II was colocalized by immunohistochemistry 
with renin and Ang-I in the cytoplasmic granules of the juxstaglomerular neonatal 
kidney cells, whereas angiotensinogen was localized throughout the cytosol [217]. By 
reverse haemolytic plaque assay it was revealed that kidney cortical cells retain 
approximately the number of Ang-I secreting cells as renin secreting cells and that the 
concentration of Ang-I and renin were upregulated when cells were treated with ACE 
[218]. Large amounts of Ang-II were reported in renin-containing storage granules 
and mechanistically Ang-II biosynthesis involved the action of resident renin on 
internalized, exogenous angiotensinogen [219]. Angiotensinogen, prorenin, and renin 
were also co-expressed in the same secretory granules of all glandular cell types 
isolated from rat anterior pituitary [220]. Stretch-induced Ang-II release from neonatal 
cardiomyocytes and low-passage cultures of cardiac microvascular endothelial cells 
further support the local biosynthesis, and subsequent storage and/or secretion 
theory [70,221].   
The second model of the intracrine RAS involves non-secretory cellular 
compartments composed principally of the cytoplasm, mitochondria, and nucleus. 
The exact intracellular trafficking of RAS constituents under physiological and 
pathological conditions remains largely unknown; however, RAS components 
targeted to intracellular organelles may be generated as a result of alternative 
splicing, post-transcriptional processing of coding mRNA and/or post-translational 
modification. Human astrocytoma cell line, CCF-STTG1, and primary cultures of glial 
cells isolated from transgenic mice expressing human angiotensinogen expresses a 
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non-glycosylated form of angiotensinogen, which primarily localizes to the nucleus 
[222]. Alternatively-spliced renin transcripts generate a secretory renin or an 
alternative isoform lacking the pre-pro-fragment. In the adrenal gland, heart, and 
brain, the renin isoform lacking the pre-pro-fragment is retained intracellularly 
[223,224].  Furthermore, renin and ACE were localized within mitochondrial dense 
bodies of the rat adrenal cortex [225]. Overexpression of a non-secretory, 
intracellularly retained renin in transgenic rat hearts increases aldosterone production 
and in transgenic mice brains, increases arterial pressure and fluid consumption 
[226,227]. Cytoplasmic renin encoded by the alternatively-spliced renin transcript in 
H9c2 rat cardiomyoblasts promotes apoptotic cell death [228]. Endogenous ACE has 
been shown to be localized in the nucleus of mesangial, smooth muscle, and 
endothelial cells and administration of exogenous ACE correlates with activation of 
focal adhesion kinase, SRC homology 2 domain-containing protein-tyrosine 
phosphatase and modulation of platelet-derived growth factor receptor β signalling  
[229,230]. All of the above observations support the notion of subcellularly 
compartmentalized functional RAS.   
 
5.2.2 Significance of the Cardiac Intracellular RAS 
The rationale for examining the biological signal transduction mechanisms 
associated with intracrine RAS in the heart is related to accumulating clinical 
evidence suggesting that RAS blockade with either direct renin inhibitors, ACE 
inhibitors and/or AT1R blockers provides incomplete protection against cardiac 
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complications of a variety of remodeling-inducing conditions. A recent meta-analysis 
by The Blood Pressure Lowering Treatment Trialists’ Collaborators combining 31 
clinical trials with 190,606 participants showed no strong evidence between regimens 
to support recommendations for a particular blood pressure lowering drug class [231]. 
Furthermore, despite a strong biological rationale, in ONgoing Telmisartan Alone and 
in combination with Ramipril Global Endpoint Trial (ONTARGET), combination of ACE 
inhibitor, Ramipril, with AT1R blocker, Telmisartan, did not result in increased 
cardiovascular benefit but was associated with additional adverse events [232-234]. 
In Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE), 
combination of renin inhibitor (aliskeren) with either ACE inhibitor or AT1R blocker did 
not produce any beneficial outcome but rather, was associated with increased 
incidence of hypotension, hyperkalemia, renal complications, and nonfatal stroke 
[235,236]. Likewise in the The Aliskiren Trial on Acute Heart Failure Outcomes 
(ASTRONAUT) study, administration of alsikiren in addition to standard ACE inhibitor 
or AT1R blocker did not reduce cardiovascular death or heart failure rehospitalisation 
[237]. 
 These results led to the following question: if AT1R blockers and ACE 
inhibitors have such well-documented benefits in preventing the cardiovascular 
consequences of heightened Ang-II activity, why are the benefits of dual RAS 
inhibition not superior to what can be obtained by other classes of antihypertensive 
drugs? We hypothesized that the discrepancy might be explained, at least in part, by 
the following possibilities: 1) Ang-II acts at intracellular locations where extracellular 
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ACE inhibitors or AT1R blockers might have limited access; 2) intracellular and tissue 
Ang-II biosynthesis may involve ACE independent enzymatic pathways, which in 
certain pathological conditions may become a dominant mechanism; 3) the clinical 
benefits of RAS inhibitors may be influenced by parallel mechanisms including the 
kallikrein–kinin system and/or peroxisome proliferator-activated receptor-gamma 
(PPARγ) activation. To specifically address the potential role of intracellular RAS, 
central to hypotheses 1) and 2) above, we performed the studies described in this 
thesis.              
 
5.2.2.1 Intracellular ANG II Receptors and Actions 
There is strong accumulating evidence that Ang-II, either produced within 
cellular compartments or incorporated through vesicular pathways from the 
extracellular biological environment, leads to hypertrophic, inflammatory, and fibrotic 
responses [238-240]. In Chapter 2, we demonstrated the presence of nuclear AT1R 
and AT2R in native cardiomyocytes and the functional role of nuclear AT1R and 
AT2R in the regulation of transcriptional and Ca2+, thus providing a framework for the 
concept of intracrine RAS signalling. Other investigators have shown previously that 
intracellular Ang-II changes cellular electrophysiological properties including action 
potential duration, conduction velocity, and cardiac refractoriness, and can induce 
pathological events like early afterdepolarizations,  [208,241]. Furthermore, 
microinjected Ang-II in vascular smooth muscle cells leads to a rapid increase in 
cytosolic and nuclear Ca2+ concentrations and the rise in intracellular Ca2+ is only 
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inhibited by intracellular, and not extracellular, administration of an AT1R blocker 
[242]. Cytosolic delivery of Ang-II using multilamellar liposomes, in de-endothelized 
aortic rings, resulted in a concentration-dependent contraction that was insensitive to 
extracellular administration of an AT1R blocker but pre-treatment with an intracellular 
AT1R blocker completely abolished the contractile response [243]. In chapter 3, we 
employed a novel photoreleasable [Tyr(DMNB)4]Ang-II to demonstrate that 
intracellular Ang-II generated Ca2+ responses are not abolished by conventional 
extracellular AT1R blockers. Additionally, in chapter 4 we showed, in cultured cardiac 
fibroblasts, that intracellular Ang-II regulates proliferation plus the transcription and 
secretion of collagen, These effects are not prevented by the combination of 
PD123177 and valsartan in the extracellular medium. Thus, there is substantial 
evidence that intracellular Ang-II actions on intracellular AT1R and AT2R escapes 
inhibition from conventional pharmacological probes that act either in the extracellular 
compartment or the cell surface membrane. However, further studies are necessary 
to elucidate the mechanisms of intracrine RAS in pathological conditions, since 
sustained biological and pathological actions of RAS may represent a combination of 
both intracellular and extracellular Ang II-mediated pathways. A genetic model of 
mice lacking intracellular AT1 or AT2 receptor would provide solid insight on the role 
of intracrine Ang-II signalling in cardiac physiology. Nonetheless these in vivo models 
are, and will, remain a challenge as long as the mechanisms responsible for selective 
trafficking of ATRs to the cell surface and intracellular membranes are not 
understood. Moreover, the links between the development of HF and changes in 
nuclear AT1R/AT2R in whole heart preparations (physiologically close to an in vivo 
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condition), and complete transcriptome analysis need to be explored in future studies. 
GPCR regulators, including β-arrestin and GRK, were also found to be present in 
nuclei, but it’s uncertain under which conditions the nuclear function of GPCR 
regulators are physiologically relevant. Thus more detailed studies will be required to 
clearly establish the role of GPCR regulators in mediating nuclear AT1R/AT2R 
signalling and allow the identification of novel biological functions [244,245].    
 
5.2.2.2 Novel Routes for Intracellular Ang-II Biosynthesis 
The concept of an ACE independent biosynthesis of Ang-II is gaining new 
momentum. Cardiac chymase-mediated Ang-II synthesis has emerged as an 
unconventional pathway in cardiac tissue and particularly under pathological 
conditions [246,247]. Chymase-generated Ang-II has been proposed to dominate 
over ACE in human heart and vasculature and to have a key role in cardiac 
remodeling, cardiomyopathies, heart failure and diabetes [76,247-249]. Electron 
microscopic immunocytochemistry showed that chymase, a chymotrypsin-like serine 
protease, is localized predominantly in cytosolic granules of mast cells, endothelial 
cells, and mesenchymal interstitial cells of the heart [250]. Paralleling these findings, 
studies identified in human atrial appendage tissue Ang-(1-12) as a non-renin 
dependent alternate precursor for the generation of cardiac Ang-II. In atrial cardiac 
cells Ang-(1-12) was primarily hydrolyzed by chymase whereas ACE contribution was 
almost undetectable [251-254]. Hearts perfused with Ang-(1-12) revealed a striking 
increase of Ang-II production that was not blocked by ACE inhibitors, whereas the 
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generation of Ang-II and consequent vasoconstriction and myocardial damage 
following ischemia were significantly attenuated by a chymase inhibitor (chymostatin) 
[255,256]. Hence, the primacy of chymase as a novel intracellular cardiac Ang-II 
producing enzyme should generate cautionary notes as to the direct applicability of 
animal models of cardiac ACE overexpression in addressing the role of cardiac RAS 
in human pathologies. In chapter 4, we observed that atrial fibroblasts isolated from 
HF animals contain significantly higher Ang-II levels as compared to control animals, 
which potently exerts trophic and profibrotic effects on the heart. It would be of great 
interest to investigate in further studies the role of chymase or ACE dependent 
hydrolytic activity in governing the biosynthesis of Ang-II in normal and pathological 
conditions.   
 
5.2.2.3 Significance of Parallel Mechanisms     
ACE inhibitors and AT1R blockers by acting at distinct points in the RAS may 
compensate to some extent and therefore reduce the influence of intracrine RAS 
signalling. In AT1R knockout mice, ACE inhibitors prevent cardiac fibrosis and 
improve myocardial function, suggesting that non-AT1R mediated mechanisms play a 
significant role in myocardial remodeling [257]. Several studies reported that kallikrein 
and bradykinin receptors are key determinants of the cardioprotective effect of ACE 
or AT1R blockade [258,259]. In tissue from kallikrein gene-deficient mice (TK –/–) 
subjected to 30 min of coronary artery occlusion followed by 3 h of reperfusion, 
administration of losartan prior to reperfusion did not reduce infarct size. Wild-type 
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mice pretreated with the bradykinin-2 receptor (B2R) antagonist icatibant reproduced 
the effect of TK deficiency [260]. AT1R-B2R heterodimerization was confirmed with 
BRET and FRET biophysical methods and in vitro / in vivo results established a role 
of the AT1R-B2R heterodimer in sensitizing AT1R-regulated vasoconstrictor activity 
[261]. Furthermore, AT1R blockers have been demonstrated to induce PPARγ activity 
[262]. PPARγ is a nuclear receptor that regulates the expression of genes by binding 
to peroxisome proliferator response elements. Telmisartan (AT1R blocker), acting 
through PPARγ, activates phosphoenolpyruvate carboxykinase-1 (PEPCK-C) and 
acetyl coenzyme A carboxylase 2 (ACC2) genes, markers of the differentiation of 
mouse embryonic fibroblasts into adipocytes [263]. Recently non-AT1R and non-
AT2R binding sites with high affinity and specificity for Ang-II were described, 
however little is known about their functional significance [264]. Future research will 
need to focus on the role of non-classical RAS-mediated mechanisms, including 
investigating whether the AT1R and B2R heterodimerize at the nucleus and if they 
can be selectively targeted by biased ligands to deliver safer and more efficacious 
cardiac pharmacotherapy. 
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5.3 Conclusions 
The concept of intracrine RAS signalling has evolved rapidly in the last decade. 
Once judged as an idiosyncratic phenomenon of unclear importance, intracrine RAS 
is now well characterized at the level of ligands (Ang-II), receptors (AT1R/AT2R), 
effectors, signalling mechanisms and actions, and increasingly, regarded as a viable 
cardiovascular drug target. This thesis has contributed to this field by providing novel 
tools with which to investigate the intracellular RAS and novel insights into its role and 
signalling mechanisms in cardiac cells. There remain many unanswered questions, 
before the translation of experimental research on intracrine RAS can head to the 
clinic, particularly those related to the origin of intracellular AT1R/AT2R, the precise 
site of intracellular Ang-II biosynthesis, and the exact in vivo role of intracrine RAS in 
pathological conditions.      
 
 
 
 
  
 
 
233 
 
References 
1. Wong ND (2014) Epidemiological studies of CHD and the evolution of preventive 
cardiology. Nat Rev Cardiol 11: 276-289. 
2. Tang CM, Insel PA (2004) GPCR expression in the heart; "new" receptors in 
myocytes and fibroblasts. Trends Cardiovasc Med 14: 94-99. 
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2005) 
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of 
Chronic Heart Failure in the Adult: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(Writing Committee to Update the 2001 Guidelines for the Evaluation and 
Management of Heart Failure): developed in collaboration with the American 
College of Chest Physicians and the International Society for Heart and Lung 
Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-
235. 
4. Guyton AC (1981) The relationship of cardiac output and arterial pressure control. 
Circulation 64: 1079-1088. 
5. Kang M, Chung KY, Walker JW (2007) G-protein coupled receptor signaling in 
myocardium: not for the faint of heart. Physiology (Bethesda) 22: 174-184. 
6. Brette F, Orchard C (2003) T-tubule function in mammalian cardiac myocytes. Circ 
Res 92: 1182-1192. 
7. Rivard K, Grandy SA, Douillette A, Paradis P, Nemer M, et al. (2011) 
Overexpression of type 1 angiotensin II receptors impairs excitation-
 
 
234 
 
contraction coupling in the mouse heart. Am J Physiol Heart Circ Physiol 301: 
H2018-2027. 
8. Hohendanner F, McCulloch AD, Blatter LA, Michailova AP (2014) Calcium and IP3 
dynamics in cardiac myocytes: experimental and computational perspectives 
and approaches. Front Pharmacol 5: 35. 
9. Sumandea MP, Steinberg SF (2011) Redox signaling and cardiac sarcomeres. J 
Biol Chem 286: 9921-9927. 
10. Maeder MT, Kaye DM (2009) Heart failure with normal left ventricular ejection 
fraction. J Am Coll Cardiol 53: 905-918. 
11. Oudot A, Vergely C, Ecarnot-Laubriet A, Rochette L (2003) Angiotensin II 
activates NADPH oxidase in isolated rat hearts subjected to ischaemia-
reperfusion. Eur J Pharmacol 462: 145-154. 
12. Donato AJ, Pierce GL, Lesniewski LA, Seals DR (2009) Role of NFkappaB in 
age-related vascular endothelial dysfunction in humans. Aging (Albany NY) 1: 
678-680. 
13. Johnson JL (2014) Emerging regulators of vascular smooth muscle cell function in 
the development and progression of atherosclerosis. Cardiovasc Res 103: 
452-460. 
14. Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A (2014) Treating 
Coronary Disease and the Impact of Endothelial Dysfunction. Prog Cardiovasc 
Dis. 
15. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. 
Circulation 109: III27-32. 
 
 
235 
 
16. Stout KK, Verrier ED (2009) Acute valvular regurgitation. Circulation 119: 3232-
3241. 
17. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, et al. (2004) 
Induction of local angiotensin II-producing systems in stenotic aortic valves. J 
Am Coll Cardiol 44: 1859-1866. 
18. Bates ER (2011) Treatment options in severe aortic stenosis. Circulation 124: 
355-359. 
19. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, et al. (2006) Burden 
of valvular heart diseases: a population-based study. Lancet 368: 1005-1011. 
20. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, et al. (2010) Part 8: adult 
advanced cardiovascular life support: 2010 American Heart Association 
Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular 
Care. Circulation 122: S729-767. 
21. Kattwinkel J, Perlman JM, Aziz K, Colby C, Fairchild K, et al. (2010) Part 15: 
neonatal resuscitation: 2010 American Heart Association Guidelines for 
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. 
Circulation 122: S909-919. 
22. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S (2011) Recent advances in the 
molecular pathophysiology of atrial fibrillation. J Clin Invest 121: 2955-2968. 
23. Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial 
fibrillation. Lancet 375: 1212-1223. 
 
 
236 
 
24. Tadros R, Ton AT, Fiset C, Nattel S (2014) Sex differences in cardiac 
electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and 
mechanisms. Can J Cardiol 30: 783-792. 
25. Nattel S, Maguy A, Le Bouter S, Yeh YH (2007) Arrhythmogenic ion-channel 
remodeling in the heart: heart failure, myocardial infarction, and atrial 
fibrillation. Physiol Rev 87: 425-456. 
26. Doronin SV, Potapova IA, Lu Z, Cohen IS (2004) Angiotensin receptor type 1 
forms a complex with the transient outward potassium channel Kv4.3 and 
regulates its gating properties and intracellular localization. J Biol Chem 279: 
48231-48237. 
27. Valderrabano M (2007) Influence of anisotropic conduction properties in the 
propagation of the cardiac action potential. Prog Biophys Mol Biol 94: 144-168. 
28. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, et al. (2006) Angiotensin II and 
angiotensin II receptor blocker modulate the arrhythmogenic activity of 
pulmonary veins. Br J Pharmacol 147: 12-22. 
29. Khandaker MH, Espinosa RE, Nishimura RA, Sinak LJ, Hayes SN, et al. (2010) 
Pericardial disease: diagnosis and management. Mayo Clin Proc 85: 572-593. 
30. Little WC, Freeman GL (2006) Pericardial disease. Circulation 113: 1622-1632. 
31. Miyazaki T, Pride HP, Zipes DP (1990) Prostaglandins in the pericardial fluid 
modulate neural regulation of cardiac electrophysiological properties. Circ Res 
66: 163-175. 
 
 
237 
 
32. Rouleau JL (2011) New and emerging drugs and device therapies for chronic 
heart failure in patients with systolic ventricular dysfunction. Can J Cardiol 27: 
296-301. 
33. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling--concepts and clinical 
implications: a consensus paper from an international forum on cardiac 
remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am 
Coll Cardiol 35: 569-582. 
34. Cohn JN (1995) Structural basis for heart failure. Ventricular remodeling and its 
pharmacological inhibition. Circulation 91: 2504-2507. 
35. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, et al. (2014) Noncardiac 
comorbidities in heart failure with reduced versus preserved ejection fraction. J 
Am Coll Cardiol 64: 2281-2293. 
36. Bhuiyan T, Maurer MS (2011) Heart Failure with Preserved Ejection Fraction: 
Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep 5: 440-
449. 
37. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, et al. 
(2006) Myocardial structure and function differ in systolic and diastolic heart 
failure. Circulation 113: 1966-1973. 
38. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, et al. (2002) 
Pathophysiological characterization of isolated diastolic heart failure in 
comparison to systolic heart failure. JAMA 288: 2144-2150. 
39. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, et al. 
(2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, 
 
 
238 
 
advanced glycation end products, and myocyte resting tension. Circulation 
117: 43-51. 
40. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, et al. (2005) 
Cardiomyocyte stiffness in diastolic heart failure. Circulation 111: 774-781. 
41. van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP, 
et al. (2012) Low myocardial protein kinase G activity in heart failure with 
preserved ejection fraction. Circulation 126: 830-839. 
42. Kehat I, Molkentin JD (2010) Molecular pathways underlying cardiac remodeling 
during pathophysiological stimulation. Circulation 122: 2727-2735. 
43. Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial 
infarction. Experimental observations and clinical implications. Circulation 81: 
1161-1172. 
44. Sutton MG, Sharpe N (2000) Left ventricular remodeling after myocardial 
infarction: pathophysiology and therapy. Circulation 101: 2981-2988. 
45. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, et al. (1993) Activation of 
neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll 
Cardiol 22: 390-398. 
46. Warren SE, Royal HD, Markis JE, Grossman W, McKay RG (1988) Time course 
of left ventricular dilation after myocardial infarction: influence of infarct-related 
artery and success of coronary thrombolysis. J Am Coll Cardiol 11: 12-19. 
47. Ahuja P, Sdek P, MacLellan WR (2007) Cardiac myocyte cell cycle control in 
development, disease, and regeneration. Physiol Rev 87: 521-544. 
 
 
239 
 
48. Sadoshima J, Izumo S (1997) The cellular and molecular response of cardiac 
myocytes to mechanical stress. Annu Rev Physiol 59: 551-571. 
49. Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S (1992) Molecular 
characterization of the stretch-induced adaptation of cultured cardiac cells. An 
in vitro model of load-induced cardiac hypertrophy. J Biol Chem 267: 10551-
10560. 
50. Takemura G, Kanoh M, Minatoguchi S, Fujiwara H (2013) Cardiomyocyte 
apoptosis in the failing heart--a critical review from definition and classification 
of cell death. Int J Cardiol 167: 2373-2386. 
51. Gonzalez A, Fortuno MA, Querejeta R, Ravassa S, Lopez B, et al. (2003) 
Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 59: 
549-562. 
52. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, et al. (2011) 
Cardiomyocyte death: mechanisms and translational implications. Cell Death 
Dis 2: e244. 
53. Kung G, Konstantinidis K, Kitsis RN (2011) Programmed necrosis, not apoptosis, 
in the heart. Circ Res 108: 1017-1036. 
54. Kalra D, Sivasubramanian N, Mann DL (2002) Angiotensin II induces tumor 
necrosis factor biosynthesis in the adult mammalian heart through a protein 
kinase C-dependent pathway. Circulation 105: 2198-2205. 
55. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116: 205-
219. 
 
 
240 
 
56. Lipinski MM, Hoffman G, Ng A, Zhou W, Py BF, et al. (2010) A genome-wide 
siRNA screen reveals multiple mTORC1 independent signaling pathways 
regulating autophagy under normal nutritional conditions. Dev Cell 18: 1041-
1052. 
57. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular 
mechanisms and biological functions of autophagy. Dev Cell 6: 463-477. 
58. Gustafsson AB, Gottlieb RA (2009) Autophagy in ischemic heart disease. Circ 
Res 104: 150-158. 
59. Souders CA, Bowers SL, Baudino TA (2009) Cardiac fibroblast: the renaissance 
cell. Circ Res 105: 1164-1176. 
60. Camelliti P, Borg TK, Kohl P (2005) Structural and functional characterisation of 
cardiac fibroblasts. Cardiovasc Res 65: 40-51. 
61. Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: 
involvement in cardiac hypertrophy. Circ Res 91: 1103-1113. 
62. Schuetze KB, McKinsey TA, Long CS (2014) Targeting cardiac fibroblasts to treat 
fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol 70: 100-107. 
63. Gan Q, Yoshida T, Li J, Owens GK (2007) Smooth muscle cells and 
myofibroblasts use distinct transcriptional mechanisms for smooth muscle 
alpha-actin expression. Circ Res 101: 883-892. 
64. Bai J, Zhang N, Hua Y, Wang B, Ling L, et al. (2013) Metformin inhibits 
angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. 
PLoS One 8: e72120. 
 
 
241 
 
65. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG (2005) Inhibition of 
cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. 
Am J Physiol Heart Circ Physiol 288: H1131-1138. 
66. Louault C, Benamer N, Faivre JF, Potreau D, Bescond J (2008) Implication of 
connexins 40 and 43 in functional coupling between mouse cardiac fibroblasts 
in primary culture. Biochim Biophys Acta 1778: 2097-2104. 
67. Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and 
mechanism of cardiac fibrosis. J Cell Physiol 225: 631-637. 
68. Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: 
mechanisms: part 1 of 2. Circulation 128: 388-400. 
69. Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of 
hypertrophy in the human left ventricle. J Clin Invest 56: 56-64. 
70. Sadoshima J, Xu Y, Slayter HS, Izumo S (1993) Autocrine release of angiotensin 
II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 
977-984. 
71. Francis GS (2011) Neurohormonal control of heart failure. Cleve Clin J Med 78 
Suppl 1: S75-79. 
72. Parsons KK, Coffman TM (2007) The renin-angiotensin system: it's all in your 
head. J Clin Invest 117: 873-876. 
73. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE (2001) Bradykinin 
contributes to the vasodilator effects of chronic angiotensin-converting enzyme 
inhibition in patients with heart failure. Circulation 104: 2177-2181. 
 
 
242 
 
74. Kramkowski K, Mogielnicki A, Buczko W (2006) The physiological significance of 
the alternative pathways of angiotensin II production. J Physiol Pharmacol 57: 
529-539. 
75. Rykl J, Thiemann J, Kurzawski S, Pohl T, Gobom J, et al. (2006) Renal cathepsin 
G and angiotensin II generation. J Hypertens 24: 1797-1807. 
76. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, et al. (2004) Involvement of 
chymase-mediated angiotensin II generation in blood pressure regulation. J 
Clin Invest 114: 112-120. 
77. Leung PS (2007) The physiology of a local renin-angiotensin system in the 
pancreas. J Physiol 580: 31-37. 
78. Zisman LS, Meixell GE, Bristow MR, Canver CC (2003) Angiotensin-(1-7) 
formation in the intact human heart: in vivo dependence on angiotensin II as 
substrate. Circulation 108: 1679-1681. 
79. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, et al. (2002) Hydrolysis of 
biological peptides by human angiotensin-converting enzyme-related 
carboxypeptidase. J Biol Chem 277: 14838-14843. 
80. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, et al. (2008) 
Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling 
pathway in cardiomyocytes. Hypertension 52: 542-548. 
81. Gomes ER, Lara AA, Almeida PW, Guimaraes D, Resende RR, et al. (2010) 
Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a 
nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway. 
Hypertension 55: 153-160. 
 
 
243 
 
82. Regitz-Zagrosek V, Fielitz J, Fleck E (1998) Myocardial angiotensin receptors in 
human hearts. Basic Res Cardiol 93 Suppl 2: 37-42. 
83. Booz GW, Baker KM (1996) Role of type 1 and type 2 angiotensin receptors in 
angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 28: 635-640. 
84. Hou M, Pantev E, Moller S, Erlinge D, Edvinsson L (2000) Angiotensin II type 1 
receptors stimulate protein synthesis in human cardiac fibroblasts via a Ca2+-
sensitive PKC-dependent tyrosine kinase pathway. Acta Physiol Scand 168: 
301-309. 
85. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union 
of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-
472. 
86. Sadoshima J, Izumo S (1996) The heterotrimeric G q protein-coupled angiotensin 
II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in 
cardiac myocytes. EMBO J 15: 775-787. 
87. Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T, et al. (1999) 
Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle 
cells. Hypertension 33: 201-206. 
88. Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, et al. (1998) Angiotensin II 
type 1 receptor-induced extracellular signal-regulated protein kinase activation 
is mediated by Ca2+/calmodulin-dependent transactivation of epidermal 
growth factor receptor. Circ Res 82: 1338-1348. 
 
 
244 
 
89. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, et al. (2007) Angiotensin II 
signal transduction through the AT1 receptor: novel insights into mechanisms 
and pathophysiology. Clin Sci (Lond) 112: 417-428. 
90. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, et al. (2006) Angiotensin 
II signal transduction through small GTP-binding proteins: mechanism and 
significance in vascular smooth muscle cells. Hypertension 48: 534-540. 
91. Fujii T, Onohara N, Maruyama Y, Tanabe S, Kobayashi H, et al. (2005) 
Galpha12/13-mediated production of reactive oxygen species is critical for 
angiotensin receptor-induced NFAT activation in cardiac fibroblasts. J Biol 
Chem 280: 23041-23047. 
92. Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, et al. (1998) A requirement 
for the rac1 GTPase in the signal transduction pathway leading to cardiac 
myocyte hypertrophy. J Clin Invest 102: 929-937. 
93. Tilley DG (2011) G protein-dependent and G protein-independent signaling 
pathways and their impact on cardiac function. Circ Res 109: 217-230. 
94. Gaborik Z, Szaszak M, Szidonya L, Balla B, Paku S, et al. (2001) Beta-arrestin- 
and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol 
Pharmacol 59: 239-247. 
95. Violin JD, Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seven-
transmembrane receptors. Trends Pharmacol Sci 28: 416-422. 
96. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, et al. (2011) 
Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the 
 
 
245 
 
angiotensin II type I receptor, in healthy and heart failure canines: a novel 
therapeutic strategy for acute heart failure. Circ Heart Fail 4: 770-778. 
97. Kim KS, Abraham D, Williams B, Violin JD, Mao L, et al. (2012) beta-Arrestin-
biased AT1R stimulation promotes cell survival during acute cardiac injury. Am 
J Physiol Heart Circ Physiol 303: H1001-1010. 
98. Anderson KM, Murahashi T, Dostal DE, Peach MJ (1993) Morphological and 
biochemical analysis of angiotensin II internalization in cultured rat aortic 
smooth muscle cells. Am J Physiol 264: C179-188. 
99. Kule CE, Karoor V, Day JN, Thomas WG, Baker KM, et al. (2004) Agonist-
dependent internalization of the angiotensin II type one receptor (AT1): role of 
C-terminus phosphorylation in recruitment of beta-arrestins. Regul Pept 120: 
141-148. 
100. Wyse BD, Prior IA, Qian H, Morrow IC, Nixon S, et al. (2003) Caveolin interacts 
with the angiotensin II type 1 receptor during exocytic transport but not at the 
plasma membrane. J Biol Chem 278: 23738-23746. 
101. Carey RM, Wang ZQ, Siragy HM (2000) Role of the angiotensin type 2 receptor 
in the regulation of blood pressure and renal function. Hypertension 35: 155-
163. 
102. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, et al. (1997) Angiotensin II 
type 2 receptors mediate inhibition of mitogen-activated protein kinase 
cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 
325 ( Pt 2): 449-454. 
 
 
246 
 
103. Horiuchi M, Akishita M, Dzau VJ (1999) Recent progress in angiotensin II type 2 
receptor research in the cardiovascular system. Hypertension 33: 613-621. 
104. van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA, 
et al. (1997) Angiotensin II-mediated growth and antigrowth effects in cultured 
neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol 29: 2147-
2157. 
105. Yamada T, Horiuchi M, Dzau VJ (1996) Angiotensin II type 2 receptor mediates 
programmed cell death. Proc Natl Acad Sci U S A 93: 156-160. 
106. Tanaka M, Ohnishi J, Ozawa Y, Sugimoto M, Usuki S, et al. (1995) 
Characterization of angiotensin II receptor type 2 during differentiation and 
apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res 
Commun 207: 593-598. 
107. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM (1997) 
Angiotensin II induces apoptosis of human endothelial cells. Protective effect 
of nitric oxide. Circ Res 81: 970-976. 
108. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, et al. (1998) 
Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis 
and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer 
study. Life Sci 63: PL289-295. 
109. Turu G, Szidonya L, Gaborik Z, Buday L, Spat A, et al. (2006) Differential beta-
arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett 580: 41-45. 
110. Ruilope LM, Schmieder RE (2008) Left ventricular hypertrophy and clinical 
outcomes in hypertensive patients. Am J Hypertens 21: 500-508. 
 
 
247 
 
111. Drazner MH (2011) The progression of hypertensive heart disease. Circulation 
123: 327-334. 
112. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, et al. (2000) 
Continuous relation between left ventricular mass and cardiovascular risk in 
essential hypertension. Hypertension 35: 580-586. 
113. Cuspidi C, Sala C, Muiesan ML, De Luca N, Schillaci G, et al. (2013) Right 
ventricular hypertrophy in systemic hypertension: an updated review of clinical 
studies. J Hypertens 31: 858-865. 
114. Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II--
induced hypertrophy of cardiac myocytes and hyperplasia of cardiac 
fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423. 
115. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, et al. (1990) Increased 
rat cardiac angiotensin converting enzyme activity and mRNA expression in 
pressure overload left ventricular hypertrophy. Effects on coronary resistance, 
contractility, and relaxation. J Clin Invest 86: 1913-1920. 
116. Suzuki J, Matsubara H, Urakami M, Inada M (1993) Rat angiotensin II (type 1A) 
receptor mRNA regulation and subtype expression in myocardial growth and 
hypertrophy. Circ Res 73: 439-447. 
117. Sadoshima J, Izumo S (1993) Signal transduction pathways of angiotensin II--
induced c-fos gene expression in cardiac myocytes in vitro. Roles of 
phospholipid-derived second messengers. Circ Res 73: 424-438. 
118. Sadoshima J, Izumo S (1995) Rapamycin selectively inhibits angiotensin II-
induced increase in protein synthesis in cardiac myocytes in vitro. Potential 
 
 
248 
 
role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 
77: 1040-1052. 
119. Aoki H, Izumo S, Sadoshima J (1998) Angiotensin II activates RhoA in cardiac 
myocytes: a critical role of RhoA in angiotensin II-induced premyofibril 
formation. Circ Res 82: 666-676. 
120. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S (1996) Survival after 
myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 27: 
714-719. 
121. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, et al. (1997) Effects of 
angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor 
antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 
receptors. J Clin Invest 99: 1926-1935. 
122. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, et al. (2002) Effects of 
losartan on cardiovascular morbidity and mortality in patients with isolated 
systolic hypertension and left ventricular hypertrophy: a Losartan Intervention 
for Endpoint Reduction (LIFE) substudy. JAMA 288: 1491-1498. 
123. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, et al. (2001) Reduction of 
cardiovascular risk by regression of electrocardiographic markers of left 
ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. 
Circulation 104: 1615-1621. 
124. Yang LY, Ge X, Wang YL, Ma KL, Liu H, et al. (2013) Angiotensin receptor 
blockers reduce left ventricular hypertrophy in dialysis patients: a meta-
analysis. Am J Med Sci 345: 1-9. 
 
 
249 
 
125. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, et al. (2009) Effects 
of telmisartan, ramipril, and their combination on left ventricular hypertrophy in 
individuals at high vascular risk in the Ongoing Telmisartan Alone and in 
Combination With Ramipril Global End Point Trial and the Telmisartan 
Randomized Assessment Study in ACE Intolerant Subjects With 
Cardiovascular Disease. Circulation 120: 1380-1389. 
126. Nishida K, Datino T, Macle L, Nattel S (2014) Atrial fibrillation ablation: 
translating basic mechanistic insights to the patient. J Am Coll Cardiol 64: 823-
831. 
127. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, et al. (1994) 
Independent risk factors for atrial fibrillation in a population-based cohort. The 
Framingham Heart Study. JAMA 271: 840-844. 
128. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk 
factor for stroke: the Framingham Study. Stroke 22: 983-988. 
129. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) 
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial 
fibrillation-executive summary: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines and 
the European Society of Cardiology Committee for Practice Guidelines (Writing 
Committee to Revise the 2001 Guidelines for the Management of Patients with 
Atrial Fibrillation). Eur Heart J 27: 1979-2030. 
130. Allessie M, Ausma J, Schotten U (2002) Electrical, contractile and structural 
remodeling during atrial fibrillation. Cardiovasc Res 54: 230-246. 
 
 
250 
 
131. Nattel S, Burstein B, Dobrev D (2008) Atrial remodeling and atrial fibrillation: 
mechanisms and implications. Circ Arrhythm Electrophysiol 1: 62-73. 
132. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC, Jr., et al. (2004) Mice 
with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial 
enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165: 1019-
1032. 
133. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, et al. (2001) Effects of 
angiotensin-converting enzyme inhibition on the development of the atrial 
fibrillation substrate in dogs with ventricular tachypacing-induced congestive 
heart failure. Circulation 104: 2608-2614. 
134. Goette A, Staack T, Rocken C, Arndt M, Geller JC, et al. (2000) Increased 
expression of extracellular signal-regulated kinase and angiotensin-converting 
enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35: 1669-
1677. 
135. Pellman J, Lyon RC, Sheikh F (2010) Extracellular matrix remodeling in atrial 
fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 48: 
461-467. 
136. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, et al. (2004) Atrial extracellular 
matrix remodeling and the maintenance of atrial fibrillation. Circulation 109: 
363-368. 
137. Lin CS, Pan CH (2008) Regulatory mechanisms of atrial fibrotic remodeling in 
atrial fibrillation. Cell Mol Life Sci 65: 1489-1508. 
 
 
251 
 
138. Casaclang-Verzosa G, Gersh BJ, Tsang TS (2008) Structural and functional 
remodeling of the left atrium: clinical and therapeutic implications for atrial 
fibrillation. J Am Coll Cardiol 51: 1-11. 
139. Investigators G-A, Disertori M, Latini R, Barlera S, Franzosi MG, et al. (2009) 
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606-
1617. 
140. Investigators AI, Yusuf S, Healey JS, Pogue J, Chrolavicius S, et al. (2011) 
Irbesartan in patients with atrial fibrillation. N Engl J Med 364: 928-938. 
141. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, et al. (2012) Angiotensin 
II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm 
Electrophysiol 5: 43-51. 
142. Tardif JC TM (2007) Perindopril and prevention of atrial fibrillation. European 
Heart Journal 9: E25-E29. 
143. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Heart 
disease and stroke statistics--2014 update: a report from the American Heart 
Association. Circulation 129: e28-e292. 
144. Chatterjee K (2005) Neurohormonal activation in congestive heart failure and the 
role of vasopressin. Am J Cardiol 95: 8B-13B. 
145. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, et al. (2013) 
2013 ACCF/AHA guideline for the management of heart failure: a report of the 
American College of Cardiology Foundation/American Heart Association Task 
Force on practice guidelines. Circulation 128: e240-327. 
 
 
252 
 
146. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, et al. (2003) Effects 
of candesartan in patients with chronic heart failure and reduced left-ventricular 
systolic function intolerant to angiotensin-converting-enzyme inhibitors: the 
CHARM-Alternative trial. Lancet 362: 772-776. 
147. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, et al. (2003) 
Valsartan, captopril, or both in myocardial infarction complicated by heart 
failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906. 
148. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. 
FASEB J 18: 816-827. 
149. Dobaczewski M, Chen W, Frangogiannis NG (2011) Transforming growth factor 
(TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51: 600-606. 
150. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, et al. (1999) The 
integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for 
regulating pulmonary inflammation and fibrosis. Cell 96: 319-328. 
151. Hyytiainen M, Penttinen C, Keski-Oja J (2004) Latent TGF-beta binding proteins: 
extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin 
Lab Sci 41: 233-264. 
152. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell 113: 685-700. 
153. Lo RS, Massague J (1999) Ubiquitin-dependent degradation of TGF-beta-
activated smad2. Nat Cell Biol 1: 472-478. 
 
 
253 
 
154. Almendral JL, Shick V, Rosendorff C, Atlas SA (2010) Association between 
transforming growth factor-beta(1) and left ventricular mass and diameter in 
hypertensive patients. J Am Soc Hypertens 4: 135-141. 
155. Villar AV, Cobo M, Llano M, Montalvo C, Gonzalez-Vilchez F, et al. (2009) 
Plasma levels of transforming growth factor-beta1 reflect left ventricular 
remodeling in aortic stenosis. PLoS One 4: e8476. 
156. Gramley F, Lorenzen J, Koellensperger E, Kettering K, Weiss C, et al. (2010) 
Atrial fibrosis and atrial fibrillation: the role of the TGF-beta1 signaling pathway. 
Int J Cardiol 143: 405-413. 
157. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, et al. (2002) 
Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic 
mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 283: 
H1253-1262. 
158. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, et al. (2002) Transforming 
growth factor-beta function blocking prevents myocardial fibrosis and diastolic 
dysfunction in pressure-overloaded rats. Circulation 106: 130-135. 
159. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, et al. (2000) Role 
of transforming growth factor-beta1 in cardiovascular inflammatory changes 
induced by chronic inhibition of nitric oxide synthesis. Hypertension 35: 86-90. 
160. Moussad EE, Brigstock DR (2000) Connective tissue growth factor: what's in a 
name? Mol Genet Metab 71: 276-292. 
 
 
254 
 
161. Abreu JG, Ketpura NI, Reversade B, De Robertis EM (2002) Connective-tissue 
growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell 
Biol 4: 599-604. 
162. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, et al. (2008) Plasma 
connective tissue growth factor is a novel potential biomarker of cardiac 
dysfunction in patients with chronic heart failure. Eur J Heart Fail 10: 373-379. 
163. Ohnishi H, Oka T, Kusachi S, Nakanishi T, Takeda K, et al. (1998) Increased 
expression of connective tissue growth factor in the infarct zone of 
experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 30: 
2411-2422. 
164. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, et al. (2003) 
Angiotensin II induces connective tissue growth factor gene expression via 
calcineurin-dependent pathways. Am J Pathol 163: 355-366. 
165. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, et al. (2007) Increased 
connective tissue growth factor relative to brain natriuretic peptide as a 
determinant of myocardial fibrosis. Hypertension 49: 1120-1127. 
166. Hishikawa K, Oemar BS, Nakaki T (2001) Static pressure regulates connective 
tissue growth factor expression in human mesangial cells. J Biol Chem 276: 
16797-16803. 
167. Ahmed MS, Oie E, Vinge LE, Yndestad A, Oystein Andersen G, et al. (2004) 
Connective tissue growth factor--a novel mediator of angiotensin II-stimulated 
cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 36: 393-
404. 
 
 
255 
 
168. Recchia AG, Filice E, Pellegrino D, Dobrina A, Cerra MC, et al. (2009) 
Endothelin-1 induces connective tissue growth factor expression in 
cardiomyocytes. J Mol Cell Cardiol 46: 352-359. 
169. Lipson KE, Wong C, Teng Y, Spong S (2012) CTGF is a central mediator of 
tissue remodeling and fibrosis and its inhibition can reverse the process of 
fibrosis. Fibrogenesis Tissue Repair 5: S24. 
170. Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective 
tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21: 473-
482. 
171. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH (2000) CTGF expression 
is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a 
potential role in heart fibrosis. J Mol Cell Cardiol 32: 1805-1819. 
172. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, et al. (1999) 
Connective tissue growth factor mediates transforming growth factor beta-
induced collagen synthesis: down-regulation by cAMP. FASEB J 13: 1774-
1786. 
173. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, et al. (2010) 
Connective tissue growth factor promotes fibrosis downstream of TGFbeta and 
IL-6 in chronic cardiac allograft rejection. Am J Transplant 10: 220-230. 
174. Liu C, Zhao W, Meng W, Zhao T, Chen Y, et al. (2014) Platelet-derived growth 
factor blockade on cardiac remodeling following infarction. Mol Cell Biochem 
397: 295-304. 
 
 
256 
 
175. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, et al. (2010) Structures of a platelet-
derived growth factor/propeptide complex and a platelet-derived growth 
factor/receptor complex. Proc Natl Acad Sci U S A 107: 11307-11312. 
176. Heldin CH, Eriksson U, Ostman A (2002) New members of the platelet-derived 
growth factor family of mitogens. Arch Biochem Biophys 398: 284-290. 
177. Simon AR, Rai U, Fanburg BL, Cochran BH (1998) Activation of the JAK-STAT 
pathway by reactive oxygen species. Am J Physiol 275: C1640-1652. 
178. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, et al. (2003) The role of focal 
adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate 
cell proliferation and type I collagen expression. J Biol Chem 278: 8083-8090. 
179. Fan B, Ma L, Li Q, Wang L, Zhou J, et al. (2014) Role of PDGFs/PDGFRs 
signaling pathway in myocardial fibrosis of DOCA/salt hypertensive rats. Int J 
Clin Exp Pathol 7: 16-27. 
180. Zhao W, Zhao T, Huang V, Chen Y, Ahokas RA, et al. (2011) Platelet-derived 
growth factor involvement in myocardial remodeling following infarction. J Mol 
Cell Cardiol 51: 830-838. 
181. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, et al. (2010) Cardiac mast 
cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-
overloaded mouse hearts. J Clin Invest 120: 242-253. 
182. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, et al. (2002) Kruppel-like 
zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II 
signaling and an essential regulator of cardiovascular remodeling. Nat Med 8: 
856-863. 
 
 
257 
 
183. Burstein B, Libby E, Calderone A, Nattel S (2008) Differential behaviors of atrial 
versus ventricular fibroblasts: a potential role for platelet-derived growth factor 
in atrial-ventricular remodeling differences. Circulation 117: 1630-1641. 
184. Ponten A, Li X, Thoren P, Aase K, Sjoblom T, et al. (2003) Transgenic 
overexpression of platelet-derived growth factor-C in the mouse heart induces 
cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163: 
673-682. 
185. Tuuminen R, Nykanen A, Keranen MA, Krebs R, Alitalo K, et al. (2006) The 
effect of platelet-derived growth factor ligands in rat cardiac allograft 
vasculopathy and fibrosis. Transplant Proc 38: 3271-3273. 
186. Zhao T, Zhao W, Chen Y, Li VS, Meng W, et al. (2013) Platelet-derived growth 
factor-D promotes fibrogenesis of cardiac fibroblasts. Am J Physiol Heart Circ 
Physiol 304: H1719-1726. 
187. Liao S, Bodmer J, Pietras D, Azhar M, Doetschman T, et al. (2009) Biological 
functions of the low and high molecular weight protein isoforms of fibroblast 
growth factor-2 in cardiovascular development and disease. Dev Dyn 238: 
249-264. 
188. Kaye D, Pimental D, Prasad S, Maki T, Berger HJ, et al. (1996) Role of 
transiently altered sarcolemmal membrane permeability and basic fibroblast 
growth factor release in the hypertrophic response of adult rat ventricular 
myocytes to increased mechanical activity in vitro. J Clin Invest 97: 281-291. 
 
 
258 
 
189. Florkiewicz RZ, Anchin J, Baird A (1998) The inhibition of fibroblast growth 
factor-2 export by cardenolides implies a novel function for the catalytic subunit 
of Na+,K+-ATPase. J Biol Chem 273: 544-551. 
190. Clarke MS, Caldwell RW, Chiao H, Miyake K, McNeil PL (1995) Contraction-
induced cell wounding and release of fibroblast growth factor in heart. Circ Res 
76: 927-934. 
191. Mignatti P, Morimoto T, Rifkin DB (1991) Basic fibroblast growth factor released 
by single, isolated cells stimulates their migration in an autocrine manner. Proc 
Natl Acad Sci U S A 88: 11007-11011. 
192. Detillieux KA, Sheikh F, Kardami E, Cattini PA (2003) Biological activities of 
fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 57: 8-19. 
193. Bogoyevitch MA, Glennon PE, Andersson MB, Clerk A, Lazou A, et al. (1994) 
Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated 
protein kinase signaling cascade in cardiac myocytes. The potential role of the 
cascade in the integration of two signaling pathways leading to myocyte 
hypertrophy. J Biol Chem 269: 1110-1119. 
194. Mima T, Ueno H, Fischman DA, Williams LT, Mikawa T (1995) Fibroblast growth 
factor receptor is required for in vivo cardiac myocyte proliferation at early 
embryonic stages of heart development. Proc Natl Acad Sci U S A 92: 467-
471. 
195. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, et al. (2002) Acute protection of 
ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase 
C. Am J Physiol Heart Circ Physiol 282: H1071-1080. 
 
 
259 
 
196. Sheikh F, Sontag DP, Fandrich RR, Kardami E, Cattini PA (2001) 
Overexpression of FGF-2 increases cardiac myocyte viability after injury in 
isolated mouse hearts. Am J Physiol Heart Circ Physiol 280: H1039-1050. 
197. Hellman U, Hellstrom M, Morner S, Engstrom-Laurent A, Aberg AM, et al. (2008) 
Parallel up-regulation of FGF-2 and hyaluronan during development of cardiac 
hypertrophy in rat. Cell Tissue Res 332: 49-56. 
198. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, et al. (1999) Fibroblast 
growth factor-2 mediates pressure-induced hypertrophic response. J Clin 
Invest 104: 709-719. 
199. Tang W, Wei Y, Le K, Li Z, Bao Y, et al. (2011) Mitogen-activated protein 
kinases ERK 1/2- and p38-GATA4 pathways mediate the Ang II-induced 
activation of FGF2 gene in neonatal rat cardiomyocytes. Biochem Pharmacol 
81: 518-525. 
200. Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, et al. (2001) Dilated 
cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II 
in mice lacking FGF-2. J Clin Invest 108: 1843-1851. 
201. Peters J, Farrenkopf R, Clausmeyer S, Zimmer J, Kantachuvesiri S, et al. (2002) 
Functional significance of prorenin internalization in the rat heart. Circ Res 90: 
1135-1141. 
202. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, et al. (2004) 
Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac 
hypertrophy. Regul Pept 120: 5-13. 
 
 
260 
 
203. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, et al. (2000) Myocardial 
cell death in human diabetes. Circ Res 87: 1123-1132. 
204. Singh VP, Baker KM, Kumar R (2008) Activation of the intracellular renin-
angiotensin system in cardiac fibroblasts by high glucose: role in extracellular 
matrix production. Am J Physiol Heart Circ Physiol 294: H1675-1684. 
205. Singh VP, Le B, Bhat VB, Baker KM, Kumar R (2007) High-glucose-induced 
regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac 
myocytes. Am J Physiol Heart Circ Physiol 293: H939-948. 
206. Singh VP, Le B, Khode R, Baker KM, Kumar R (2008) Intracellular angiotensin II 
production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative 
stress, and cardiac fibrosis. Diabetes 57: 3297-3306. 
207. De Mello WC (1998) Intracellular angiotensin II regulates the inward calcium 
current in cardiac myocytes. Hypertension 32: 976-982. 
208. De Mello WC (2011) Intracrine action of angiotensin II in the intact ventricle of 
the failing heart: angiotensin II changes cardiac excitability from within. Mol 
Cell Biochem 358: 309-315. 
209. De Mello WC (1996) Renin-angiotensin system and cell communication in the 
failing heart. Hypertension 27: 1267-1272. 
210. Filipeanu CM, Brailoiu E, Kok JW, Henning RH, De Zeeuw D, et al. (2001) 
Intracellular angiotensin II elicits Ca2+ increases in A7r5 vascular smooth 
muscle cells. Eur J Pharmacol 420: 9-18. 
 
 
261 
 
211. Filipeanu CM, Henning RH, de Zeeuw D, Nelemans A (2001) Intracellular 
Angiotensin II and cell growth of vascular smooth muscle cells. Br J Pharmacol 
132: 1590-1596. 
212. Weber MA, Giles TD (2006) Inhibiting the renin-angiotensin system to prevent 
cardiovascular diseases: do we need a more comprehensive strategy? Rev 
Cardiovasc Med 7: 45-54. 
213. Tigerstedt RB, PG. (1898) Niere und Kreislauf. Scand Arch Physiol 8: 221-271. 
214. Basso N, Terragno NA (2001) History about the discovery of the renin-
angiotensin system. Hypertension 38: 1246-1249. 
215. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM (2012) The intracrine 
renin-angiotensin system. Clin Sci (Lond) 123: 273-284. 
216. Celio MR, Inagami T (1981) Angiotensin II immunoreactivity coexists with renin 
in the juxtaglomerular granular cells of the kidney. Proc Natl Acad Sci U S A 
78: 3897-3900. 
217. Hunt MK, Ramos SP, Geary KM, Norling LL, Peach MJ, et al. (1992) 
Colocalization and release of angiotensin and renin in renal cortical cells. Am J 
Physiol 263: F363-373. 
218. Carey RM, Geary KM, Hunt MK, Ramos SP, Forbes MS, et al. (1990) 
Identification of individual renocortical cells that secrete renin. Am J Physiol 
258: F649-659. 
219. Mercure C, Ramla D, Garcia R, Thibault G, Deschepper CF, et al. (1998) 
Evidence for intracellular generation of angiotensin II in rat juxtaglomerular 
cells. FEBS Lett 422: 395-399. 
 
 
262 
 
220. Vila-Porcile E, Corvol P (1998) Angiotensinogen, prorenin, and renin are Co-
localized in the secretory granules of all glandular cells of the rat anterior 
pituitary: an immunoultrastructural study. J Histochem Cytochem 46: 301-311. 
221. Fischer TA, Ungureanu-Longrois D, Singh K, de Zengotita J, DeUgarte D, et al. 
(1997) Regulation of bFGF expression and ANG II secretion in cardiac 
myocytes and microvascular endothelial cells. Am J Physiol 272: H958-968. 
222. Sherrod M, Liu X, Zhang X, Sigmund CD (2005) Nuclear localization of 
angiotensinogen in astrocytes. Am J Physiol Regul Integr Comp Physiol 288: 
R539-546. 
223. Lee-Kirsch MA, Gaudet F, Cardoso MC, Lindpaintner K (1999) Distinct renin 
isoforms generated by tissue-specific transcription initiation and alternative 
splicing. Circ Res 84: 240-246. 
224. Clausmeyer S, Reinecke A, Farrenkopf R, Unger T, Peters J (2000) Tissue-
specific expression of a rat renin transcript lacking the coding sequence for the 
prefragment and its stimulation by myocardial infarction. Endocrinology 141: 
2963-2970. 
225. Peters J, Kranzlin B, Schaeffer S, Zimmer J, Resch S, et al. (1996) Presence of 
renin within intramitochondrial dense bodies of the rat adrenal cortex. Am J 
Physiol 271: E439-450. 
226. Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, et al. (2006) Evidence 
supporting a functional role for intracellular renin in the brain. Hypertension 47: 
461-466. 
 
 
263 
 
227. Peters J, Wanka H, Peters B, Hoffmann S (2008) A renin transcript lacking exon 
1 encodes for a non-secretory intracellular renin that increases aldosterone 
production in transgenic rats. J Cell Mol Med 12: 1229-1237. 
228. Wanka H, Kessler N, Ellmer J, Endlich N, Peters BS, et al. (2009) Cytosolic 
renin is targeted to mitochondria and induces apoptosis in H9c2 rat 
cardiomyoblasts. J Cell Mol Med 13: 2926-2937. 
229. Camargo de Andrade MC, Di Marco GS, de Paulo Castro Teixeira V, Mortara 
RA, Sabatini RA, et al. (2006) Expression and localization of N-domain ANG I-
converting enzymes in mesangial cells in culture from spontaneously 
hypertensive rats. Am J Physiol Renal Physiol 290: F364-375. 
230. Lucero HA, Kintsurashvili E, Marketou ME, Gavras H (2010) Cell signaling, 
internalization, and nuclear localization of the angiotensin converting enzyme 
in smooth muscle and endothelial cells. J Biol Chem 285: 5555-5568. 
231. Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Ninomiya T, 
Algert C, et al. (2008) Effects of different regimens to lower blood pressure on 
major cardiovascular events in older and younger adults: meta-analysis of 
randomised trials. BMJ 336: 1121-1123. 
232. Scheen AJ, Krzesinski JM (2008) [ONTARGET: similar protection of telmisartan 
and ramipril and lack of benefit of combined therapy in patients at high risk for 
vascular events]. Rev Med Liege 63: 213-219. 
233. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, et al. (2008) 
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular 
 
 
264 
 
risk (the ONTARGET study): a multicentre, randomised, double-blind, 
controlled trial. Lancet 372: 547-553. 
234. Investigators O, Yusuf S, Teo KK, Pogue J, Dyal L, et al. (2008) Telmisartan, 
ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 
1547-1559. 
235. Messerli FH, Bangalore S (2013) ALTITUDE trial and dual RAS blockade: the 
alluring but soft science of the surrogate end point. Am J Med 126: e1-3. 
236. Mallat SG (2013) Dual renin-angiotensin system inhibition for prevention of renal 
and cardiovascular events: do the latest trials challenge existing evidence? 
Cardiovasc Diabetol 12: 108. 
237. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, et al. (2013) 
Effect of aliskiren on postdischarge mortality and heart failure readmissions 
among patients hospitalized for heart failure: the ASTRONAUT randomized 
trial. JAMA 309: 1125-1135. 
238. Danser AH (2010) Cardiac angiotensin II: does it have a function? Am J Physiol 
Heart Circ Physiol 299: H1304-1306. 
239. Baker KM, Kumar R (2006) Intracellular angiotensin II induces cell proliferation 
independent of AT1 receptor. Am J Physiol Cell Physiol 291: C995-1001. 
240. Kumar R, Singh VP, Baker KM (2008) The intracellular renin-angiotensin 
system: implications in cardiovascular remodeling. Curr Opin Nephrol 
Hypertens 17: 168-173. 
 
 
265 
 
241. De Mello WC (2009) Cell swelling, impulse conduction, and cardiac arrhythmias 
in the failing heart. Opposite effects of angiotensin II and angiotensin (1-7) on 
cell volume regulation. Mol Cell Biochem 330: 211-217. 
242. Haller H, Lindschau C, Erdmann B, Quass P, Luft FC (1996) Effects of 
intracellular angiotensin II in vascular smooth muscle cells. Circ Res 79: 765-
772. 
243. Brailoiu E, Filipeanu CM, Tica A, Toma CP, de Zeeuw D, et al. (1999) 
Contractile effects by intracellular angiotensin II via receptors with a distinct 
pharmacological profile in rat aorta. Br J Pharmacol 126: 1133-1138. 
244. Beaulieu JM, Caron MG (2005) Beta-arrestin goes nuclear. Cell 123: 755-757. 
245. Martini JS, Raake P, Vinge LE, DeGeorge BR, Jr., Chuprun JK, et al. (2008) 
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase 
kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 105: 
12457-12462. 
246. Miyazaki M, Takai S (2006) Tissue angiotensin II generating system by 
angiotensin-converting enzyme and chymase. J Pharmacol Sci 100: 391-397. 
247. Bacani C, Frishman WH (2006) Chymase: a new pharmacologic target in 
cardiovascular disease. Cardiol Rev 14: 187-193. 
248. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, et al. (2006) 
Advanced glycation end products activate a chymase-dependent angiotensin 
II-generating pathway in diabetic complications. Circulation 113: 1353-1360. 
249. Dell'Italia LJ, Husain A (2002) Dissecting the role of chymase in angiotensin II 
formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379. 
 
 
266 
 
250. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, et al. (1993) Cellular 
localization and regional distribution of an angiotensin II-forming chymase in 
the heart. J Clin Invest 91: 1269-1281. 
251. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, et al. (2011) 
Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in 
human atrial tissue. PLoS One 6: e28501. 
252. Carey RM (2013) Newly discovered components and actions of the renin-
angiotensin system. Hypertension 62: 818-822. 
253. Ahmad S, Wei CC, Tallaj J, Dell'Italia LJ, Moniwa N, et al. (2013) Chymase 
mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc 
Hypertens 7: 128-136. 
254. Ahmad S, Varagic J, Groban L, Dell'Italia LJ, Nagata S, et al. (2014) 
Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr 
Hypertens Rep 16: 429. 
255. Prosser HC, Forster ME, Richards AM, Pemberton CJ (2009) Cardiac chymase 
converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon 
cardiac haemodynamics. Cardiovasc Res 82: 40-50. 
256. Zheng J, Wei CC, Hase N, Shi K, Killingsworth CR, et al. (2014) Chymase 
mediates injury and mitochondrial damage in cardiomyocytes during acute 
ischemia/reperfusion in the dog. PLoS One 9: e94732. 
257. Yoshiyama M, Nakamura Y, Omura T, Izumi Y, Matsumoto R, et al. (2005) 
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling 
 
 
267 
 
after myocardial infarction in angiotensin II type 1 receptor knockout mice. 
Heart 91: 1080-1085. 
258. Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, et al. (2000) Role of 
kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in 
kininogen-deficient rats. Am J Physiol Heart Circ Physiol 278: H507-514. 
259. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, et al. (2001) Diminished 
cardioprotective response to inhibition of angiotensin-converting enzyme and 
angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ 
Res 88: 1072-1079. 
260. Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, et al. 
(2007) Tissue kallikrein is involved in the cardioprotective effect of AT1-
receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 323: 
210-216. 
261. Quitterer U, AbdAlla S (2014) Vasopressor meets vasodepressor: The AT1-B2 
receptor heterodimer. Biochem Pharmacol 88: 284-290. 
262. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 
receptor blockers induce peroxisome proliferator-activated receptor-gamma 
activity. Circulation 109: 2054-2057. 
263. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, et al. (2004) 
Identification of telmisartan as a unique angiotensin II receptor antagonist with 
selective PPARgamma-modulating activity. Hypertension 43: 993-1002. 
264. Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, et al. (2012) 
Identification of membrane-bound variant of metalloendopeptidase neurolysin 
 
 
268 
 
(EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin 
binding site. J Biol Chem 287: 114-122. 
 
 
 
 
 
 
